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WIRKLICHES NEULAND IN EINER WISSENSCHAFT 
KANN WOHL NUR GEWONNEN WERDEN, 
WENN MAN AN EINER ENTSCHEIDENDEN STELLE 
BEREIT IST, DEN GRUND ZU VERLASSEN, 
AUF DEM DIE BISHERIGE WISSENSCHAFT RUHT, 
UND GEWISSERMASSEN INS LEERE ZU SPRINGEN. 
WERNER HEISENBERG (1901-1976)  
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Für	meine	Eltern,	
die	mir	all	dies	ermöglicht	haben	
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1 Introduction	
1.1 Mixed	lineage	leukemia	
1.1.1 Cancer	and	leukemia	
Cancer	constitutes	a	group	of	diseases	characterized	by	uncontrolled	cell	division.	This	results	in	
unregulated	cell	growth	and	the	formation	of	malignant	tumors	that	can	spread	to	other	organs.	
Cancer	typically	originates	from	a	single	cell	which	has	undergone	progressive	genetic	aberrations	
to	escape	cell	death	and	promote	proliferation.	
In	2011,	 roughly	450	 in	100	000	 individuals	were	newly	diagnosed	with	 cancer	 [1].	The	most	
common	 forms	of	 cancer	 in	Europe	are	 lung	 cancer	 (13.3	%),	 colorectal	 cancer	 (13.2	%),	 and	
breast	cancer	(13	%)	[2].	In	principle,	tumors	can	occur	in	every	tissue,	and	currently	more	than	
200	cancer	types	are	described	[3].	
However,	all	tumor	cells	share	some	features	by	which	they	can	be	distinguished	from	healthy	
cells.	Essentially,	 they	 found	ways	to	successfully	unbalance	the	delicate	and	strictly	regulated	
balance	of	proliferation	and	apoptosis.	Hanahan	and	Weinberg	proposed	six	essential	alterations	
common	for	the	majority	of	tumors:	(i)	apoptosis	evasion,	(ii)	self‐sufficiency	in	growth	signals,	
(iii)	insensitivity	to	anti‐growth	signals,	(iv)	metastasis,	(v)	limitless	replicative	potential,	and	(vi)	
sustained	angiogenesis	(figure	1.1;	[4]).	
	
	
Figure	1.1	Hallmarks	of	cancer.	
Most	cancers	have	acquired	the	same	set	of	functional	alterations	in	a	series	of	steps.	These	new	capabilities	
are	termed	hallmarks	of	cancer.	According	to	[4].	
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This	 model	 was	 later	 on	 extended	 by	 evasion	 of	 immune	 surveillance	 and	 mechanisms	 to	
compensate	for	stress	generated	by	the	tumor	transformation,	including	metabolic,	proteotoxic,	
mitotic,	oxidative,	as	well	as	DNA	damage	stress.	Each	aberration	depicted	in	figure	1.1	represents	
the	breaching	of	an	anticancer	mechanism	and	is	acquired	by	point	mutation,	gene	amplification,	
deletion,	or	chromosomal	translocation.	Tumor‐associated	genes	can	be	classified	as	oncogenes	
or	 tumor	 suppressor	 genes.	 While	 oncogenes,	 such	 as	 growth	 factors,	 can	 promote	 tumor	
proliferation,	tumor	suppressors	are	responsible	for	cell	cycle	control	as	well	as	apoptosis,	and	
are	therefore	often	repressed	in	tumors.	
Malignant	transformations	occur	not	only	in	solid	tissues,	but	also	in	blood	cells.	Such	types	of	
cancer	 are	 referred	 to	 as	 leukemia	 and	 describe	 cancers	 of	 the	 hematopoietic	 system	
characterized	by	a	rapid	proliferation	of	white	blood	cells.	These	cells	replace	the	normal	bone	
marrow	cells,	which	results	in	an	increased	release	of	immature	progenitor	cells,	called	blasts,	to	
the	peripheral	blood	system.	Eventually,	these	malignant	cells	suppress	the	production	of	normal	
blood	cells,	which	causes	a	deficiency	of	functional	red	and	white	blood	cells.	As	a	consequence,	
most	patients	suffer	from	immunodeficiency,	impaired	blood	clotting,	or	anemia.	In	Germany,	26	
in	100	000	individuals	are	newly	diagnosed	with	leukemia	every	year	(number	from	2012;	[5]).	
Moreover,	concerning	children	under	 the	age	of	15,	 leukemia	 is	 the	most	 frequent	malignancy	
accounting	for	31	%	of	all	cancer	cases	[6].	
Clinically,	leukemias	can	be	subdivided	into	acute	and	chronic	forms.	Patients	with	acute	leukemia	
usually	show	a	sudden	appearance	of	symptoms	in	combination	with	a	rapid	progression	of	the	
disease.	 Acute	 leukemias	 end	 lethal	 within	weeks,	 if	 not	 treated	 immediately	 [7].	 In	 contrast,	
chronic	 leukemias	 typically	 develop	 over	 a	 longer	 period	 of	 time	 and	 progress	 slowly	 [8].	
Additionally,	 both	 acute	 and	 chronic	 leukemia	 can	 be	 subdivided	 into	 lymphocytic	 and	
myelogenous	forms,	according	to	the	type	of	affected	blood	cells.	While	lymphocytic	forms	arise	
in	 progenitor	 cells	 of	 lymphocytes,	 myelogenous	 forms	 affect	 myeloid	 cells	 which	 normally	
differentiate	 into	 erythrocytes,	 as	well	 as	 thrombocytes	 and	 other	 types	 of	white	 blood	 cells.	
Altogether,	the	four	major	types	of	leukemia	are	acute	lymphatic	leukemia	(ALL),	acute	myeloic	
leukemia	(AML),	chronic	lymphatic	leukemia	(CLL)	and	chronic	myeloic	leukemia	(CML).	
One	exception	from	this	classification	is	the	myeloic‐lymphoid	or	mixed	lineage	leukemia	(MLL).	
This	 aggressive	 leukemia	 affects	 both	 the	 lymphoid	 and	myeloid	 lineage	 [9]	 and	 its	molecular	
pathogenesis	is	explained	in	detail	below.	
	
1.1.2 Translocations	are	associated	with	leukemia	
Although	the	causative	factors	for	leukemia	are	still	unclear	in	most	cases,	some	risk	factors	were	
determined.	Especially	 ionizing	radiation	contributes	 significantly	 to	acute	 leukemias	 [10],	 but	
also	 chemicals,	 such	 as	 pesticides	 [11]	 or	 benzenes	 [12]	 increase	 the	 risk	 for	 leukemia.	
Nevertheless,	even	 if	other	 factors,	 such	as	age,	 smoking,	obesity	and	 familial	background,	are	
considered,	only	15‐20	%	of	all	leukemia	cases	can	be	explained	with	these	risk	factors	[13].	
Moreover,	also	at	the	molecular	level	the	causes	for	most	cases	of	leukemia	are	yet	to	be	identified.	
However,	several	studies	pinpointed	that	translocations	play	an	important	role	in	leukemogenesis	
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and	are	commonly	observed	in	all	 four	major	types	of	 leukemia,	with	more	than	400	different	
translocations	described	for	acute	leukemias	[14].	Translocations	require	a	double	strand	break,	
occurring	either	spontaneously	or	 induced	by	 irradiation	or	cytotoxic	agents,	with	subsequent	
reciprocal	fusion	to	a	nonhomologous	chromosome	[15].	Importantly,	two	separate	genes	can	be	
joined	to	a	fusion	gene	in	this	process.	If	a	proto‐oncogene	is	fused	to	an	abundantly	expressed	
gene	 with	 a	 strong	 promoter	 or	 the	 fusion	 protein	 has	 different	 functions,	 the	 cell	 can	 be	
transformed	to	a	tumor	cell.	
Interestingly,	 particular	 translocations	 are	 associated	 with	 certain	 leukemias	 [16].	 The	 most	
prominent	 example	 is	 the	 CML‐related	 Philadelphia	 chromosome,	 which	 is	 the	 result	 of	 a	
reciprocal	translocation	of	chromosomes	9	and	22	(t(9;22)(q34;q11)).	This	translocation	fuses	
the	ABL	gene	(Abelson	murine	 leukemia	viral	oncogene	homolog	1)	to	the	BCR	gene	(breakpoint	
cluster	 region;	 [17])	 and	 generates	 a	 fusion	 protein	 with	 permanently	 active	 tyrosine	 kinase	
activity.	
	
1.1.3 11q23	translocations	cause	mixed	lineage	leukemia	
11q23	translocations	 involving	the	MLL	gene,	also	referred	to	as	ALL‐1	or	HRX,	are	among	the	
most	common	non‐random	translocations	[16].	Such	rearrangements	join	the	N‐terminal	part	of	
the	MLL	gene	to	a	fusion	partner	gene	by	non‐homologous	end	joining	[18–20]	and	are	related	to	
mixed	lineage	leukemia	(MLL).	In	contrast	to	other	translocations,	MLL	is	a	promiscuous	oncogene	
with	 more	 than	 60	 different	 fusion	 partner	 genes	 [21].	 However,	 the	 fusion	 partners	 can	 be	
categorized	into	two	groups.	The	first	group	comprising	the	six	most	frequent	fusion	partners	AF4,	
AF9,	ENL,	AF10,	ELL,	and	AF6	accounts	for	more	than	85	%	of	all	clinical	cases	[19].	
Further	studies	showed	that	all	frequent	partners	except	for	AF6	are	nuclear	proteins,	while	the	
remaining	 fusion	 partners	 of	 the	 second	 group	 are	 predominantly	 localized	 in	 the	 cytoplasm	
(table	1.1).	Due	to	the	nuclear	localization	signal	in	the	MLL	protein,	all	resulting	fusion	proteins	
are	found	in	the	nucleus	[9].	
	
Table	1.1	Selection	of	MLL	fusion	partners.	
According	to	[9].	
Name	 Features	 Localization
ENL	 Binds	histone	H3,	assembles	ENL	associated	proteins	
elongation/chromatin	remodeling	complex	
Nucleus	
AF4	 ENL	homolog Nucleus	
AF6	 Dimerization	domain	 Cytoplasma
AF9	 Founder	of	AF4	family,	member	of	ENL	associated	proteins Nucleus	
AF10	 Interacts	with	DOT1L	histone	methyltransferase Nucleus	
ELL	 Elongation	factor,	interacts	with	a	AF4	related	protein Nucleus	
AF1p	 Dimerization	domain	 Cytoplasma
ABI1	 Interacts	with	ENL	when	imported	to	nucleus Cytoplasma
GAS7	 Dimerization	domain	 Cytoplasma
	
In	spite	of	the	promiscuity	of	MLL	with	respect	to	its	fusion	partners,	not	every	protein	causes	
leukemia	in	mice	when	fused	to	MLL	[22,23].	Moreover,	a	mere	truncation	of	the	MLL	protein	is	
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not	sufficient	to	cause	leukemia	[19].	For	most	MLL	translocations,	the	double	strand	break	occurs	
in	 an	 8	 kb	 spanning	 region	 of	 the	MLL	 gene	 called	 breakpoint	 cluster	 region	 [24].	 Such	MLL‐
involving	translocations	are	of	high	clinical	relevance,	as	they	are	found	in	roughly	70	%	of	infant	
ALL	and	occur	in	10	%	of	all	other	ALL	cases	[9,25].	
The	cellular	mechanisms	leading	to	the	exhibition	of	tumor	features	are	multifaceted	[19].	Current	
data	indicate	that	MLL	translocations	cause	increased	expression	of	Hox	genes	by	MLL	itself	and	
recruitment	of	transcription	control	complexes	by	the	fusion	partner	genes,	which	also	enhances	
transcription	of	MLL	target	genes.	Altogether,	this	t(4;11)‐triggered	mixed	lineage	leukemia	is	a	
very	aggressive	type	of	acute	leukemia	with	dismal	prognosis:	Only	40	%	of	all	infants	survive	five	
years	 after	MLL	 diagnosis	 [26],	whereas	 the	 five‐year	 survival	 rate	 of	 infants	with	 non‐mixed	
lineage	leukemia	is	near	90	%	[27].	
In	1996,	the	first	mouse	model	for	MLL	studies	was	successfully	generated.	These	mice	expressed	
the	MLL‐AF9	fusion	protein	under	the	control	of	the	endogenous	MLL	promoter	and	were	found	
to	 develop	 AML	 and	 rarely	 ALL	 [28].	 Moreover,	 MLL	 translocations	 differ	 from	 other	
translocations	in	that	both	of	the	two	fusion	genes	generated	by	the	reciprocal	translocation	were	
recently	 reported	 to	 function	 as	 oncogenes.	 In	 the	 respective	 study,	 the	 two	 oncoproteins	
resulting	from	the	fusion	of	AF4	and	MLL,	namely	AF4‐MLL	and	MLL‐AF4,	contributed	concertedly	
to	the	pathologic	mechanism	[29,30].	
	
1.2 The	MLL	protein	
1.2.1 MLL	is	a	multidomain	protein	
	
Figure	1.2	Domains	of	the	MLL	protein.	
Schematic	representation	of	 the	mixed	 lineage	 leukemia	(MLL)	gene.	Protein	binding	sites	are	 indicated	
above	the	respective	domains.	ATH:	AT‐hook	motif	mediating	binding	to	the	minor	groove	of	AT‐rich	DNA	
sequences;	SNL:	speckled	nuclear	localization	site;	TRD:	transcriptional	repression	domain	comprising	the	
two	functional	subunits	RD1	and	RD2;	PHD:	plant	homology	domain;	TA:	transcriptional	activation	domain;	
SET:	Su(var)3‐9,	enhancer‐of‐zeste,	trithorax	domain;	BCR:	breakpoint	cluster	region.	According	to	[19].	
	
Owing	to	the	high	clinical	 importance	of	the	ubiquitously	expressed	MLL	protein	for	 leukemia,	
several	studies	were	conducted	to	unravel	its	functions.	Consisting	of	3969	amino	acids,	the	MLL	
protein	comprises	multiple	conserved	domains	(figure	1.2):	Binding	to	AT	rich	DNA	regions	 is	
mediated	by	three	N‐terminal	AT‐hook	motifs	[31],	which	are	followed	by	a	repression	domain	
with	 DNA	 methyltransferase	 homology	 [32],	 and	 zinc	 fingers	 that	 mediate	 binding	 to	 the	
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cyclophilin	 CYP33	 [33].	 In	 the	C‐terminal	 region	 of	 the	MLL	protein,	 a	 transactivation	domain	
interacting	with	CREB‐binding	protein	(CBP)	is	found,	as	well	as	a	SET	(Su(var)3‐9,	enhancer‐of‐
zeste,	trithorax)	domain	with	histone	H3K4	methyltransferase	activity.	
With	 the	 help	 of	 these	 domains,	 MLL	 functions	 as	 transcriptional	 regulator.	 In	 particular,	 it	
regulates	 Hox	 gene	 expression	 and	 is	 therefore	 found	 widely	 expressed	 during	 embryonic	
development,	while	most	adult	tissues	display	only	low	expression	levels	[16].	Of	note,	MLL	seems	
indispensable	for	vertebrate	development	and	thus	MLL	knockout	mice	show	embryonic	lethality	
in	addition	to	homeotic	transformations	[16,34,35].		
Closer	 mechanistic	 analysis	 of	 the	 underlying	 processes	 revealed	 that	 especially	 the	 H3K4	
methyltransferase	activity	of	the	SET	domain	is	reported	to	be	important	for	Hox	gene	regulation	
[36].	Consequently,	mice	with	MLL	protein	lacking	the	SET	domain	showed	skeletal	defects	and	
altered	Hox	gene	expression	similar	to	MLL	knockout	mice	[37].	
	
1.2.2 MLL	fusion	proteins	
MLL	fusion	proteins	result	from	genetic	translocations	involving	the	MLL	gene	(section	1.1.2).		
Both	the	wild	type	and	MLL	fusion	proteins	exert	their	central	role	in	gene	expression	regulation	
by	interactions	with	a	plethora	of	other	proteins.	For	this,	MLL	and	also	the	MLL	fusion	proteins	
serve	 as	 a	 platform	 for	 the	 formation	 of	 a	 supercomplex	 composed	 of	more	 than	 30	 proteins	
(figure	1.3;	[38,39]).	
	
	
	
Figure	1.3	MLL	fusions	proteins.	
The	AF4‐MLL	fusion	protein	is	bound	by	SIAHs	and	subjected	to	proteasomal	degradation.	Activation	by	
proteolytic	 cleavage	 at	 defined	 cleavage	 sites	 (CS)	 allows	 heterodimerization	 and	 formation	of	 a	 stable	
multiprotein	supercomplex	resistant	to	SIAH‐mediated	degradation.	According	to	[38].	
	
In	2003,	Hsieh	and	colleagues	reported	another	critical	step	necessary	for	MLL	activity:	The	MLL	
protein	requires	proteolytic	cleavage	and	the	two	subunits	form	a	heterodimer	mediated	by	the	
interaction	of	a	FYRN	domain	in	the	320	kDa	N‐terminal	fragment	and	the	FYRK	and	SET	domains	
in	the	180	kDa	C‐terminal	fragment	(figure	1.4;	[40]).	
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The	uncleaved	AF4‐MLL	fusion	protein	interacts	with	seven	in	absentia	homologs	(SIAHs)	via	the	
SIAH‐dependent	 degron	 located	 in	 the	N‐terminal	 half	 of	 the	 AF4	 protein,	which	 subjects	 the	
precursor	fusion	protein	to	proteasomal	degradation.	In	contrast,	the	activated	MLL	heterodimer	
is	protected	against	degradation	and	the	MLL	complex	including	SIAHs	is	stabilized	(figure	1.3;	
[38]).	This	mechanism	is	thought	to	trap	SIAH	and	prevent	SIAH‐mediated	degradation	of	other	
tumor‐relevant	proteins.	
	
	
Figure	1.4	Processing	of	Taspase	and	MLL.	
a	The	MLL	protein	comprises	two	similar	Taspase	cleavage	sites,	termed	CS1	(left	sequence)	and	CS2	(right	
sequence).	 b	 Upon	 Taspase	 cleavage,	 the	 52	 amino	 acids	 fragment	 between	 the	 two	 cleavage	 sites	 is	
degraded	and	the	two	large	MLL	fragments	assemble	to	a	dimer	via	a	FYRN	interaction	domain	in	the	N‐
terminal	fragment	and	FYRC	and	SET	domains	in	the	C‐terminal	fragment.	
	
Further	analyses	revealed	that	MLL	is	cleaved	at	two	similar	proteolytic	cleavage	sites	53	amino	
acids	apart	from	each	other,	referred	to	as	CS1	and	CS2	(figure	1.4).	While	CS2	is	highly	conserved	
among	 all	 MLL	 homologs,	 including	 the	 human	 MLL2	 protein	 and	 the	 trithorax	 protein	 in	
Drosophila	melanogaster,	CS1	is	present	only	in	vertebrates.	Subsequently,	the	protease	for	MLL	
cleavage	was	discovered.	Due	to	the	threonine	as	its	active	site	residue	and	the	specific	cleavage	
after	 aspartate,	 this	 protease	was	 named	 threonine	 aspartase	 1	 (Taspase).	 Taspase	 is	 able	 to	
cleave	both	 cleavage	 sites	 (CS1	and	CS2)	 in	 the	MLL	protein	and	has	gained	 in	 importance	as	
protease‐mediated	cleavage	is	indispensable	for	MLL	activation.	
	
1.3 The	role	of	Taspase	in	cancer	
1.3.1 Proteases	and	cancer	
Proteases	are	enzymes	that	catalyze	 the	hydrolysis	of	peptide	bonds	and	are	therefore	able	to	
cleave	proteins	and	peptides.	They	play	key	roles	in	food	digestion,	degradation	of	misfolded	and	
unneeded	proteins,	but	also	in	the	regulation	of	other	cellular	processes,	such	as	apoptosis,	blood	
coagulation,	immune	response,	and	cell	cycle	progression	[41].	
Due	 to	 the	 irreversibility	nature	of	proteolytic	cleavage,	proteases	are	strictly	regulated	 in	 the	
body.	Besides	posttranslational	modification	[42,43],	activation	of	an	inactive	precursor	protein	
(zymogen)	by	limited	proteolysis	is	a	common	mechanism,	which	represents	an	essential	step	in	
many	important	cellular	pathways:	The	activation	of	caspases	during	apoptosis	[44],	the	activation	
of	blood	clotting	factors	[45],	the	activation	of	trypsin	and	other	proteases	as	well	as	signaling	via	
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protease‐activated	receptors	(PARs)	 [46]	are	only	a	 few	examples	 for	proteolytic	activation.	 In	
contrast	to	protein	degradation,	proteolytic	activation	events	occur	in	a	site‐specific	manner	and	
the	respective	proteases	are	highly	specific	[41].	
Cleavage	of	target	proteins	by	proteases	occurs	either	at	the	N‐	or	C‐termini	(exopeptidases)	or	
within	 the	 polypeptide	 chain	 (endopeptidases)	 at	 protease	 specific	 cleavage	 sites,	 termed	
consensus	sequences.	The	amino	acids	N‐terminal	of	the	cleavage	site	are	referred	to	as	P1,	P2,	
etc.,	while	the	amino	acids	C‐terminal	of	the	scissile	bond	are	numbered	P1’,	P2’,	etc.	(figure	1.5a).	
The	sites	at	the	surface	of	the	protease	that	can	bind	a	single	substrate	residue	are	called	subsites,	
and	numbered	Sn	or	Sn’	according	to	its	respective	substrate	position.	Consequently,	the	scissile	
bond	is	located	between	the	P1	and	P1’	site.	
	
	
Figure	1.5	Substrate	binding	and	protease	families.	
a	Substrate	binding	to	a	protease.	Substrate	residues	participating	 in	binding	to	 the	protease	(gray)	are	
numbered	P1‐Pn	(non‐primed	sites;	blue)	N‐terminal	of	the	cleavage	site	and	P1’‐Pn’	(primed	sites;	red)	C‐
terminal	of	the	cleavage	site.	The	respective	binding	sites	at	the	surface	of	the	protease	that	accommodate	
the	amino	acid	side	chains	are	numbered	S1‐Sn	and	S1’‐Sn’,	respectively.	Cleavage	occurs	between	the	P1	
and	P1’	position.	
b	Human	proteases	can	be	classified	according	to	their	active	site	into	five	classes	that	can	be	either	intra‐	
(inner	ring)	or	extracellular	(outer	ring).	Numbers	inside	the	rings	indicate	the	number	of	members	of	the	
color	coded	classes.	According	to	[47].	
The	more	than	500	human	proteases	can	be	classified	into	five	classes	according	to	their	active	
site,	that	is,	serine,	cysteine,	cysteine,	aspartate,	and	metalloproteases	(figure	1.5b;	[47,48]).	All	
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five	classes	of	proteases	are	involved	in	tumor	initiation,	growth,	metastasis	as	well	as	invasion	
into	other	sites	[49].	For	this,	the	tumor	associated	proteases	target	and	regulate	diverse	cellular	
processes.	Up	regulation	of	cell	proliferation,	down	regulation	of	cell	death,	angiogenesis,	as	well	
as	induction	of	multi‐drug	resistance	are	only	a	few	examples	of	cellular	processes	governed	by	
proteases	 [50].	 In	 this	 regard,	 trypsin	 is	 involved	 in	 colorectal	 carcinogenesis,	 as	 it	 positively	
regulates	proliferation	and	metastasis	[51],	cathepsins	B	and	D	are	closely	related	with	invasion	
and	progression	of	oral	squamous	cell	carcinoma	[52],	and	caspase	deregulation	is	known	to	cause	
neuroblastomas	[53].	As	some	proteases	are	specific	for	certain	cancer	types,	proteases	can	also	
serve	as	useful	prognostic	and	diagnostic	markers	to	improve	cancer	treatment	[54].	
Some	 proteases	 possess	 tumor	 suppressive	 effects	 and	 loss‐of‐function	 mutations	 in	 the	
respective	genes	promote	malignant	transformation	[55].	Investigating	the	role	of	tumor‐related	
proteases	and	their	mechanism	can	therefore	yield	new	targets	for	cancer	therapies.	
	
1.3.2 Taspase	is	a	type	II	asparaginase	
Taspase	was	discovered	in	2003	as	the	protease	responsible	for	the	proteolytic	activation	of	the	
MLL	 protein.	 As	 a	 member	 of	 the	 type	 II	 asparaginase	 family,	 Taspase	 displays	 the	 typical	
asparaginase	 fold	with	a	central	β‐sheet	sandwich	surrounded	on	both	 faces	by	α‐helices	 [56].	
However,	Taspase	shares	only	low	sequence	similarity	with	other	type	II	asparaginases	and	the	
proteasome	as	related	threonine	protease	(table	4.1).	Nevertheless,	the	structure	of	this	family	is	
highly	conserved	with	RMSD	values	below	2	Å	(figure	1.6a).	
	
	
Figure	1.6	Taspase	displays	a	conserved	asparaginase	fold.	
a	 Overlay	 of	 the	 crystal	 structure	 of	 Taspase	 (red;	 PDB	 2a8j)	 with	 human	 asparaginase	 (4gdw),	 plant	
asparaginase	 (2gez),	 E.	 coli	 asparaginase	 (2zal)	 and	 F.	 meningosepticum	 glycosylasparaginase	 (1ayy)	
reveals	a	conserved	asparaginase	fold.	The	structures	were	aligned	using	PyMOL.	b	Close‐up	view	of	the	
active	site	residues	of	Taspase	(red)	and	its	homologs	(gray)	shows	a	conserved	side	chain	orientation.	Side	
chains	are	displayed	as	sticks	and	the	catalytic	threonine	is	highlighted	in	yellow.	
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Although	 all	 other	 asparaginases	 do	 not	 act	 as	 proteases	 but	 hydrolyze	 the	 free	 amino	 acid	
asparagine	to	aspartate	[57],	the	active	site	is	similar	to	Taspase,	including	the	orientation	of	the	
catalytic	threonine	(figure	1.6b).	Despite	the	small	differences	found	between	the	active	sites	of	
Taspase	and	other	type	II	asparaginases,	the	reason	for	the	diverse	reactions	which	are	catalyzed	
is	 yet	 to	 be	 elucidated.	 To	 become	 catalytically	 competent,	 the	 45	 kDa	 Taspase	 proenzyme	
undergoes	proteolytic	cleavage	into	two	subunits	(figure	1.7).	
	
	
Figure	1.7	Autocatalytic	processing	of	Taspase.	
a	The	Taspase	proenzyme	comprises	420	amino	acids	and	undergoes	spontaneous	autoproteolytic	cleavage	
between	Asp233	and	Thr234.	b	This	process	yields	a	25	kDa	α‐subunit	 (amino	acids	1‐233;	 red)	and	a	
20	kDa	β‐subunit	(amino	acids	234‐420;	orange).	In	this	process,	Thr234	becomes	the	N‐terminal	amino	
acid	 of	 the	 β‐subunit	 and	 its	 free	 hydroxyl	 group	 renders	 Taspase	 proteolytically	 active.	 Two	 αβ‐
heterodimers	assemble	to	a	hetero‐tetramer	with	αββα	structure.	N:	Amino‐terminus;	C:	carboxy‐terminus	
	
Such	a	removal	of	a	propeptide	is	typical	for	type	II	asparaginases	and	other	proteases,	with	renin	
[58]	and	chymotrypsin	[59]	as	well‐studied	examples,	and	serves	to	inhibit	enzyme	activity	and	as	
folding	 helper	 [60].	 The	 autocatalytic	 proteolytic	 processing	 of	 the	 type	 II	 asparaginase	
proenzymes	 has	 been	 elucidated	 in	 detail	 [61,62].	 In	 short,	 the	 catalytic	 threonine	 side	 chain	
attacks	the	peptide	bond	to	the	preceding	aspartate,	before	the	protein	backbone	and	side	chain	
bonds	 between	 threonine	 and	 aspartate	 are	 broken	 (figure	 1.8).	 For	 Taspase,	 the	 whole	
maturation	process	was	found	to	be	a	spontaneous	reaction	and	not	catalyzed	by	other	Taspase	
proteins	in	trans	[63].	
	
	
Figure	1.8	Autocatalytic	activation	of	Taspase	and	other	type	II	asparaginases.	
The	 side	 chain	 OH‐group	 of	 the	 catalytic	 threonine	 forms	 a	 covalent	 bond	 to	 the	 CO	 of	 the	 preceding	
aspartate,	yielding	a	tetrahedral	intermediate	and	a	general	base	(B)	captures	the	proton	of	the	threonine	
OH‐group	(first	reaction).	Subsequently,	the	backbone	C‐N	bond	is	broken	and	a	general	acid	(HA)	donates	
a	proton	to	the	newly	created	N‐terminus	(second	reaction).	Eventually,	a	water	attack	to	the	CO	breaks	the	
bond	between	the	aspartate	backbone	and	the	threonine	side	chain	(third	reaction).	Modified	according	to	
[61].	
	
Eventually,	this	process	renders	a	free	hydroxyl	group	at	the	N‐terminal	threonine	234	of	the	β‐
subunit.	 Hence,	 Taspase	 and	 other	 asparaginases	 belong	 to	 the	 N‐terminal	 nucleophile	 (Ntn)	
INTRODUCTION	 THE	ROLE	OF	TASPASE	IN	CANCER	
	
23	
	
family	of	proteases.	Detailed	analysis	of	the	crystal	structure	of	Taspase	revealed	a	rotation	of	the	
Thr234	side	chain	in	addition	to	a	backbone	shift	upon	activation	[56].	Mutation	of	the	active	site	
threonine	 to	 valine	 does	 not	 only	 prevent	 the	 autocatalytic	 activation	 event,	 but	 also	 renders	
Taspase	unable	to	cleave	its	substrates	in	trans	[56,57].	
After	 autoprocessing,	 the	α‐	 and	β‐subunits	 form	a	 heterodimer,	 and	 two	of	 these	 dimers	 are	
supposed	 to	 assemble	 to	 a	 hetero‐tetramer	 (figure	 1.7b;	 [64]).	 The	 resulting	 αββα	 fold	 after	
autoprocessing	is	a	common	feature	of	all	Ntn	hydrolases	despite	very	low	sequence	similarity	
and	 was	 described	 for	 glycosylasparaginase	 [65],	 plant	 asparaginase	 [66],	 and	 the	 only	 other	
threonine	protease	 in	 the	Ntn	 family,	 the	 proteasome	 [67].	 However,	 the	 formation	 of	 a	 αββα	
shaped	 hetero‐tetramer	 in	 solution	 is	 controversially	 discussed	 for	 Taspase,	 as	 analytical	 gel	
filtrations	 indicate	 the	 presence	 of	 Taspase	 as	 heterodimer	 and	 enforced	 dimerization	 could	
effectively	inhibit	Taspase	in	cells	[68].	
In	2005,	Lee	and	 colleagues	presented	a	hypothetical	 cleavage	mechanism	based	on	 the	 close	
homology	to	asparaginases	(figure	1.9).	 In	this	model,	Taspase	does	not	directly	hydrolyze	the	
peptide	bond	of	the	protein	backbone,	but	the	substrate	first	undergoes	a	rearrangement.	After	
an	attack	of	the	P1’	glycine	by	the	P1	aspartate	side	chain,	a	succinimide‐hydrate	intermediate	is	
formed.	In	a	second	step,	the	former	peptide	bond	is	hydrolyzed,	yielding	an	isoaspartate	with	the	
protein	 backbone	 transferred	 to	 the	 aspartate	 side	 chain.	 Finally,	 Taspase	 cleaves	 the	 newly	
formed	isoaspartate	and	releases	the	two	fragments.	
	
	
Figure	1.9	Proposed	Taspase	cleavage	mechanism.	
The	aspartate	side	chain	of	the	substrate	attacks	the	following	glycine	(red	arrow),	yielding	a	succinimide‐
hydrate	 intermediate.	 Subsequently,	 hydrolysis	 of	 the	 former	 peptide	 bond	 results	 in	 a	 transfer	 of	 the	
protein	backbone	chain	to	the	aspartate	side	chain.	This	isoaspartate	is	then	cleaved	by	Taspase	(red	dashed	
line)	and	the	two	fragments	are	released.	According	to	[69].	
	
Furthermore,	the	chloride	ion	found	in	the	crystal	structure	revealed	another	surprising	feature	
of	 Taspase.	 It	 is	 bound	 to	 the	 active	 site	 and	 inhibits	 Taspase	 activity	 already	 at	 intracellular	
chloride	concentrations	[56].	Hence,	Taspase	is	assumed	to	be	present	as	inhibited	enzyme	in	the	
cell	and	its	substrate	proteins	are	expected	to	temporarily	displace	the	chloride	ion	for	proteolytic	
processing.	The	first	substrate	described	for	Taspase	was	the	MLL	protein	[57],	which	is	activated	
after	Taspase	cleavage	at	two	cleavage	sites	(figure	1.4).	Subsequent	alanine	scans	determined	the	
Taspase	consensus	sequence	as	either	Q‐[F,I,L,V]‐D	|	G‐X‐D‐X	or	Q‐[F,I,L,V]‐D	|	G‐X‐X‐D	[63,70].	
With	this	sequence	at	hand,	27	putative	Taspase	target	proteins	were	identified	[71].	By	now,	the	
experimentally	verified	targets	comprise	MLL,	MLL2	[72],	the	transcription	factors	TFIIA	[73]	and	
ALF	[73],	upstream	stimulatory	factor	2	(USF2),	myosin	1F	(MYO1F),	and	MLL4	[70].	Strikingly,	
many	Taspase	substrates	are	nuclear	factors	involved	in	gene	expression	control,	indicating	a	role	
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of	Taspase‐mediated	cleavage	in	the	regulation	of	these	factors.	However,	for	other	targets	than	
MLL,	 the	 role	 of	 Taspase	 cleavage	 is	 still	 elusive.	 For	 example,	 Taspase‐mediated	 cleavage	 of	
transcription	factor	IIa	(TFIIA)	seems	to	be	a	fine	tuning	mechanism	of	TFIIA	activity	and	was	
speculated	to	be	important	for	the	expression	of	a	certain	subset	of	genes	[73].	
Localization	studies	with	fluorescent	tags	pinpointed	a	nuclear	localization	of	Taspase	due	to	its	
bipartite	 nuclear	 localization	 signal	 [74].	 However,	 closer	 investigation	 revealed	 a	 dynamic	
shuttling	process	between	nucleus	and	cytoplasm.	The	nuclear	import	via	a	nuclear	localization	
signal	 (NLS)	 is	 mediated	 by	 importin‐α	 and	 could	 also	 be	 confirmed	 for	 the	 proenzyme.	 In	
contrast,	 interaction	with	 the	 nucleolar	 shuttle	 protein	 nucleophosmin	was	 only	 observed	 for	
autocatalytically	processed	Taspase.	Although	Taspase	does	not	possess	a	nuclear	export	signal,	
it	has	access	to	the	cytoplasm	and	is	able	to	process	its	cytoplasmic	target	proteins.	This	export	
process	is	nucleophosmin‐dependent	and	can	be	inhibited	by	leptomycin	B	[74].	
Taspase	knockdown	in	Hela	cells	resulted	in	impaired	MLL	cleavage	and	verified	that	no	other	
protease	is	able	to	activate	MLL.	The	close	correlation	of	Taspase	and	MLL	is	also	reflected	in	the	
fact	that	both	genes	coevolved	in	vertebrates	[57].	Consequently,	Taspase	plays	a	key	role	for	MLL,	
as	the	histone	methyltransferase	activity	of	MLL	is	crucially	dependent	on	activation	by	Taspase	
cleavage	[72].	Accordingly,	also	the	MLL	fusion	proteins	are	inactive,	unless	they	are	processed	by	
Taspase	[29].	
	
1.3.3 Taspase	is	a	non‐oncogene	addiction	protease	
Despite	 the	 importance	 of	 Taspase	 for	 leukemia,	 Taspase	 alone	 is	 not	 sufficient	 for	 the	
transformation	of	fibroblasts.	Hence,	Taspase	is	not	classified	as	oncogene,	but	as	non‐oncogene	
addiction	protease	[75,76].	This	means	that	although	Taspase	is	no	oncogene,	certain	leukemias	
heavily	rely	on	Taspase	and	are	therefore	susceptible	for	Taspase	inhibition	(figure	1.10).	
This	 permissive	 role	 of	 Taspase	 in	 leukogenesis	was	 corroborated	 by	 the	 finding	 that	mouse	
embryonic	fibroblasts	(MEFs)	lacking	Taspase	are	resistant	to	oncogenic	transformation	induced	
by	Myc,	 E1A,	 RAS,	 and	 p53	 [76].	Moreover,	 Taspase‐deficient	mice	 exhibited	 decreased	 cyclin	
levels	 as	 well	 as	 increased	 expression	 of	 cyclin	 dependent	 kinase	 (CDK)	 inhibitors	 and	 thus	
showed	 a	 disrupted	 cell	 cycle	 [72].	 Additionally,	 Taspase	 expression	 is	 upregulated	 in	 many	
human	 cancers	 as	 well	 as	 cancer	 cell	 lines	 and	 required	 for	 tumor	 maintenance.	 Generally,	
increased	Taspase	 levels	 correlate	with	a	dependency	on	Taspase	expression	 [72,76].	Of	note,	
recent	 studies	 imply	 a	 crucial	 role	 of	 Taspase	 not	 only	 in	 leukemia,	 but	 also	 in	 solid	 tumors	
[57,70,76].	 Consequently,	 Taspase	 knockdowns	 in	 these	 tumors	 cause	 a	 disruption	 of	
proliferation	and	promote	apoptosis	 [76].	 Interestingly,	 although	Taspase	 is	 critical	 for	mouse	
embryonic	development,	the	few	surviving	Taspase‐deficient	adult	mice	exhibited	a	normal	life	
span	[63].	Hence,	inhibition	of	Taspase	is	regarded	as	new	approach	to	treat	leukemia.	
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Figure	1.10	Taspase	addiction	in	tumor	cells.	
Taspase	 inhibition	 is	 only	 lethal	 for	MLL	 tumor	 cells,	while	 healthy	 cells	 are	not	 affected.	Healthy	 cells	
express	normal	Taspase	and	MLL	levels,	and	Taspase	inhibition	(black	line)	does	not	impair	viability	(left	
column).	Aberrant	Taspase	expression	is	not	sufficient	for	a	malignant	transformation,	as	long	as	MLL	levels	
are	normal.	Under	these	conditions,	Taspase	inhibition	is	not	fatal	(middle	column).	Aberrant	levels	of	the	
oncogene	MLL	cause	malignant	transformation	and	are	often	accompanied	by	aberrant	Taspase	levels.	As	
these	cells	heavily	rely	on	Taspase	for	the	activation	of	MLL,	Taspase	inhibition	results	in	cell	death.	
	
Targeting	non‐oncogene	addiction	proteins	opens	new	ways	in	combating	cancer	and	differs	from	
the	 classical	 approaches	 that	 either	 aim	 at	 suppressing	 oncogene	 activity	 or	 restoring	 tumor	
suppressor	function	[75].	In	recent	years,	several	non‐oncogene	addiction	proteins	were	detected	
and	detailed	analyses	of	these	proteins	achieved	novel	concepts	for	cancer	therapy.	In	fact,	some	
inhibitors	for	non‐oncogene	addiction	proteins	are	already	approved	as	anticancer	drugs.	
One	example	in	this	respect	is	the	heat	shock	protein	90	(HSP90)	inhibitor	geldanamycin™.	Since	
HSP90	client	proteins	are	crucial	 for	 the	regulation	of	cell	 survival,	 cell	growth,	cell	 cycle,	and	
apoptosis,	tumor	cells	relying	on	these	client	proteins	are	effectively	hit	by	the	HSP90	inhibitor	
geldanamycin™	 [77].	 Furthermore,	 Luo	 and	 colleagues	 reported	 that	 inhibition	 of	 the	 non‐
oncogene	polo‐like	kinase	1	(PLK1)	is	toxic	for	cells	with	mutated	Ras	oncogene	[78].	Moreover,	
also	the	proteasome	inhibitor	bortezomib	can	be	regarded	as	a	non‐oncogene	addiction	drug.	It	is	
active	 against	 a	 variety	 of	 tumors,	 including	myeloma,	 CLL,	 prostate	 and	 colon	 cancer,	 and	 is	
approved	for	treating	multiple	myeloma	and	mantle	cell	lymphoma	[79].	Tumor	cells	acquire	a	
variety	 of	 genetic	 aberrations	 and	 thus	 suffer	 from	 the	 stress	 generated	 by	 mutated	 and	
aggregated	proteins.	Consequently,	inhibition	of	the	proteasome	exacerbates	the	stress	in	tumor	
cells	more	than	in	healthy	cells.	
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1.3.4 Endeavors	towards	Taspase	inhibition	
As	 non‐oncogene	 addiction	 protease,	 Taspase	 is	 of	 high	 interest	 for	 cancer	 therapy,	 since	
inhibition	 of	 Taspase	 is	 considered	 a	 promising	 way	 to	 prevent	 leukemogenesis.	 However,	
inhibition	of	Taspase	activity	is	not	trivial,	as	Taspase	is	insensitive	against	inhibition	by	general	
serine,	 cysteine,	 or	 metalloprotease	 inhibitors	 [57].	 Hence,	 different	 approaches	 were	
hypothesized	 to	 obtain	 Taspase	 inhibitors,	 including	 compound	 screening,	 virtual	 docking,	
rational	design,	and	enforced	dimerization	(figure	1.11).	
	
	
Figure	1.11	Strategies	for	new	Taspase	inhibitors.	
a+b	Inhibitors	(red)	for	Taspase	(blue)	can	be	found	by	databank	screening.	The	compounds	can	bind	to	
the	active	site	(a)	or	allosteric	(b).	c	Rational	design	can	yield	substrate	analog	compounds	d	Genetically	
enforced	dimerization	was	found	to	inhibit	Taspase	activity.	
	
1.3.4.1 Compound	screening	
High‐throughput	screening	of	small	molecules	(figure	1.11a+b)	is	a	common	method	to	find	new	
inhibitors	and	has	been	applied	successfully	for	many	other	enzymes	[80,81].	Consequently,	small	
molecule	screenings	aiming	at	Taspase	inhibitors	have	been	published	previously	[63,71,82].	The	
most	promising	candidate	was	the	anti‐angiogenic	arsenic	inhibitor	NSC48300.	This	compound	
was	found	in	a	high‐throughput	screening	assay	of	a	small	molecule	library	and	was	reported	to	
inhibit	 Taspase	 allosterically	 with	 a	 Ki	 of	 4.2	 µM	 [63].	 However,	 the	 arsenic	 moiety	 of	 the	
compound	poses	a	high	toxic	risk,	is	known	for	unspecific	effects	[83]	and	its	application	in	vivo	is	
limited.	
	
1.3.4.2 Virtual	docking	
The	 available	 crystal	 structure	 reveals	 the	 conformation	 of	 the	 active	 site	 and	 thus	 allows	
targeting	Taspase	by	virtual	docking	(figure	1.11a).	Knauer	and	colleagues	performed	an	in	silico	
screening	with	a	database	comprising	roughly	180	000	compounds	[71].	However,	the	resulting	
top	candidates	(CHC‐A4	and	DHC‐C1)	displayed	only	weak	inhibition	of	Taspase	activity.	
	
1.3.4.3 Substrate	analogs	
Besides	 compound	 library	 screening,	 inhibitors	 can	be	derived	 from	 the	 substrate	 by	 rational	
design	(figure	1.11c).	Regarding	this,	 the	Bogyo	group	developed	a	series	of	substrate‐derived	
vinyl	 sulfone	 and	 vinyl	 ketone	 derivatives	 [69].	 However,	 these	 compounds	 displayed	 only	
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moderate	inhibition	of	Taspase	activity	with	an	IC50	of	30	µM	determined	for	the	best	compound	
yzm18.	
	
1.3.4.4 Enforced	dimerization	
Another	 way	 for	 Taspase	 inhibition	 exploits	 the	 quaternary	 structure	 by	 enforced	 protein	
interaction	(figure	1.11d),	as	suggested	by	Thiel	et	al.	[84].	Notably,	co‐expression	of	active	and	
inactive	Taspase	does	not	reduce	Taspase	activity,	indicating	that	catalysis	in	the	two	protomers	
of	the	hetero‐tetramer	is	independent	[85].	However,	Bier	and	colleagues	enforced	the	Taspase	
dimer	by	the	fusion	of	Jun‐	and	Fos‐tags	to	the	C‐terminus	of	Taspase	and	found	that	the	enforced	
dimer	was	catalytically	inactive	[68].	So	far,	Taspase	dimerization	was	only	artificially	achieved	by	
genetic	manipulation	and	no	chemical	dimerizers	for	Taspase	have	been	developed.	
	
In	 summary,	 all	 these	 studies	 failed	 to	 find	 a	 potent	 inhibitor	 for	 in	 vivo	 applications.	
Consequently,	novel	Taspase	inhibitors	are	still	urgently	needed.	
	
1.4 Nanoparticles	
Nanoparticles	 are	 solid	 particles	 with	 a	 size	 of	 roughly	 10‐100	 nm	 [86]	 and	 have	 gained	 in	
importance	during	the	last	decades.	These	particles	can	either	be	released	incidentally	(car	and	
industrial	exhausts,	volcanic	eruptions)	or	engineered	purposefully	[87].	The	latter	are	frequently	
prepared	either	by	dispersion	of	preformed	polymers	or	built	up	by	polymerization	of	monomers	
[88].	Important	parameters	of	nanoparticles	besides	size	include	the	material,	particle	shape,	zeta	
potential	(i.	e.	charge),	curvature,	hydrophilicity,	biodegradability,	and	surface	modifications	[89].	
The	surface‐to‐volume	ratio	of	spherical	particles	increases	with	decreasing	particle	diameter.	For	
example,	particles	of	50	nm	diameter	possess	a	surface	area	of	44	m2	per	gram.	As	a	consequence	
of	this,	materials	possess	different	properties	at	nanoscale	compared	to	the	bulk	material	and	are	
therefore	industrially	used	for	example	for	cosmetics	(e.	g.	sunscreen),	textiles	(e.	g.	self‐cleaning	
textiles)	as	well	as	computers	(e.	g.	nanotransistors).	
Nevertheless,	 the	 progressive	 usage	 of	 nanoparticles	 is	 controversially	 discussed,	 as	
nanoparticles	 taken	up	via	 the	skin,	 lung,	and	gut	are	distributed	by	the	bloodstream	 [90]	and	
possible	hazards	and	long‐term	influences	are	insufficiently	researched	[90].	Especially	the	long	
retention	half‐times	of	 inhaled	nanoparticles	 in	 the	alveolar	region	of	70	days	 in	rats	and	 two	
years	in	humans	[91]	pose	a	threat	to	cells,	since	nanoparticles	are	internalized	by	endocytosis	
[92].	Once	the	particles	are	inside	the	cell,	they	can	generate	reactive	oxygen	species	(ROS)	[93],	
disrupt	membranes	 [94],	 cause	protein	aggregation	 [95],	 interfere	with	 cellular	pathways	 [96],	
unfold	proteins	[97],	or	intercalate	into	DNA	[98].	
On	the	other	hand,	the	interaction	with	biomolecules	and	the	nano‐bio‐interface	is	of	high	interest	
for	 medical	 applications.	 In	 particular,	 the	 high	 free	 surface	 energy	 and	 therefore	 strong	
adsorption	of	biomolecules	is	exploited.	Hence,	nanoparticles	do	not	exist	as	bare	particles	in	a	
biological	environment,	but	are	covered	by	a	surface	layer	of	biomolecules,	which	is	named	the	
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corona	[99].	The	effect	of	this	corona	is	essential	for	biomedical	research	and	medicine	to	improve	
the	properties	of	pharmaceutical	drugs.	In	most	cases,	medicinal	applications	of	nanoparticles	aim	
at	 cancer	 treatment	 and	 improved	 drug	 delivery.	 Examples	 are	 (i)	 alginate	 coated	 chitosan	
nanoparticles,	which	enhance	the	oral	absorption	of	enoxaparin,	a	low	molecular	weight	heparin	
[100],	(ii)	specifically	designed	silica	particles	to	deliver	peptide	mimetics	to	transplanted	cells	
[101],	and	(iii)	recently	described	gold	nanorods	of	5‐15	nm	diameter	with	promising	results	in	
the	thermal	therapy	of	cancer	in	mice	[102].	
As	the	vasculature	of	tumors	is	usually	leaky,	nanoparticles	can	accumulate	in	tumors	due	to	a	
phenomenon	 termed	 enhanced	 permeability	 and	 retention	 (EPR)	 effect	 [103].	 Especially	 the	
accumulation	of	nanoparticles	in	solid	tumors	with	a	reduced	lymphatic	drainage	and	deficient	
vasculature	can	help	to	reverse	multidrug	resistance	due	to	an	improved	drug	delivery	to	cancer	
cells	 [104].	Recently,	also	L‐asparaginase	was	entrapped	in	hydrogel‐magnetic	nanoparticles	of	
30	nm	diameter	for	improved	bioavailability	and	cell	penetration	[105].	Moreover,	another	group	
showed	that	200	nm	silica	shells	can	be	used	to	overcome	allergic	reactions	against	asparaginase	
while	retaining	the	enzyme	activity	[106].	
Another	medical	application	for	nanoparticles	is	the	diagnosis	of	diseases	in	biochemical	assays.	
Recently,	 a	 gold	 nanoparticle‐based	 immunoassay	 was	 described	 to	 detect	 the	 Alzheimer’s	
disease	 related	β‐amyloid	peptide	 in	 cerebrospinal	 fluids	 [107].	 Even	 lung	 cancer	diagnosis	 in	
exhaled	 breath	 was	 reported.	 For	 this,	 chemiresistors	 (microsensors)	 based	 on	 5	 nm	 gold	
nanoparticles	covered	with	different	organic	substances	were	used	to	quantify	volatile	organic	
compounds	in	the	exhaled	breath	[108].	
The	 versatile	 applicability	 of	 nanoparticles	 furthermore	 allows	 the	 inhibition	 of	 enzymes,	 as	
shown	 for	 soybean	 peroxidase	 and	 chymotrypsin	 with	 carbon	 nanotubes	 [109].	 However,	
interactions	of	nanoparticles	with	Taspase	are	not	described	so	far.	
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1.5 Aims	of	this	thesis	
Although	the	survival	rates	 for	 leukemia	have	significantly	 improved	in	the	 last	decades	 [110],	
leukemias	still	account	 for	more	 than	one	 third	of	all	 cancer	deaths	 in	children	and	9	%	of	all	
cancer	deaths	[1].	Therefore,	new	anticancer	targets	are	of	high	interest,	as	they	allow	the	design	
of	novel	anticancer	drugs.	Recently,	the	non‐oncogene	addiction	protease	Taspase	has	moved	into	
focus	as	new	target	for	cancer	drugs,	since	Taspase	is	required	for	the	initiation	and	progression	
of	 certain	 types	 of	mixed	 lineage	 leukemia	 (MLL)	 and	 is	 upregulated	 in	 various	 solid	 tumors	
[71,76].	In	this	respect,	these	tumors	are	highly	dependent	on	Taspase	and	thus	hypersensitive	to	
a	loss	of	Taspase	activity	[76].	Despite	first	achievements	in	the	direction	of	Taspase	inhibitors,	
the	 compounds	originating	 from	 these	 studies	 exhibit	 either	weak	 inhibition	 [69,71]	 or	 broad	
bioactivities	[63].	Hence,	potent	Taspase	inhibitors	are	still	of	paramount	importance.	
To	develop	 novel	 Taspase	 inhibitors,	 a	 comprehensive	 analysis	 of	 the	 biochemical	 properties,	
such	as	activity,	substrate	specificity,	and	stability,	 is	helpful	and	can	give	deeper	 insights	 into	
Taspase‐mediated	catalysis.	To	this	end,	Taspase	as	well	as	active	and	inactive	mutants	will	be	
characterized.	Moreover,	 the	 structure	 of	 the	 long	 loop	 regions	 lacking	 in	 the	 Taspase	 crystal	
structure	will	 be	 assessed	by	nuclear	magnetic	 resonance	 (NMR)	 and	 circular	dichroism	 (CD)	
spectroscopy,	as	the	structure	of	the	loop	could	reveal	new	structural	targets	for	inhibitors.	The	
resulting	data	will	be	used	to	evaluate	Taspase	inhibitors	and	understand	their	mechanisms.	
	
To	obtain	novel	inhibitors,	three	approaches	will	be	employed:		
 Compounds	will	 be	 derived	 from	 virtual	 docking	 of	 a	 databank	 comprising	 12	million	
small	molecules.	
 Silica	based	nanoparticles,	which	were	recently	found	to	bind	proteins,	will	be	tested	for	
size	dependence	and	inhibition	mechanism.	
 Substrate	analog	succinimide	peptides	will	be	tested	and	optimized	in	cooperation	with	
the	Kaiser	group	for	chemical	biology.	
	
First,	the	inhibitors	will	be	tested	in	a	fluorogenic	in	vitro	assay	and	subsequently	in	vivo	using	cell	
lysates	and	a	cell‐based	activity	assay.	The	resulting	data	can	yield	both	novel	classes	of	Taspase	
inhibitors	and	assist	the	design	of	future	Taspase	inhibitors.	Additionally,	these	studies	could	shed	
light	on	the	catalytic	mechanism	and	might	contribute	to	understand	the	interaction	of	enzymes	
with	nanoparticles	in	general.	
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2 Material	and	Methods	
2.1 Material	
2.1.1 Chemicals	
All	chemicals	used	for	this	project	are	listed	in	table	2.1.	Names	can	differ	from	the	conventional	
names.	Some	names	are	trademarks	and	underlie	copyright	restrictions.	
	
Table	2.1	Chemicals	used.	
Name	(abbreviation)	 Supplier	
Acetic	acid		 Caldic,	Düsseldorf	
Acetonitrile	 Caldic,	Düsseldorf	
Adenosine‐5‐triphosphate	disodium	salt	(ATP) Roth,	Karlsruhe	
Agar		 Roth,	Karlsruhe	
Agarose		 Roth,	Karlsruhe	
15N	Ammonium	chloride	(15NH4Cl)	 Cambridge	Isotopes,	Andover
Ammonium	hydrogen	citrate	(DAC)	 Fluka,	Buchs	
Ammonium	peroxydisulfate	(APS)		 Roth,	Karlsruhe	
Ampicillin	sodium	salt	(Amp)		 Roth,	Karlsruhe	
Amsil8,	Amsil20,	Amsil125	 Nyacol,	Ashland	
Antifade	gold™	 Life	technologies,	Darmstadt
Antifoam™	 Sigma‐Aldrich,	Steinheim
Atto488	maleimide		 Attotec,	Siegen	
Atto594	NHS	ester		 Attotec,	Siegen	
Biotin		 AppliChem,	Darmstadt	
Boric	acid	(H3BO3)		 Roth,	Karlsruhe	
Bovine	serum	albumin	(BSA)		 NEB,	Ipswich	
Bromophenole	blue		 Roth,	Karlsruhe	
Buffer	green	DNA	polymerase	(10x)		 Thermo	Scientific,	Darmstadt
Buffer	green	restriction	enzymes	(10x)	 Fermentas,	St.	Leon‐Rot	
Calcium	chloride	dihydrate	(CaCl2)		 Roth,	Karlsruhe	
CasyTon	solution™	 OMNI	Life	Science,	Bremen
Chloramphenicol	(Cam)		 Roth,	Karlsruhe		
Cobalt(II)	chloride	hexahydrate	(CoCl2)	 Fluka,	Buchs		
cOmplete	protease	inhibitor™	 Roche,	Basel	
Coomassie	Brilliant	Blue	G250		 Fluka,	Buchs	
Copper(II)	chloride	(CuCl2)		 Sigma,	Steinheim	
Desoxyribonucleotide	triphosphates	(dNTPs)	 Metabion,	Martinsried		
Deuterium	oxide	(D2O)	99,9	%	 Sigma‐Aldrich,	Steinheim
Dihydroxyacetone	phosphate	lithium	salt	(DHAP)	 Sigma‐Aldrich,	Steinheim
2,2‐Dimethyl‐2‐silaptane‐5‐sulfonate	(DSS)	 Sigma‐Aldrich,	Steinheim
Dimethyl	sulfoxide	(DMSO)		 Roth,	Karlsruhe	
1,4‐Dithiothreitol	(DTT)		 Biomol,	Hamburg	
Dulbecco’s	Modified	Eagle’s	Medium	(DMEM)	 PAN‐Biotech,	Aidenbach	
Ethanol		 Caldic,	Düsseldorf	
Ethylendiamine	tetraacetic	acid	(EDTA)	disodium	salt Roth,	Karlsruhe		
Fetal	calf	serum	(FCS)	 PAN‐Biotech,	Aidenbach	
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Name	(abbreviation)	 Supplier	
Fmoc‐valine	 Novabiochem,	Darmstadt
Gel	Filtration	HMW	Calibration	Kit	 GE	Healthcare,	Solingen	
Gel	Filtration	LMW	Calibration	Kit	 GE	Healthcare,	Solingen	
D‐Glucose	 Roth,	Karlsruhe		
13C6	D‐Glucose		 Cambridge	Isotopes,	Andover
L‐Glutathione	reduced	(GSH)		 Roth,	Karlsruhe	
Glycerol		 Roth,	Karlsruhe		
Glycine		 AppliChem,	Darmstadt	
Hellmanex	II™	 Hellma	Analytics,	Müllheim
Hoechst	33258	 Life	technologies,	Darmstadt
Hydrochloric	acid	(HCl)		 AppliChem,	Darmstadt	
4‐(2‐Hydroxyethyl)piperazine‐1‐ethanesulfonic	acid	(HEPES) Roth,	Karlsruhe	
Imidazole		 Fluka,	Buchs	
Immersion	oil		 Roth,	Karlsruhe	
Iron(III)	citrate		 Sigma‐Aldrich,	Steinheim
Isopropanol		 Caldic, Düsseldorf	
Isopropyl‐β‐D‐thiogalactopyranoside	(IPTG)	 Applichem,	Darmstadt	
Kanamycin	sulfate	(Kan)		 Roth,	Karlsruhe		
Magnesium	chloride	(MgCl2)		 Roth,	Karlsruhe	
Magnesium	sulfate	(MgSO4)		 Fluka,	Buchs	
Manganese(II)	chloride	(MnCl2)		 Fluka,	Buchs	
Meat	extract		 Fluka,	Buchs	
2‐Mercaptoethanol		 Roth,	Karlsruhe	
Midori	Green™	 Nippon	Genetics,	Düren	
Minimum	Essential	Medium	(MEM;	1000x)	 PAN‐Biotech,	Aidenbach	
Nickel(II)	chloride	(NiCl2)		 Roth,	Karlsruhe	
Nicotineamide	adenine	dinucleotide	(NADH)	 Roth,	Karlsruhe	
Optimem	 Life	technologies,	Darmstadt
Orange	G	 Sigma‐Aldrich,	Steinheim
Paraformaldehyde	(PFA)	 Sigma‐Aldrich,	Steinheim
PCR	water		 Life	technologies,	Darmstadt	
Penicillin‐streptomycin		 Life	technologies,	Darmstadt
Peptone		 Fluka,	Buchs	
Phenylmethylsulfonyl	fluoride	(PMSF)	 Serva,	Heidelberg	
Phosphoenolpyruvic	acid	(PEP)		 Sigma‐Aldrich,	Steinheim
Potassium	chloride	(KCl)		 Roth,	Karlsruhe		
Potassium	dihydrogen	phosphate	(KH2PO4) Roth,	Karlsruhe		
Reaction	buffer	T4	ligase		 Metabion,	Martinsried	
Rotiphorese	Gel	30		 Roth,	Karlsruhe	
Rubidium	chloride	(RbCl2)		 Sigma‐Aldrich,	Steinheim
Sodium	chloride	(NaCl)		 Roth,	Karlsruhe		
Sodium	dihydrogen	phosphate	(NaH2PO4)	 Roth,	Karlsruhe	
Sodium	dodecyl	sulfate	(SDS)		 Roth,	Karlsruhe	
Sodium	hydroxide	(NaOH)		 Roth,	Karlsruhe	
Sodium	molybdate	(Na2MoO4)		 Roth,	Karlsruhe	
Sodium	selenite	(Na2SeO3)	 Fluka,	Buchs	
D‐Sucrose	 Roth,	Karlsruhe	
N,N,N',N'‐Tetramethylethylenediamine	(TEMED)	 Roth,	Karlsruhe	
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Name	(abbreviation)	 Supplier	
Thiamine	hydrochloride	(vitamin	B1)	 Merck,	Darmstadt	
Tricine		 Roth,	Karlsruhe	
Trifluoroacetic	acid	(TFA)	 Caldic,	Düsseldorf	
Tris(hydroxymethyl)aminomethane	(Tris)	 AppliChem,	Darmstadt	
Triton	X‐100		 AppliChem,	Darmstadt	
Trypsin‐EDTA	 PAN‐Biotech,	Aidenbach	
Tryptone		 Roth,	Karlsruhe	
Tween	20	 Roth,	Karlsruhe	
XtremeGene™	 Roche,	Basel	
Yeast	extract		 Roth,	Karlsruhe	
ZINC	database	compounds	 ChemDiv,	San	Diego	
Zinc	sulfate	(ZnSO4)		 Roth,	Karlsruhe	
	
2.1.2 Purchased	peptides	
Purchased	peptides	used	for	this	thesis	are	listed	in	table	2.3.	All	peptides	were	synthesized	by	
the	manufacturers	using	solid	phase	peptide	synthesis	and	purified	to	>	95	%	purity	using	high‐
pressure	liquid	chromatography	(HPLC).	
	
Table	2.2	Peptides	used.	
Sequence*	 Description Supplier	
[Mca]-GKGQVDGADDK-[DNP] CS1	Taspase	substrate China	Peptides,	Shanghai
[Abz]-KISQLDGVDDK-[DNP] CS2	Taspase	substrate CASLO	ApS,	Lyngby	
[Abz]-KISQLAAVDDK-[DNP] Mutated	Taspase	substrate CASLO	ApS,	Lyngby	
[Succ]-AAPF-[pNA] Chymotrypsin	substrate Bachem,	Bubendorf	
APPNIMTTRFSLAAFKRNKRKLELAERV
DTDFMQLKKRRQSS 
Short	Taspase	loop CASLO	ApS,	Lyngby	
*	[Mca]:	7‐amino‐4‐methylcoumarin;	[Dnp]:	dinitrophenol;	[Abz]:	anthranilic	acid;	[Succ]:	succinate;	[pNA]:	
p‐nitroaniline	
	
2.1.3 Buffers	and	media	
Buffers	and	media	used	for	this	thesis	are	 listed	in	table	2.3.	pH	values	were	adjusted	at	room	
temperature.	Media	were	autoclaved	for	sterilization.	
	
Table	2.3	Buffers	and	media	used.	
Solution	 Composition
Bradford	reagent	 5 %	ethanol,	10 %	H3PO4,	0.01 %	Coomassie	brilliant	blue	G250,	
ddH2O	
4x	Laemmli	stacking	gel	buffer	 500 mM	Tris/HCl	pH	6.8,	ddH2O
4x	Laemmli	separating	gel	buffer	 3 M	Tris/HCl	pH	8.8,	ddH2O
2x	Laemmli	sample	buffer	 125 mM	 Tris/HCl	 pH	 6.7,	 50 %	 glycerin,	 10	 %	 SDS,	 10 mM	
2‐mercaptoethanol,	0.01	%	bromophenole	blue,	ddH2O	
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Solution	 Composition
Laemmli	buffer	 0.1 %	SDS,	0.303 %	Tris,	1.441 %	glycine,	ddH2O	
Coomassie	staining	solution	 1.25 g	Coomassie	brilliant	blue	G250,	227	ml	ethanol,	46	ml	
acetic	acid,	227	ml	ddH2O	
Coomassie	destaining	solution	 50 ml	acetic	acid,	75 ml	ethanol,	875 ml	ddH2O	
PBS	 137 mM	NaCl,	2.7 mM	KCl,	10 mM	NaH2PO4,	2	mM	KH2PO4,	
ddH2O	
TBST	buffer	 50 mM	Tris‐HCl,	150 mM	NaCl,	1 %	Tween‐20,	ddH2O,	pH	7.5
TAE	buffer	 40 mM	Tris	pH 8.5,	1 mM	EDTA,	20 mM	acetic	acid,	ddH2O
Lysis	buffer	 25 mM	Tris	pH	7.4,	150 mM	KCl,	5 mM	MgCl2,	5	%	glycerol,	1 %	
Triton	X‐100,	2	mM	2‐mercaptoethanol,	1	mM	PMSF,	1	tablet	
cOmplete,	ddH2O	
GST	wash	buffer	 50 mM	NaH2PO4,	450 mM	NaCl,	1 mM	DTT,	1	%	Triton	X‐100,	
pH	7.3	
GST	elution	buffer	 50 mM	NaH2PO4,	450 mM	NaCl,	1 mM	DTT,	20	mM	glutathione,	
pH	8.0	
GST	equilibration	buffer	 50 mM	NaH2PO4,	450 mM	NaCl,	1 mM	DTT,	1	%	Triton	X‐100,	
pH	7.3	
NiNTA	equilibration	buffer	 50 mM	NaH2PO4, 450 mM	NaCl,	10 mM	imidazole,	pH	8.0	
NiNTA	wash	buffer	 50 mM	NaH2PO4,	450 mM	NaCl,	20 mM	imidazole,	pH	8.0	
NiNTA	elution	buffer	 50 mM	NaH2PO4,	450 mM	NaCl,	250 mM	imidazole,	pH	8.0
Gel	filtration	buffer	 50 mM	NaH2PO4,	450 mM	NaCl,	1 mM	DTT,	pH	7.9	
Activity	assay	buffer	 50 mM	NaH2PO4,	10 %	sucrose,	1 mM	DTT,	pH	7.9	
50x	TS2	 2.4 mM	ZnSO4,	0.15 mM	MnCl2,	4.9 mM	H3BO3,	0.84	mM	CoCl2,	
0.84	mM	NiCl2,	58	µM	CuCl2,	4.3	mM	Na2MoO4,	0.12	mM	Na2SeO4,	
ddH2O	
LB	medium	 1 %	tryptone,	0.5 %	yeast	extract,	1 %	NaCl,	ddH2O,	pH	7.0
LB	agar	plates	 500 ml	LB	medium,	7.5 g	agar
M9	medium	 0.68 %	Na2HPO4,	0.3 %	KH2PO4,	0.05 %	NaCl,	0.1	%	NH4Cl,	0.2 %	
1	M	MgSO4,	0.2	%	50x	TS2,	0.1	%	10	mM	iron(III)	citrate,	0.4	%	
glucose,	0.01	%	CaCl2,	0.01	%	0.5	%	vitamin	B1,	ddH2O	
Nutrient	medium	 0.5 %	peptone,	0.3 %	meat	extract,	ddH2O	
SOC	medium	 2 %	tryptone,	0.5 %	yeast	extract,	10 mM	NaCl,	2.5	mM	KCl,	
10	mM	MgCl2,	10	mM	MgSO4,	20	mM	glucose,	ddH2O	
Hela	medium	 10 %	FCS,	1 %	MEM,	1 %	penicillin‐streptomycin,	DMEM	
HCT116/HEK293T	medium	 10 %	FCS,	1 %	penicillin‐streptomycin,	DMEM	
	
2.1.4 Kits	
All	kits	used	are	listed	in	table	2.4.	
	
Table	2.4	Kits	used.	
Kit	 Supplier
Lightning	QC	site‐directed	mutagenesis	kit Agilent,	Santa	Clara
Nucleo	Spin	Plasmid	 Macherey	Nagel,	Düren	
Nucleo	Spin	Extract	II	kit	 Macherey	Nagel,	Düren	
Pierce	ECLplus	kit	 Thermo	Scientific,	Waltham	
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2.1.5 Instruments	
Instruments	and	devices	used	are	listed	in	table	2.5.	Standard	laboratory	equipment	is	not	listed.	
	
Table	2.5	Instruments	and	devices	used.	
Description	 Instrument Manufacturer	
Agarose	gel	analyzer	 BioDoc	Analyze Biometra,	Göttingen	
Casy	TT	 Cell	counter OMNI	Life	Science,	Bremen	
CD	spectrometer	 J‐710	CD	spectrometer Jasco,	Gross‐Umstadt	
Centrifuge	 Centrifuge	5415R Eppendorf,	Hamburg	
Cleanbench	 HERA	safe Thermo	Scientific,	Langenselbold
Cuvettes	 Quartz	cuvettes	(104‐QS,	108F‐
QS,	105.251‐QS,	110‐QS)	
Hellma	Analytics,	Müllheim	
Developer	for	films	 Cawomat	2000 Cawo,	Schrobenhausen	
DNA	gel	system	 Mini	Subcell	GT BioRad,	Berkeley	
Electroporation	cuvette	 Electroporation	cuvette,	0.2 cm BioRad,	Berkeley	
Electroporation	device MicroPulser BioRad,	Berkeley	
Fluorescence	microscope	 BX61	fluorescence	microscope Olympus,	Hamburg	
Fluorescence	spectrometer	 Cary	Eclipse Agilent	Technologies,	Waldbronn
FPLC	system	 BioRad	DuoFlow BioRad,	Berkeley	
FPLC	system	 Äkta	FPLC	P920 GE	Healthcare,	Solingen	
Incubator	 BD53	 Binder,	USA	
Incubator	 Thermomixer	HT Infors,	Bottmingen	
LC‐MS	ESI‐TOF	system LCQ	Fleet	ESI	spectrometer Thermo	Scientific,	Darmstadt
MALDI‐MS	system	 Autoflex	speed Bruker	Daltonics,	Bremen	
Microwave	 	 Sharp
MST	device	 Monolith	NT.115 NanoTemper,	Munich	
MST	device	(label	free) Monolith	NT.LabelFree NanoTemper,	Munich	
Nanodrop	 NanoDrop	ND	1000 Peqlab,	Erlangen	
NMR	spectrometer	 Ultrashield	700	NMR Bruker	BioSpin,	Fällanden	
PCR	cycler	 T	3000	thermocycler Biometra,	Göttingen	
pH	meter	 SevenEasy Mettler‐Toledo,	Gießen	
Photometer	 Bio	Photometer Eppendorf,	Hamburg	
Power	supply	 PowerPac	basic BioRad,	Berkeley	
Scanner	 Scanjet	8200 Hewlett	Packard,	China	
SDS	gel	shaker	 Duomax	1030 Heidolph,	Schwalbach	
SDS	gel	system	 XCell	Mini	Protean	3 BioRad,	Berkeley	
Thermomixer	 Thermomixer	comfort Eppendorf,	Hamburg	
Triggered	Fview	II	FW	
camera	
Fluorescence	microscopy	camera Olympus,	Hamburg	
Ultracentrifuge	 Optima	L‐90	K Beckmann,	Palo	Alto	
Ultrasound	device	 Sonopuls Bandelin,	Hamburg	
UV/Vis	spectrophotometer	 Cary	100 Agilent	Technologies,	Waldbronn
Water	filter	unit	 Milli‐Q	Biocel Millipore,	Schwalbach	
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2.1.6 Consumables	
Consumables	used	are	listed	in	table	2.6.	Standard	laboratory	equipment	is	not	listed.	
	
Table	2.6	Consumables	used.	
Description	 Name	 Supplier	
Cell	culture	dishes	 100x20 mm Greiner	Bio	One,	Solingen
Centricon	 Amicon	Ultra	concentrator Millipore,	Schwalbach	
Centricon	 Concentrator	5301 Eppendorf,	Hamburg	
Cover	slips	 15x15	mm Menzel,	Brunswick	
Desalting	tips	 Supel	Tips	C18 Sigma‐Aldrich,	Seelze	
Gel	filtration	column	 HiLoad	16/600	Superdex	200	pg GE	Healthcare,	Solingen	
Gel	filtration	column	 HiLoad	26/600	Superdex	200	pg GE	Healthcare,	Solingen	
Gel	filtration	column	 10/300	GL	Superdex	200	pg GE	Healthcare,	Solingen	
GST	column	 GSTrap	FF	16/10,	20 ml GE	Healthcare,	Solingen	
NiNTA	column	 Protino	NiNTA	Agarose Macherey	Nagel,	Düren	
MALDI	target	frame	 MTP	384	ground	steel Bruker	Daltonics,	Bremen
NAP	column	 PD‐10	gravity	flow	column GE	Healthcare,	Solingen	
Nitrocellulose	membrane	 Protran Whatman,	Dassl	
NMR	tubes	 AP5‐800‐7	NMR	tubes Schott	Economics,	Mainz
Object	slides	 Superfrost	Plus Thermo	Scientific,	Darmstadt
Sterile	filter	 0.22	µm Millipore,	Tullagreen	
X‐Ray	films	 CL‐Xposure	films Thermo	Scientific,	Darmstadt
	
2.1.7 Software	
Software	used	is	listed	in	table	2.7	
	
Table	2.7	Software	used.	
Software	 Application Reference	
CcpNmr	Analysis	2.3 Visualization,	editing and	evaluation	of	
NMR	spectra	
[111]
ACD/ChemSketch	
12.00	
Visualization	of	chemical	structures,	
calculation	of	logP	
Advanced	Chemistry	
Development,	Toronto	
Chimera	 Visualization	of	protein	structures,	
preparation	of	structures	for	docking	
[112]
ClustalO	 Sequence	alignments [113]
DOCK	6	 Virtual	docking [114]
Flex	Control	 MALDI	mass	spectra Bruker	Daltonics,	Bremen
GraphPad	Prism	5.04 Statistical	data	evaluation [115]
Image	J	1.47v	 Evaluation	of	microscopy	images [116]
NanoTemper	
analysis	software	
NanoTemper	analysis	software NanoTemper,	Munich	
OligoCalc	 Calculation	of	primer	properties [117]
CellP	 Florescence	microscopy	imaging Olympus,	Hamburg	
OPTIMIZER	 E.	coli	optimization	of	DNA	sequences [118]
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Software	 Application	 Reference	
Protparam	 Calculation	of	protein	properties [119]
PyMOL	1.4	 Visualization	of	protein	structures [120]
SIAS	 Calculation	of	sequence	homology [121]
SnapGene	Viewer	
2.2.2	
Visualization	of	plasmid	maps GSL	Biotech,	Chicago	
Spectra	Manager	2.0 Evaluation	of	CD	spectra Jasco,	Gross‐Umstadt	
Swiss‐Model	 Homology	modeling [122]
Topspin	3.0	 Recording	and	processing	of	NMR	spectra Bruker	Biospin,	Rheinstetten
YASARA	Twinset	
11.12.31	/	WHAT	IF	
Visualization	of	protein	structures,	MD	
simulations,	homology	modeling	
YASARA	Biosciences,	Vienna
	
2.1.8 Enzymes	and	antibodies	
Enzymes	and	antibodies	used	are	listed	in	table	2.8	and	were	stored	at	‐20	°C.	
	
Table	2.8	Enzymes	and	antibodies	used.	
Enzyme	 Supplier
ApaI	 Fermentas,	St.	Leon‐Rot	
Chymotrypsin	 Sigma‐Aldrich,	Steinheim	
DreamTaq	Green	DNA	polymerase	 Thermo	Scientific,	Darmstadt	
Lactic	dehydrogenase Sigma‐Aldrich,	Steinheim	
Lysozyme	 Fluka,	Buchs
Parvalbumin	 made	in‐house
PreScission	protease	 made	in‐house
Proteinase	K	 New	England	Biolabs
T4	ligase	 Metabion,	Martinsried
Trypsin	 Sigma‐Aldrich,	Steinheim	
XhoI	 Fermentas,	St.	Leon‐Rot	
Actin	(ACTB/ACTC)	polyclonal	antibody	(N‐term) Abgent,	Heidelberg
TASP1	monoclonal	antibody	 Origene,	Rockville
	
2.1.9 Bacterial	strains	
Bacterial	strains	used	for	plasmid	amplification	and	protein	expression	are	given	in	table	2.9.	
	
Table	2.9	Bacterial	strains	used.	
Strain	 Genotype	 Supplier	
E.	coli	ElectroSHOX	
competent	cells	
F‐	mcrA	Δ(mrr‐hsdRMS‐mcrBC)	ɸ80lacZ	
ΔM15	ΔlacX74	recA1	endA1	ara	Δ139	Δ(ara,	
leu)7697	galU	galK	‐	rpsL	(StrR)	nupG	λ‐	
Bioline,	Luckenwalde	
E.	coli	BL21(DE3)‐T1R F‐	ompT	hsdSB(rB‐ mB‐)	gal	dcm	λ(DE3)	tonA Sigma‐Aldrich,	Steinheim
E.	coli	C43	pLys	DE3	 F	–	ompT	hsdSB	(rB‐ mB‐)	gal	dcm	(DE3)	
pLysS	(CmR)	
Lucigen,	Heidelberg	
E.	coli	Rosetta2(DE3)	 F‐	ompT	hsdSB(rB‐ mB‐)	gal	dcm (DE3)	
pRARE2	(CamR)	
Merck,	Darmstadt	
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2.1.10 Plasmids	
Vector	maps	of	 the	plasmids	used	 in	 this	work	can	be	 found	 in	 the	supplement	(supplemental	
figure	 7.1	 and	 figure	 7.2).	 The	 plasmid	with	 human	 Taspase	 cDNA	 and	 Taspase	 plasmids	 for	
eukaryotic	transfection	were	courtesy	of	the	Knauer	group	and	the	pRARE2	plasmid	was	courtesy	
of	 the	 Ehrmann	 group.	 For	 cloning	 with	 GST	 tag,	 a	 modified	 pET‐41b(+)	 vector	 (Merck,	
Darmstadt)	was	used.	In	this	vector,	a	PreScission	cleavage	site	and	an	ApaI	cleavage	site	were	
inserted	in	the	multiple	cloning	site	after	the	GST	tag	between	the	BamHI	and	SacII	cleavage	sites.	
The	original	ApaI	cleavage	site	 in	 the	 lacI	 gene	was	mutated	(figure	2.1).	With	 this	vector,	 the	
target	protein	has	only	an	N‐terminal	Gly‐Pro	addition	after	PreScission	cleavage.	
	
	
Figure	2.1	Vector	map	of	the	modified	pET‐41b	vector.	
The	ApaI	restriction	site	(red)	was	mutated	and	a	PreScission	cleavage	site	was	inserted	between	the	SacII	
(green)	and	BamHI	(blue)	restriction	site.	The	inserted	sequence	is	shown	at	the	bottom.	
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2.1.11 Protein	and	DNA	marker	
PageRuler	Unstained	Broad	Range	Protein	Ladder	(Thermo	Scientific;	figure	2.2a)	and	PageRuler	
Plus	Prestained	Protein	Ladder	(Metabion;	figure	2.2b)	were	used	as	protein	markers.	mi‐100	bp+	
DNA	marker	Go	(Metabion;	figure	2.2c)	and	mi‐1	kb(‐)	DNA	Marker	Go	(Metabion;	figure	2.2)	were	
used	as	DNA	marker.	
	
	
Figure	2.2	Protein	and	DNA	marker.	
a	PageRuler	Unstained	Broad	Range	Protein	Ladder	 for	SDS‐PAGE.	b	PageRuler	Plus	Prestained	Protein	
Ladder	for	SDS‐PAGE.	c	mi‐100	bp+	DNA	marker	Go	for	agarose	gel	electrophoresis.	d	mi‐1	kb(‐)	DNA	Marker	Go	
for	agarose	gel	electrophoresis.	
	
2.2 Molecular	biological	methods	
2.2.1 Cloning	of	active	Taspase	and	the	inactive	mutant	
The	nucleotide	sequence	of	the	bicistronic	construct	referred	to	as	active	Taspase	was	designed	
in	silico	based	on	the	construct	described	by	Khan	et	al.	[56].	The	expression	construct	comprises	
the	 α‐subunit	 with	 an	 N‐terminal	 hexahistidine	 tag,	 followed	 by	 a	 stop	 codon	 and	 a	 second	
ribosomal	binding	site	for	the	β‐subunit	following	downstream	(figure	2.3).	The	unstructured	loop	
at	the	C‐terminus	of	the	α‐subunit	was	shortened	by	27	amino	acids,	ending	at	Ala	206.	The	codon	
usage	of	the	whole	sequence	was	optimized	for	expression	in	E.	coli	using	OPTIMIZER	[118].	The	
gene	was	synthesized	and	cloned	into	a	modified	pET‐41b	vector	described	in	figure	2.1	(GeneArt,	
Regensburg).	
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Figure	2.3	Construct	for	active	Taspase.	
The	construct	comprises	an	N‐terminal	His‐tag,	followed	by	the	shortened	α‐subunit	(amino	acids	1‐206)	
and	a	stop	codon.	After	a	short	linker	sequence,	the	ribosomal	binding	site	(RBS)	enables	the	transcription	
of	the	β‐subunit	(amino	acids	234‐420).	This	construct	was	cloned	in	a	modified	pET‐41b	vector.	
	
The	inactive	mutant	is	based	on	the	wild	type	construct	of	human	Taspase	cDNA	in	a	pET‐22b	
vector	with	N‐terminal	hexahistidine	tag	generated	by	Jens	Rabenstein	[82].	Two	mutations	in	the	
active	 site	 (D233A	 and	 T234A)	 prevent	 autocatalytic	 activation	 of	 the	 proenzyme	 and	 hence	
reduce	 catalytic	 activity.	 These	 mutations	 were	 inserted	 with	 the	 help	 of	 a	 QuikChange	 kit	
(Agilent,	 Santa	 Clara)	 using	 wild	 type	 Taspase	 as	 template.	 Primers	 were	 designed	 with	
NEBaseChanger	 (NEB,	 Ipswich;	 table	 2.10),	 synthesized	 (Metabion,	Martinsried)	 and	 used	 for	
QuikChange	according	to	the	manufacturer’s	protocol	(table	2.11)	with	a	PCR	program	described	
in	table	2.12.	
	
Table	2.10	Primers	used	to	generate	the	inactive	Taspase	mutant.	
Substituted	bases	are	highlighted	in	yellow.	
Primer	 Sequence
Forward	 5’-CTCAGGCACTTTGGCGGCGGTAGGCGCTGTGG-3’ 
Reverse	 5’-CCACAGCGCCTACCGCCGCCAAAGTGCCTGAG-3’ 
	
Table	2.11	PCR	components	to	generate	the	inactive	Taspase	mutant.	
Component	 Amount	[µl]
10x	buffer	 2.5	
Wild	type	Taspase	(template)	 1	(=100	pg)
Forward	primer	 0.6	(=125	ng)
Reverse	primer	 0.6	(=125	ng)
dNTP	mix	 0.5	(=0.5	mM)
QuikChange	reagent	 0.75
DNA	polymerase	 0.5	
PCR	water	 19.2
	
Table	2.12	PCR	program	to	generate	the	inactive	Taspase	mutant.	
Temperature	[°	C]	 Time	[min]	 Number	of	cycles
95	 2:00	 1
95	 0:20	
25	68	 0:10	
68	 4:00	
68	 5:00	 1
37	 ∞	
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The	PCR	product	was	treated	with	1	µl	DpnI	for	20	minutes	at	37	°C	to	digest	template	DNA	and	
then	transformed	into	competent	E.	coli	shox	cells	(section	2.3.2).	Three	clones	were	selected	for	
DNA	isolation	using	the	MiniPrep	kit	(Macherey	Nagel,	Düren)	according	to	the	manufacturer’s	
instructions	and	the	construct	was	sequenced	(GATC	Biotech,	Cologne)	to	verify	the	correct	DNA	
sequence	(supplemental	figure	7.1b).	Permanent	plasmid	stocks	in	shox	cells	were	obtained	by	
mixing	600	µl	of	an	overnight	culture	with	400	µl	of	sterile	86	%	glycerol.	The	stock	solution	was	
shock	frozen	and	stored	at	‐80	°C.	
	
2.2.2 Cloning	of	the	Taspase	loop	
The	 construct	 for	 the	 GST‐tagged	 Taspase	 loop	 comprising	 56	 amino	 acids	 (G178‐D233)	was	
generated	 by	 amplification	 of	 the	 loop	 sequence	 using	 wild	 type	 Taspase	 as	 template	 and	
subsequently	cloned	into	a	modified	pET‐41	vector	with	N‐terminal	GST	tag	(supplemental	figure	
7.3	and	figure	2.1).	
	
PCR	amplification	of	the	insert:	
For	PCR,	 the	primer	pair	 listed	 in	 table	2.13	was	used	with	 the	plasmid	 for	wild	 type	Taspase	
(supplemental	figure	7.1a	and	figure	2.1)	as	template.	The	pipetting	scheme	and	PCR	program	are	
listed	in	table	2.16	and	table	2.17,	respectively.	After	amplification,	a	1.3	%	agarose	gel	was	used	
to	verify	the	correct	size	of	 the	 fragment	and	the	DNA	was	extracted	using	a	gel	extraction	kit	
(Macherey	Nagel,	Düren)	according	to	the	manufacturer’s	instructions.	
	
Table	2.13	PCR	primers	used	to	generate	the	Taspase	loop.	
Primer	 Sequence Tm	[°C]	
Forward	 5’-CACACAGGGCCCGGAATACCGTCTTGCCCTCC-3’ 59.5 
Reverse	 5’-GGTTGGCTCGAGCTTAGTCCAAAGTGCCTGAGTCGTTC-3’ 61.2 
	
Restriction	and	ligation:	
Both	the	amplified	Taspase	loop	and	the	target	vector	pET‐41‐PreSc	were	digested	with	ApaI	and	
XhoI	for	30	minutes	at	room	temperature	(table	2.14).	
	
Table	2.14	ApaI/XhoI	restriction	assay.	
Component	 Vector	[µl] Insert	[µl]
pET‐41‐PreSc	DNA	 2	(=300 ng) ‐
Loop	DNA	 ‐	 8	(=2 µg)
ApaI	 1	(=1 FDU) 1	(=1 FDU)
XhoI	 1	(=1 FDU) 1	(=1 FDU)
10x	buffer	 3	 5
PCR	water	 23	 35
	
After	DNA	cleanup	(Macherey	Nagel,	Düren),	vector	and	insert	were	mixed	in	a	molar	ratio	of	1:3	
and	ligated	for	1	h	at	16	°C	(table	2.15).	
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Table	2.15	Ligation	of	the	Taspase	loop	and	pET‐41‐PreSc.	
Component	 Vector	[µl]
pET‐41b	DNA	 1.26	(=50 ng)
Loop	DNA	 0.95	(=4.33 ng)
T4	ligase	 0.5	(=125 U)
10x	buffer	 2	
PCR	water	 15.3
	
Subsequently,	1	µl	of	the	ligated	DNA	was	used	for	transformation	into	electrocompetent	E.	coli	
shox	cells	and	the	cells	were	plated	on	LB	medium	with	kanamycin.	
	
Table	2.16	PCR	components	to	amplify	the	Taspase	loop.	
Component	 Amount	[µl]
Wild	type	Taspase	(template)	 0.5	(=10	ng)
10x	buffer	 5	
Forward	primer	 5	(=50	pg)
Reverse	primer	 5	(=50	pg)
dNTP	mix	 2.5	(=0.5 mM)
DMSO	 0.5	(=1 %)
DNA	polymerase	 1	(=5 U)
PCR	water	 30.5
	
Colony	PCR:	
Ten	colonies	were	tested	for	loop	DNA	employing	a	colony	PCR	(table	2.18)	with	the	same	PCR	
program	used	for	the	amplification	of	the	loop	(table	2.17).	
	
Table	2.17	PCR	program	used	to	amplify	the	Taspase	loop.	
Temperature	[°	C]	 Time	[min]	 Number	of	cycles
95	 0:30	 1
95	 0:30	
56	 0:30	 3
72	 0:30	
95	 0:30	
58	 0:30	 32
72	 0:30	
72	 10:00	 1
4	 ∞	
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Table	2.18	Colony	PCR	components	to	amplify	the	Taspase	loop.	
Component	 Amount	[µl]
Cell	suspension	(template)	 10	
10x	buffer	 4	
Forward	primer	 2	(=20 pg)
Reverse	primer	 2	(=20 pg)
dNTP	mix	 1	(10 mM)
DNA	polymerase	 0.5	(2.5 U)
PCR	water	 20	
	
The	plasmids	of	 clones	with	 correct	 size	were	 isolated	using	 a	MiniPrep	 kit	 (Macherey	Nagel,	
Düren)	and	verified	by	sequencing.	
	
2.3 Microbiological	methods	
2.3.1 Preparation	of	competent	cells	
Competent	cells	were	courtesy	of	other	group	members.	For	the	preparation	of	electrocompetent	
cells,	500	ml	nutrient	medium	were	 inoculated	with	1	%	of	 an	overnight	 culture	of	 shox	cells	
(Bioline,	Luckenwalde)	and	cultivated	to	an	OD600	of	0.8	at	37	°C	and	160	rpm.	The	cells	were	
cooled	down	on	ice	for	15	minutes	and	pelleted	at	4000	g	for	15	minutes	at	4	°C.	The	pellet	was	
resuspended	in	500	ml	cold	ddH2O	and	centrifuged	again.	The	pellet	was	washed	once	more	by	
resuspension	in	250	ml	cold	ddH2O	and	centrifugation,	afterwards	resuspended	in	20	ml	10	%	
glycerol,	centrifuged	and	finally	resuspended	in	0.5	ml	10	%	glycerol.	50	µl	aliquots	were	shock	
frozen	in	liquid	nitrogen	and	stored	at	‐80	°C.	
Chemically	 competent	 BL21(DE3)T1r	 cells	 were	 generated	 starting	 from	 200	ml	 LB	medium	
inoculated	with	2	ml	of	an	antibiotic‐free	overnight	culture	(160	rpm,	37	°C).	At	an	OD600	of	0.6,	
cells	were	pelleted	for	5	minutes	at	3000	rpm,	4	°C	(slow	start	and	stop)	and	resuspended	in	45	ml	
cold	0.5	M	CaCl2	solution.	After	incubation	on	ice	for	30	minutes,	cells	were	pelleted	again	and	
resuspended	in	2	ml	0.5	M	CaCl2	solution.	50	µl	aliquots	were	shock	frozen	and	stored	at	‐80	°C.	
	
2.3.2 Transformation	of	competent	cells	
Electrocompetent	cells	were	incubated	on	ice	with	1	µl	of	the	PCR	product	and	electroporated	
subsequently	with	 the	respective	bacterial	program	in	a	MicroPulser	(BioRad,	Berkeley).	After	
incubation	for	60	minutes	in	300	µl	SOC	medium	at	37	°C	and	400	rpm,	cells	were	plated	on	LB	
agar	dishes	containing	respective	antibiotics	and	incubated	over	night	at	37	°C.	
Chemically	 competent	 cells	 were	 incubated	with	 1	 µl	 of	 plasmid	 DNA	 for	 20	minutes	 on	 ice,	
followed	by	a	heat	shock	at	42	°C	for	45	seconds	and	another	incubation	step	on	ice	for	2	minutes.	
After	that,	the	cells	were	transferred	to	300	µl	of	SOC	medium	and	incubated	for	60	minutes	at	
37	 °C	 and	 400	 rpm.	 Subsequently,	 the	 cells	 were	 plated	 on	 LB	 agar	 dishes	 with	 respective	
antibiotics	and	incubated	at	37	°C	over	night.	
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2.3.3 Expression	test	
To	find	optimal	conditions	for	the	expression	and	solubility	of	the	different	Taspase	constructs,	
their	expression	was	assayed	after	various	 times	and	at	various	 temperatures.	The	expression	
plasmid	was	transformed	into	chemically	competent	E.	coli	BL21(DE3)T1r	cells	and	grown	over	
night.	For	wild	type	Taspase,	the	E.	coli	strain	Rosetta2,	which	is	designed	to	express	eukaryotic	
proteins	with	codons	rarely	used	in	E.	coli,	was	tested	in	addition	to	the	BL21(DE3)T1r	strain.	
1.5	%	of	an	LB	overnight	 culture	of	 transformed	bacteria	was	used	 to	 inoculate	100	ml	of	TB	
medium.	At	an	OD600	of	0.8,	200	µM	IPTG	was	added	and	the	cell	suspension	was	split	up	to	allow	
expression	at	different	temperatures.	Before	induction	and	at	defined	times	after	induction,	10	ml	
samples	were	taken	from	the	cell	suspensions,	pelleted	(4000	g,	4	°C,	20	min)	and	frozen.	The	
pellets	 were	 resuspended	 in	 50	 mM	 NaH2PO4,	 450	 mM	 NaCl,	 10	 mM	 imidazole,	 pH	 8.0	
(supplemented	with	1	%	Triton	X‐100	 for	 the	Taspase	 loop),	 lysed	by	 sonification	 (3	 cycles	 à	
30	seconds	at	30	%	intensity)	and	insoluble	cell	 fragments	were	removed	at	14000	rpm,	4	°C,	
90	min.	The	supernatant	was	collected	and	the	pellets	were	resuspended	in	500	µl	buffer	(50	mM	
NaH2PO4,	450	mM	NaCl,	10	mM	imidazole,	pH	8.0).	For	SDS‐PAGE,	20	µl	of	supernatant	or	pellet	
solution	were	added	to	20	µl	of	2x	SDS	sample	buffer.	
	
2.3.4 Expression	of	Taspase	constructs	
The	plasmids	containing	the	sequence	for	Taspase	(sections	2.2.1	and	2.2.2)	were	transformed	
into	competent	expression	strains	of	E.	coli.	For	active	Taspase,	the	pET‐41b	plasmid	encoding	the	
active	Taspase	was	transformed	into	the	C43(DE3)pLysS	strain	as	described	above	(section	2.3.2).	
Cells	were	plated	on	LB	medium	with	60	µg/ml	kanamycin	and	50	µg/ml	chloramphenicol.	After	
incubation	over	night	 at	 37	 °C,	 a	 single	 clone	was	used	 to	 inoculate	 an	overnight	 culture	 (see	
below).	
The	sequences	coding	for	wild	type	Taspase,	inactive	Taspase	and	the	Taspase	loop	were	based	
on	human	cDNA	and	therefore	not	optimized	for	expression	in	E.	coli.	To	overcome	this,	1	µl	of	a	
pRARE2	plasmid	(Merck,	Darmstadt)	containing	the	tRNA	for	codons	rarely	used	by	E.	coli	was	
co‐transformed	 additionally	 to	 the	 Taspase	 construct	 (in	 pET‐22b	 vector)	 into	BL21(DE3)T1r	
chemically	competent	cells	(section	2.3.2).	Plating	on	LB	medium	with	140	µg/ml	ampicillin	and	
50	 µg/ml	 chloramphenicol	 allowed	 for	 selection	 of	 cells	 that	 had	 taken	 up	 both	 the	 Taspase	
plasmid	 (with	 ampicillin	 resistance	 gene)	 and	 the	 pRARE2	 plasmid	 (with	 chloramphenicol	
resistance	gene).	
Overnight	cultures	were	grown	in	LB	medium	with	respective	antibiotics.	4	 l	TB	medium	with	
antibiotics	were	inoculated	with	15	ml	overnight	culture	per	liter	of	medium	and	bacteria	were	
grown	at	37	°C	and	160	rpm.	Growth	of	bacteria	was	monitored	by	measuring	the	optical	density	
at	600	nm	wavelength.	
For	NMR	spectroscopy,	15N	or	15N/13C	labeled	protein	was	used.	To	achieve	expression	of	isotopic	
labeled	protein,	 first,	1	 l	of	LB	medium	was	 inoculated	with	15	ml	of	an	overnight	culture	and	
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grown	at	37	°C,	160	rpm	until	the	OD600	reached	0.7.	Cells	were	pelleted	gently	(20	°C,	3000	rpm,	
15	 min)	 and	 resuspended	 in	 4	 l	 of	 M9	 minimal	 medium	 supplemented	 with	 15N	 ammonium	
chloride	and/or	13C	glucose.	Bacterial	growth	was	allowed	to	continue	at	37	°C,	160	rpm.	
For	 both	 labeled	 and	 unlabeled	 Taspase	 protein	 expression,	 at	 OD600	 of	 0.8,	 expression	 was	
induced	by	addition	of	200	µM	IPTG	and	the	temperature	was	reduced	to	30	°C.	6	h	after	induction,	
cells	were	pelleted	at	4	°C,	6300	g	for	20	minutes	and	resuspended	in	50	mM	NaH2PO4,	450	mM	
NaCl,	 10	mM	 imidazole,	 pH	8.0.	 The	Taspase	 loop	was	 expressed	 over	 night	 at	 25	 °C	 and	 the	
bacteria	pellet	was	resuspended	in	50	mM	NaH2PO4,	450	mM	NaCl,	1	mM	DTT,	1	%	Triton	X‐100,	
pH	 7.0.	 Cell	 pellets	 were	 shock	 frozen	 in	 liquid	 nitrogen	 and	 stored	 at	 ‐20	 °C	 until	 used	 for	
purification.	
	
2.3.5 Cultivation	of	eukaryotic	cell	lines	
Cervical	 cancer	 cells	 (Hela)	were	 cultivated,	 cryopreserved	 and	 passaged	 as	 suggested	 by	 the	
American	Type	Culture	Collection	(ATCC):	Cells	were	cultivated	in	10	cm	dishes	with	10	ml	cell	
culture	medium	and	split	at	70	to	90	%	confluency.	For	this,	cells	were	washed	with	PBS,	before	
1	ml	 of	 trypsin‐EDTA	was	 added	 and	 the	 cells	were	 incubated	 for	 5	minutes	 to	 detach.	 9	ml	
prewarmed	medium	was	added	and	cells	were	dispersed,	prior	to	seeding	in	a	split	ratio	of	1:5	to	
1:25	in	fresh	medium.	Medium	was	changed	as	needed.	For	cryopreservation,	2x106	cells/ml	were	
centrifuged	 gently	 (3	min,	 300	 g,	 25	 °C)	 and	 resuspended	 in	 freeze	medium	 containing	 10	%	
DMSO.	Aliquots	of	1	ml	were	placed	in	a	controlled‐rate	freezer	precooled	to	4	°C	and	cooled	down	
to	‐70	°C	with	a	rate	of	‐1	°C	per	minute.	For	long‐term	storage,	cells	were	transferred	to	a	‐130	°C	
freezer.	Recovery	of	cryopreserved	cells	was	performed	by	rapid	thawing	to	37	°C,	followed	by	
addition	of	1	ml	fresh	medium	and	gentle	centrifugation	(3	min,	300	g,	25	°C).	The	supernatant	
was	discarded,	cells	were	resuspended	in	10	ml	of	their	respective	medium	and	transferred	into	
10	cm	dishes.	Medium	was	changed	the	next	day.	
	
2.3.6 Transfection	of	eukaryotic	cells	and	preparation	for	microscopy	
Transfection	was	performed	in	12	well	plates	with	cover	slips	one	day	after	seeding	2x105	cells	
per	well.	Cells	were	counted	in	a	Casy	TT	(OMNI	Life	Science	,	Bremen)	calibrated	individually	for	
Hela	and	HEK293T	cells.	Trypsin‐EDTA	was	used	to	detach	the	cells,	before	they	were	dispersed	
in	 9	ml	 culture	medium.	 50	 µl	 of	 cells	were	 diluted	 in	 10	ml	 of	 CasyTon	 solution	 (OMNI	 Life	
Science)	and	only	counts	with	more	than	3000	events	were	regarded	as	valid.	1	µg	DNA	was	mixed	
with	3	µl	XtremeGene	Transfection	reagent	in	100	µl	Optimem	(Life	technologies)	medium	and	
incubated	for	15	minutes	at	room	temperature.	This	solution	was	added	to	the	cells	with	900	µl	
of	their	medium.	If	needed,	nanoparticles	were	added	3	hours	after	transfection.	
One	day	after	transfection,	cells	were	washed	with	PBS	and	500	µl	of	3.7	%	PFA	with	0.1	%	Tween	
was	added	for	fixation.	After	incubation	for	20	minutes	at	4	°C,	cells	were	washed	twice	with	PBS	
and	1	µg/ml	Hoechst	33258	in	PBS	was	added	for	5	minutes	to	stain	the	nuclei.	Subsequently,	the	
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cells	were	washed	 first	with	PBS	 and	 then	with	water.	 10	 µl	Antifade	 gold	 (Life	 technologies,	
Darmstadt)	was	spotted	on	a	microscope	slide,	on	which	the	cover	slip	was	placed.	
	 	
2.3.7 Fluorescence	microscopy	and	image	evaluation	
After	the	Antifade	gold	solution	had	dried	over	night,	fluorescence	microscopy	images	were	taken	
with	an	Olympus	BX61	fluorescence	microscope	equipped	with	a	triggered	Fview	II	FW	camera.	
The	 microscope	 was	 operated	 by	 the	 Olympus	 CellP	 software.	 Exposure	 times	 for	 Hoechst,	
Taspase‐mCherry,	Taspase‐GFP,	Substrate‐mCherry	and	Substrate‐GFP	are	listed	in	table	2.19.	
	
Table	2.19	Channel	settings	used	for	fluorescence	microscopy.	
Channel	 Excitation	
wavelength	
Emission	
wavelength	
Exposure	
time	
Hoechst	 345	nm	 455 nm 25 ms
GFP	 480	nm	 510 nm 500 ms
mCherry	 545	nm	 610 nm 500 ms
	
Images	were	processed	with	ImageJ	[116]	and	comprised	the	following	steps.	First,	cell	borders	
were	identified	with	the	help	of	bright‐field	and	autofluorescence.	Second,	nuclei	were	defined	
using	 the	 DAPI	 channel.	 The	 area	 of	 the	 cell	 borders	 minus	 the	 nucleic	 area	 was	 defined	 as	
cytoplasm.	The	average	intensities	of	the	nucleic	and	cytoplasmic	areas	were	calculated,	and	the	
ratio	 of	 nucleus	 to	 cytoplasm	 (N/C)	 was	 computed.	 Statistical	 evaluation	 of	 these	 ratios	 was	
executed	in	GraphPad	Prism	5.03	[115].	An	unpaired	two‐tailed	student’s	t‐test	was	applied.	p‐
values	below	0.05	were	regarded	as	significant,	values	below	0.001	as	highly	significant.	
	
2.3.8 Cell	penetration	assays	with	peptidic	inhibitor	
Uptake	 of	 rhodamine‐labeled	 peptidic	 inhibitor	 was	 assayed	 with	 Hela	 cells.	 5	 µM	 or	 50	 µM	
fluorescent	inhibitor	were	added	to	2x105	cells	in	12	well	plates.	Cells	were	either	cultivated	in	
medium	 with	 or	 without	 serum	 and	 fixated	 1	 or	 5	 hours	 after	 addition	 of	 the	 inhibitor.	
Fluorescence	microscopy	 images	were	 taken	as	described	above	 (section	2.3.7)	using	 the	RFP	
channel	 and	 the	 fluorescence	 intensity	 of	 the	 cells	 was	 compared	 to	 the	 autofluorescence	 of	
untreated	cells	using	ImageJ.	For	statistical	evaluation,	an	unpaired	two‐tailed	student’s	t‐test	was	
applied	using	GraphPad	Prism.	
2.4 	Biochemical	methods	
2.4.1 Bacterial	cell	lysis	
Bacterial	pellets	were	thawed	rapidly	in	a	water	bath	and	1	mM	of	the	protease	inhibitor	PMSF	
was	added,	as	well	as	a	spatula	tip	of	lysozyme	and	0.001	%	antifoam.	After	stirring	for	60	minutes	
at	 4	 °C,	 cells	 were	 lysed	 by	 sonification.	 For	 this,	 the	 cell	 suspension	 underwent	 3	 pulses	 of	
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sonification	(30	seconds	each,	60	%	intensity)	on	ice	with	1	minute	intervals	to	avoid	excessive	
heat.	Cell	fragments	and	insoluble	proteins	were	pelleted	by	ultracentrifugation	for	70	minutes	at	
142000	g,	4	°C	and	the	supernatant	was	collected.	After	filtration	through	a	0.22	µm	filter,	 the	
volume	was	adjusted	to	150	ml	and	loaded	into	a	Superloop	(GE	Healthcare,	Solingen).	
	
2.4.2 Protein	purification	of	His‐tagged	Taspase	
Affinity	 chromatography	was	 performed	with	 an	Äkta‐FPLC	 system	 (GE	Healthcare,	 Solingen)	
using	 a	 HisTrap	 HP	 5	ml	 NiNTA	 column	 (GE	 Healthcare)	 equilibrated	 with	 50	mM	 NaH2PO4,	
450	mM	NaCl,	10	mM	imidazole,	pH	8.0.	The	detailed	buffers,	volumes	and	flow	rates	used	for	
affinity	purification	are	listed	in	table	2.20.	In	short,	the	His‐tagged	protein	was	allowed	to	bind	to	
the	column	matrix,	before	non‐target	proteins	were	washed	away.	For	elution,	the	concentration	
of	imidazole	was	gradually	increased	to	a	maximum	of	250	mM	imidazole.	
	
Table	2.20	Program	used	for	NiNTA	affinity	purification	with	a	HisTrap	HP	5	ml	NiNTA	column.	
Step	 Buffer	 Volume Flow	rate	 Size	of	
collected	
fractions	
Equilibration	 NiNTA	equilibration	
buffer	
25 ml 1.5 ml/ml	 ‐	
Application	of	
supernatant	
Supernatant	
(in	NiNTA	
equilibration	buffer)	
150 ml 1 ml/min	 ‐	
Wash	 NiNTA	wash	buffer	 50 ml 1 ml/min	 ‐	
Elution	
gradient	
Gradient	from	NiNTA	
wash	buffer	to	NiNTA	
elution	buffer	
100 ml 1 ml/min	 3	ml	
Final	elution	 NiNTA	elution	buffer 20 ml 1 ml/min	 5	ml	
	
Elution	fractions	containing	protein	were	identified	via	absorbance	at	280	nm	and	the	correct	size	
of	the	protein	was	checked	by	SDS‐PAGE.	For	this	purpose,	20	µl	of	an	elution	fraction	was	added	
to	20	µl	of	2x	SDS	sample	buffer	and	separated	in	a	15	%	SDS	gel.	All	fractions	containing	Taspase	
were	concentrated	in	a	Centricon	with	30	kDa	cut‐off	to	a	volume	of	2	ml	and	used	for	gel	filtration.	
Preparative	gel	filtrations	were	performed	on	an	Äkta	FPLC	system	with	a	Superdex	200	HiLoad	
16/600	gel	filtration	column	(GE	Healthcare)	to	remove	soluble	aggregates	and	imidazole.	The	gel	
filtration	buffer	contained	50	mM	NaH2PO4,	450	mM	NaCl,	1	mM	DTT	at	pH	7.7.	Flow	rates	and	
fraction	sizes	used	in	the	program	are	listed	in	table	2.21.	The	eluted	protein	was	concentrated	in	
Centricons	with	30	kDa	cut‐off,	aliquots	were	shock	frozen	in	liquid	nitrogen	and	stored	at	‐20	°C.	
	
Table	2.21	Program	used	for	gel	filtration	with	a	Superdex	200	16/600	gel	filtration	column.	
Step	 Buffer	 Volume Flow	rate	 Size	of	
collected	
fractions	
Equilibration	 Gel	filtration	buffer	 130 ml 1.5 ml/ml	 ‐	
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Sample	
injection	
Concentrated	Taspase
(in	50	mM	NaH2PO4	
450	mM	NaCl	
~125	mM	imidazole	
pH	8.0)	
5 ml 1 ml/min	 ‐	
Elution	 Gel	filtration	buffer	 130 ml 1 ml/min	 3	ml	
	
2.4.3 Protein	purification	of	the	GST‐tagged	Taspase	loop	
A	20	ml	GSTrap	column	(GE	Healthcare,	Solingen)	was	equilibrated	with	an	Äkta‐FPLC	system	(GE	
Healthcare)	with	50	mM	NaH2PO4,	450	mM	NaCl,	1	mM	DTT,	1	%	Triton	X‐100,	pH	7.0,	before	the	
GST‐tagged	Taspase	 loop	was	bound,	washed	and	eluted	with	glutathione	buffer.	The	detailed	
buffers,	volumes	and	flow	rates	are	listed	in	table	2.22.	
	
Table	2.22	Program	used	for	GST	affinity	purification	with	a	20	ml	GSTrap	column.	
Step	 Buffer	 Volume Flow	rate Size	of	collected	
fractions	
Equilibration	 GST	equilibration	
buffer	
100 ml 1.5 ml/ml ‐
Application	 of	
supernatant	
Supernatant	
(in	GST	equilibration	
buffer)	
150 ml 1 ml/min ‐
Wash	 GST	wash	buffer	 100 ml 1 ml/min ‐
Elution		 GST	elution	buffer	 100 ml 1 ml/min 3 ml	
	
Although	the	Taspase	loop	itself	does	not	absorb	light	at	280	nm	due	to	its	lack	of	tyrosines	and	
tryptophans,	 the	absorbance	of	 the	GST	 tag	 can	be	used	 to	 identify	protein	 containing	elution	
fractions.	These	fractions	were	concentrated	in	a	Centricon	with	10	kDa	cut‐off	to	a	final	volume	
of	5	ml.	Protein	concentration	was	determined	using	UV/Vis	spectroscopy,	assuming	an	extinction	
coefficient	 for	 the	 GST‐loop	 fusion	 protein	 of	 42860	 M‐1	 cm‐1.	 The	 PreScission	 cleavage	 site	
between	the	GST	tag	and	the	Taspase	loop	allowed	specific	removal	of	the	tag	by	addition	of	20	µg	
PreScission	protease	per	6	mg	fusion	protein	and	incubation	over	night	at	4	°C.	This	renders	the	
cleaved	Taspase	loop	with	an	N‐terminal	Gly‐Pro	extension	from	the	GST	tag.	
Filtration	through	a	Centricon	with	10	kDa	cut‐off	resulted	in	a	retention	of	the	28	kDa	GST	tag,	
while	the	6.5	kDa	Taspase	loop	could	pass	through	the	membrane.	Hence,	the	flow‐through	was	
collected	and	concentrated	in	another	Centricon	with	3	kDa	cut‐off.	Protein	concentration	was	
determined	using	the	Bradford	assay,	aliquots	were	shock	frozen	in	liquid	nitrogen	and	stored	at	
‐20	°C.	
	
2.4.4 Quantification	of	protein,	peptide	and	DNA	concentrations	
Protein	concentrations	of	purified	protein	were	determined	via	UV/Vis	spectroscopy	using	the	
Lambert‐Beer	 law.	 Extinction	 coefficients	 at	 280	 nm	 were	 calculated	 using	 the	 online	 tool	
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Protparam	[119]	and	are	listed	in	table	2.23.	Absorbance	spectra	were	recorded	with	a	NanoDrop	
ND	1000.	
Protein	 concentrations	of	 eukaryotic	 cell	 lysates	were	determined	 in	a	Bradford	assay.	1	µl	of	
sample	was	incubated	with	999	µl	Bradford	reagent	for	5	minutes	and	absorbance	was	measured	
at	 595	nm	and	a	blank	value	was	 subtracted.	 Calibration	with	 a	 bovine	 serum	albumin	 (BSA)	
standard	curve	allowed	an	estimation	of	the	protein	concentration	in	the	sample.	
For	the	quantification	of	inhibitors	containing	an	Fmoc	moiety,	the	extinction	coefficient	of	Fmoc	
was	determined	experimentally.	For	this,	the	absorbance	of	a	serial	dilution	of	Fmoc‐valine	was	
measured	at	300	nm	wavelength.	Linear	regression	of	the	standard	curve	yielded	an	extinction	
coefficient	of	4985	M‐1	cm‐1.	This	value	was	used	to	convert	the	absorbance	at	300	nm	to	inhibitor	
concentrations.	
The	concentration	of	overexpressed	GFP‐Taspase	in	eukaryotic	cell	lysates	was	obtained	using	a	
combination	 of	 absorbance	 and	 fluorescence	 spectroscopy.	 This	 was	 necessary,	 because	 the	
concentrations	were	 too	 low	 to	 be	 detected	 by	 absorbance	 spectroscopy.	 In	 a	 first	 step,	 cells	
transfected	with	only	GFP	were	lysed	and	the	GFP	concentration	in	the	 lysate	was	determined	
with	 a	 Nanodrop	 ND	 1000	 applying	 an	 extinction	 coefficient	 of	 9500	 M‐1	 cm‐1	 at	 475	 nm.	
Transfection	 and	 expression	 is	 much	 more	 efficient	 for	 GFP	 than	 for	 GFP‐Taspase	 and	 a	
concentration	of	15.8	µM	GFP	in	the	cell	lysate	was	calculated.	From	this	lysate,	a	standard	curve	
for	 fluorescence	 emission	 at	 509	 nm	 was	 created	 (excitation	 wavelength:	 395	 nm;	
excitation/emission	slits:	10/10	nm;	PMT:	600	V).	In	a	second	step,	the	fluorescence	emission	of	
a	lysate	with	overexpressed	GFP‐Taspase	was	measured.	With	the	help	of	the	standard	curve,	this	
value	could	be	converted	to	a	GFP‐Taspase	concentration	of	370	nM.	
Concentrations	 of	 the	 peptidic	 substrate	 used	 in	 the	 kinetic	 assays	 were	 determined	 via	 the	
absorbance	 of	 the	 anthranilic	 acid.	 An	 extinction	 coefficient	 of	 14650	 M‐1	 cm‐1	 at	 355	 nm	
wavelength	 was	 used.	 The	 concentration	 of	 the	 rhodamine‐labeled	 inhibitor	 was	 determined	
likewise,	assuming	an	extinction	coefficient	of	80000	M‐1	cm‐1	at	555	nm	[123].	
DNA	 concentrations	 were	 determined	 with	 a	 Nanodrop	 ND	 1000,	 assuming	 an	 extinction	
coefficient	at	360	nm	of	0.02	µg	ml‐1	cm‐1.	
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Table	2.23	Calculated	parameters	of	Taspase	proteins.	
Protein	 Extinction	 coefficient	
at	280	nm	(ε280)	
Molecular	weight Amino	acids	
wt	Taspase	 26930	M‐1	cm‐1 45	278	Da 420	
Inactive	Taspase	 26930	M‐1	cm‐1 45	204 Da 420	
Active	Taspase	 26930	M‐1	cm‐1 42	082 Da 399	
Taspase	loop	 0	M‐1	cm‐1	 6 611 Da 58	
	
2.4.5 SDS‐PAGE	
The	 composition	 of	 polyacrylamide	 gels	 for	 sodium	 dodecyl	 sulfate	 polyacrylamide	 gel	
electrophoresis	(SDS‐PAGE)	is	given	in	table	2.24.	Proteins	were	separated	for	about	90	minutes	
at	 150	 V	 and	 stained	 with	 Coomassie.	 For	 this,	 the	 gel	 was	 immersed	 in	 staining	 solution	
(section	2.1.3),	microwaved	briefly	and	shaken	for	10	minutes.	After	this,	the	gel	was	transferred	
to	destaining	solution,	microwaved	briefly	and	shaken	for	another	10	minutes.	
	
Table	2.24	Composition	of	polyacrylamide	gels	used	for	SDS‐PAGE.	
Component	 Stacking	gel	(5x) Separating	gel	(4x)	
0.5	M	Tris,	pH	6.8	 500 µl ‐
1.5	M	Tris,	pH	8.0	 ‐ 4.4 ml
10	%	SDS	 50 µl 200 µl
Acrylamide/Bis‐acrylamide	 850 µl 10 ml
10	%	Ammonium	peroxydisulfate	(APS) 50 µl 200 µl
TEMED	 5 µl 8 µl
ddH2O	 3.5 ml 5.2 ml
	
2.4.6 Analytical	gel	filtration	
Analytical	 gel	 filtrations	 were	 performed	 with	 a	 BioRad	 DuoFlow	 FPLC	 system	 on	 a	
Superdex	 200	 10/300	 gel	 filtration	 column	 (GE	 Healthcare,	 Solingen).	 The	 column	 was	
equilibrated	with	30	ml	of	50	mM	NaH2PO4,	450	mM	NaCl,	1	mM	DTT,	pH	8.	180	µg	Taspase	was	
loaded	 into	 a	 140	 µl	 loop	 and	 separated	 with	 0.5	 ml/min	 flow	 rate.	 Due	 to	 the	 low	 protein	
concentration,	the	absorbance	of	the	peptide	bond	at	214	nm	was	used	to	evaluate	the	retention	
times.	For	calibration,	 ferritin	 (450	kDa),	aldolase	(161	kDa),	 conalbumin	(75	kDa),	α‐amylase	
(54	kDa)	and	ribonuclease	A	(13.7	kDa)	were	used.	The	retention	times	were	plotted	against	the	
logarithmic	molecular	weight	for	linear	regression.	
	
2.4.7 Labeling	of	Taspase	with	Atto594‐NHS	
The	wild	type	protein	of	Taspase	and	the	inactive	mutant	were	independently	labeled	at	the	C‐
terminus	with	Atto594.	1	mg	of	Taspase	was	diluted	in	1	ml	of	50	mM	NaH2PO4,	450	mM	NaCl,	
1	mM	DTT,	pH	8.	Afterwards,	a	1.2‐fold	molar	excess	of	Atto594	(dissolved	in	DMSO)	was	added	
and	the	solution	was	incubated	for	60	minutes	at	room	temperature	in	the	dark.	Unbound	dye	was	
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removed	with	the	help	of	a	PD‐10	column	and	the	conjugate	was	concentrated	in	a	Centricon.	To	
determine	the	protein	concentration	(c)	and	degree	of	labeling	(DOL),	the	absorbance	at	280	nm	
and	601	nm	was	measured	using	a	NanoDrop	ND	1000	and	converted	as	follows:	
	
ܦܱܮ ൌ 	 ܣହ଴ଵ ∙ 26930	ܯ
ିଵ	ܿ݉ିଵ
ሺܣଶ଼଴ െ ܣହ଴ଵ ∙ 0.51ሻ ∙ 120000	ܯିଵ	ܿ݉ିଵ	
ܿ ൌ 	 ܣଶ଼଴ െ ܣହ଴ଵ ∙ 0.511	ܿ݉	 ∙ 26930	ܯିଵ	ܿ݉ିଵ		
	
These	calculations	yielded	for	wild	type	Taspase	a	protein	concentration	of	551	µM	and	a	DOL	of	
1.0	 and	 for	 the	 inactive	mutant	 a	 concentration	 of	 87	 µM	with	 a	DOL	 of	 1.01.	 Aliquots	 of	 the	
conjugates	were	shock	frozen	and	stored	at	‐20	°C.	
	
2.4.8 Labeling	of	Taspase	with	Atto488‐maleimide	
Wild	type	Taspase	was	labeled	with	the	cysteine	reactive	dye	Atto488‐maleimide.	The	buffer	was	
changed	 for	 labeling	 to	 50	 mM	 NaH2PO4,	 450	 mM	 NaCl,	 pH	 7.4	 by	 repeated	 dilution	 and	
concentration	 in	 a	 30	 kDa	 cut‐off	 Centricon.	 A	 2.5‐fold	molar	 excess	 of	 Atto488	was	 used	 for	
labeling.	 Labeling	 and	 removal	 of	 unbound	dye	was	performed	 as	described	 for	 labeling	with	
Atto594‐NHS	(section	2.4.7).	DOL	and	protein	concentration	were	determined	using	the	following	
formula:	
	
ܦܱܮ ൌ 	 ܣହ଴ଵ ∙ 26930	ܯ
ିଵ	ܿ݉ିଵ
ሺܣଶ଼଴ െ ܣହ଴ଵ ∙ 0.1ሻ ∙ 90000	ܯିଵ	ܿ݉ିଵ	
ܿ ൌ 	 ܣଶ଼଴ െ ܣହ଴ଵ ∙ 0.11	ܿ݉	 ∙ 	26930	ܯିଵ	݈ିଵ		
	
After	 labeling	was	 completed,	 the	 buffer	was	 changed	 to	 the	 previous	 storage	 buffer	 (50	mM	
NaH2PO4,	450	mM	NaCl,	1	mM	DTT,	pH	8.0).	This	procedure	resulted	in	a	final	concentration	of	
84	µM	conjugate	with	a	DOL	of	2.45.	Aliquots	of	the	conjugate	were	shock	frozen	and	stored	at	‐
20	°C.	
	
2.4.9 Assay	for	autocatalytic	activation	of	Taspase	
Spontaneous	cleavage	of	full‐length	Taspase	between	D233	and	T234	into	α‐	and	β‐subunit	was	
visualized	with	SDS‐PAGE.	First,	9	µM	purified	Taspase	was	incubated	in	different	buffers	at	30	°C.	
Samples	were	taken	after	a	certain	period	of	time,	prepared	for	SDS‐PAGE	and	stored	at	‐20	°C	to	
stop	 the	 cleavage	process.	 The	 two	 subunits	were	 separated	 via	 SDS‐PAGE	 in	 gels	with	 15	%	
acrylamide.	
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2.4.10 Limited	proteolysis	assay	with	proteinase	K	
Limited	 proteolysis	 with	 proteinase	 K	 was	 performed	 in	 gel	 filtration	 buffer	 (section	 2.1.3).	
5	µg/ml	proteinase	K	was	used	to	digest	6.4	µg	Taspase	in	a	total	volume	of	20	µl	for	10	minutes	
at	21	°C,	before	5	mM	PMSF	was	added	to	stop	the	reaction.	Samples	were	mixed	with	SDS	sample	
buffer	and	separated	by	SDS‐PAGE.	
	
2.5 Spectroscopic	methods	
2.5.1 Taspase	enzyme	activity	assay	
For	the	determination	of	catalytic	activity	of	Taspase,	a	fluorogenic	assay	was	designed	[56].	The	
substrate	contains	the	CS2	cleavage	sequence	as	it	occurs	in	the	Taspase	target	protein	MLL,	with	
an	 additional	 anthranilic	 acid	 coupled	 to	 the	 N‐terminus	 and	 dinitrophenol‐conjugated	 lysine	
coupled	to	the	C‐terminus	of	the	peptide	(CASLO	ApS,	Lyngby).	The	fluorescent	dye	anthranilic	
acid	can	be	quenched	by	dinitrophenol.	Since	during	the	quenching	process	the	excited	electron	
transfers	 its	 excess	 energy	 to	 an	 electron	 of	 the	 quencher	molecule,	 the	 quenching	 efficiency	
depends	 on	 the	 distance	 between	 dye	 and	 quencher.	 The	 intact	 peptide	 is	 quenched	 very	
effectively,	i.e.	90	%	of	the	energy	absorbed	by	anthranilic	acid	is	transferred	to	dinitrophenol	and	
dissipated	 as	 heat	 (figure	 2.4a).	 Cleavage	 by	 Taspase	 separates	 dye	 and	 quencher	 and	 the	
quenched	fluorescence	of	the	dye	is	recovered	in	a	rate	directly	related	to	the	catalytic	activity	of	
Taspase	(figure	2.4b).	
	
	
Figure	2.4	Principle	of	the	fluorogenic	Taspase	activity	assay.	
a	The	model	substrate	contains	the	cleavage	site	for	Taspase,	an	N‐terminal	anthranilic	acid	(Abz)	and	a	C‐
terminal	dinitrophenol	moiety	(DNP).	After	excitation	of	the	Abz	dye,	the	energy	is	transferred	to	the	DNP	
and	the	fluorescence	is	quenched.	b	Upon	cleavage	by	Taspase,	Abz	dye	and	quencher	are	separated.	Hence,	
Abz	is	no	longer	quenched	and	can	emit	photons.	
	
As	long	as	the	substrate	concentration	is	at	saturating	levels,	the	increase	in	fluorescence	is	linear	
and	mirrors	the	initial	rate.	Hence,	the	change	in	fluorescence	during	the	first	180	seconds	was	
fitted	with	 linear	regression	and	converted	 to	enzyme	activity.	As	 fluorescence	 is	measured	 in	
arbitrary	 values,	 a	 quantification	 of	 the	 kinetics	 with	 absolute	 values	 was	 not	 trivial.	 One	
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prerequisite	 for	 this	 was	 that	 all	 measurements	 were	 taken	 with	 the	 same	 parameters	 with	
respect	 to	 temperature,	pH,	excitation	slit	width,	emission	slit	width,	PMT	voltage	and	sample	
purity.	Furthermore,	the	substrate	concentration	had	to	be	low	to	avoid	inner	filter	effects	and	
allow	 the	 assumption	 of	 a	 linear	 correlation	of	 intensity	 change	 and	 substrate	 cleavage.	 8	 µM	
proved	to	be	a	suitable	substrate	concentration	with	an	absorbance	well	below	0.1,	while	still	high	
enough	to	yield	an	adequate	time	to	measure	the	reaction	before	substrate	depletion	began.	
Unless	 specified	 otherwise,	 all	 samples	were	measured	 in	 3	mm	 cuvettes	with	 a	 Varian	 Cary	
Eclipse	spectrofluorimeter	equipped	with	a	peltier	element.	For	each	assay,	300	nM	Taspase	was	
added	to	8	µM	substrate	in	a	total	volume	of	60	µl	with	buffer	containing	100	mM	HEPES,	10	%	
sucrose,	10	mM	DTT,	pH	7.9.	The	temperature	was	adjusted	to	37	°C	and	measurements	were	
taken	for	10	minutes	with	the	settings	provided	in	table	2.25.	
	
Table	2.25	Parameters	used	for	kinetic	measurements	with	the	fluorogenic	assay.	
Parameter	 Value	
Excitation	wavelength 320	nm	
Emission	wavelengths
	
420	nm	
Excitation	slit	width	 20	nm	
Emission	slit	width	 20	nm	
PMT	voltage	 480	V	
Average	time	 5	s	
Temperature	 37	°C	
	
Fluorescence	 intensities	 were	 recorded	 for	 8	 µM	 of	 the	 intact	 and	 the	 completely	 cleaved	
substrate.	 The	 measured	 intensities	 (I)	 in	 arbitrary	 units	 were	 converted	 to	 substrate	
concentrations	(c)	according	to	the	following	equation	
	
ܿ ൌ 8	μܯ ܫ െ ܫ௜௡௧௔௖௧ܫ௖௟௘௔௩௘ௗ െ	ܫ௜௡௧௔௖௧	
	
where	c	is	the	concentration	of	cleaved	substrate,	I	is	the	measured	fluorescence	intensity,	Iintact	is	
the	intensity	of	the	intact	substrate	and	Icleaved	represents	the	intensity	of	the	cleaved	substrate.	
The	change	in	concentration	over	time	(Δc/Δd)	corresponds	to	the	enzymatic	activity	of	Taspase.	
Hence,	the	specific	catalytic	activity	could	be	calculated	using	the	formula	below.	
	
ܽ௦௣௘௖ ൌ 	 ∆ܿmin 	∙ ሾܶܽݏ݌ܽݏ݁ሿ	 																			ሾ
μ݉݋݈
min 	∙ ݉݃ሿ	
	
aspec	represents	the	specific	catalytic	activity	in	µmol	cleavage	per	minute	and	mg	Taspase,	Δc	is	
the	concentration	of	substrate	consumed	in	1	minute	in	µM	and	[Taspase]	is	the	concentration	of	
Taspase	in	mg/ml.		
For	 the	determination	of	 the	Michaelis	constant	KM,	 the	 initial	velocities	 (v)	were	measured	at	
different	 substrate	 concentrations	 [S].	 Nonlinear	 regression	 using	 least	 squares	 fitting	 to	 the	
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Michaelis‐Menten	equation	given	below	using	Prism	software	 [115]	yielded	maximum	velocity	
vmax	and	Michaelis	constant	Km.	
	
ݒ ൌ ݒ୫ୟ୶ 	∙ሾܵሿܭ௠ ൅	ሾܵሿ	
	
Taspase	 requires	 high	 salt	 concentrations	 (>300	mM)	 for	 stability.	 However,	 salt	 inhibits	 the	
catalytic	activity.	A	reasonable	compromise	between	stability	and	activity	is	a	buffer	containing	
sucrose,	which	was	used	for	kinetic	assays.	In	a	buffer	containing	10	%	sucrose,	the	half‐life	of	
Taspase	was	long	enough	to	perform	kinetic	measurements	without	losing	activity	due	to	protein	
denaturation.	Despite	the	stabilizing	effect	of	sucrose,	the	half‐life	was	too	short	for	a	complete	
test	series,	such	as	a	titration	curve.	To	circumvent	this	problem	and	maximize	reproducibility,	
aliquots	 of	 300	 nM	 Taspase	 in	 sucrose	 were	 flash	 frozen	 and	 stored	 at	 ‐80	 °C.	 For	 each	
measurement,	an	aliquot	was	thawed	rapidly	in	a	thermomixer	at	37	°C	and	incubated	for	exactly	
5	minutes	at	500	rpm	to	ensure	a	homogeneous	temperature.	After	the	incubation	time,	preheated	
Taspase	 was	 added	 to	 the	 equally	 preheated	 substrate	 mixed	 with	 inhibitor	 or	 buffer	 and	
immediately	 filled	 into	 cuvettes	 preheated	 to	 37	 °C.	 The	 first	 data	 point	 of	 each	 trace	 was	
measured	10	seconds	after	the	reaction	had	started.	
With	 this	 assay,	 several	 compounds	 were	 tested	 for	 inhibitory	 effects	 on	 Taspase	 activity.	
Together	with	the	substrate,	the	compounds	were	briefly	incubated	at	37	°C	as	described	above	
before	 Taspase	 was	 added.	 Some	 of	 the	 inhibitors	 tested	 were	 insoluble	 in	 water	 at	 higher	
concentrations	 and	 required	 dissolving	 in	 DMSO.	 After	 dilution	 in	 sucrose	 buffer,	 the	 DMSO	
concentration	was	below	3	%	and	all	measurements	were	referenced	to	the	buffer	controls	with	
respective	DMSO	concentrations.	
Inhibition	constant	(Ki)	and	IC50	values	were	obtained	by	applying	nonlinear	least	squares	fitting.	
For	 IC50	 fits,	 enzymatic	 activity	 of	 Taspase	 was	 plotted	 against	 logarithmic	 inhibitor	
concentrations	and	fitted	to	the	following	model.	
	
ݒ ൌ ܤ݋ݐݐ݋݉ ൅ ܶ݋݌ െ ܤ݋ݐݐ݋݉1 ൅ 10௑ି୪୭୥	ሺூ஼ହ଴ሻ	
	
Bottom	 and	 Top	 represent	 the	 inhibition	 at	 very	 low	 and	 very	 high	 inhibitor	 concentrations,	
respectively	and	IC50	is	the	concentration	at	which	50	%	of	the	effect	is	observed.	
For	 the	 experimental	 estimation	 of	 Ki	 values,	 the	 enzyme	 activity	 was	 measured	 at	 several	
combinations	 of	 substrate	 and	 inhibitor	 concentration	 and	 data	 was	 fitted	 to	 the	 following	
equation.	
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∙ ሾܵሿ
ܭ௠ ∙ ሺ1 ൅ ሾܫሿܭ௜ ሻ1 ൅ ሾܫሿ
ߙ	 ∙ ܭ௜
൅	 ሾܵሿ
	
	
Where	v	is	the	observed	velocity,	vmax	is	the	maximum	enzyme	velocity	without	inhibitor,	Km	is	
the	Michaelis	constant,	Ki	is	the	inhibition	constant,	[S]	is	the	substrate	concentration,	[I]	is	the	
inhibitor	concentration	and	α	describes	the	mechanism	of	inhibition.	Very	small	α	values	indicate	
uncompetitive	inhibition,	very	large	α	values	indicate	competitive	inhibition	and	a	value	of	1	is	
seen	 for	 noncompetitive	 inhibition.	 If	 Km	 and	 substrate	 concentration	 [S]	 is	 known,	 it	 is	 also	
possible	to	derive	the	Ki	value	from	IC50	values	using	the	Cheng‐Prusoff	equation	[124].	
	
ܭ௜ ൌ ܫܥହ଴1 ൅ ሾܵሿܭெ
	
	
The	values	obtained	 from	experimental	determination	and	 the	values	gained	by	mathematical	
conversion	 from	 IC50	 values	were	 similar.	 For	 this	 reason,	most	 of	 the	 Ki	 values	 reported	 are	
converted	from	IC50	values,	which	are	easier	to	measure	practically.	
As	negative	control,	the	amino	acids	at	the	cleavage	site	of	the	substrate	were	exchanged	against	
alanine,	yielding	[Abz]‐KISQLAAVDDK‐[DNP]	(Abz:	anthranilic	acid;	DNP:	dinitrophenol;	CASLO	
ApS,	 Lyngby).	 Another	 negative	 control	 was	 performed	with	 inactive	 Taspase	 using	 identical	
parameters.	 For	 positive	 controls,	 a	 peptide	 comprising	 the	 CS1	 cleavage	 site	 of	 MLL	 was	
synthesized	 with	 7‐amino‐4‐methylcoumarin	 (MCA)	 as	 N‐terminal	 fluorescent	 dye	
([MCA]‐GKGQVDGADDK‐[DNP];	China	Peptides,	Shanghai).	Concentrations	of	this	peptide	were	
determined	using	an	extinction	coefficient	of	15000	M‐1	cm‐1	at	350	nm.	Measurements	were	taken	
with	excitation	and	emission	wavelength	of	320	and	400	nm,	respectively.	
The	 activity	 of	 eukaryotic	 cell	 lysates	 was	 measured	 under	 slightly	 different	 conditions.	
Measurements	were	taken	 in	 lysis	buffer	(25	mM	Tris	pH	7.4,	150	mM	KCl,	5	mM	MgCl2,	5	%	
glycerol,	1	%	triton	X‐100,	2	mM	2‐mercaptoethanol,	1	mM	PMSF,	1	cOmplete	tablet)	with	8	µM	
substrate	added.	The	cOmplete	Protease	Inhibitor	Cocktail	precipitates	at	37	°C.	Hence,	the	assay	
temperature	was	lowered	to	30	°C	to	minimize	precipitation.	
	
2.5.2 Binding	studies	with	detection	of	fluorescence	anisotropy	
The	 principle	 of	 fluorescence	 anisotropy	 is	 based	 on	 photoselection.	 This	 means	 that	 after	
excitation	with	linear	polarized	light,	fluorophores	with	an	excitation	dipole	moment	parallel	to	
the	 electric	 vector	 of	 the	 incident	 light,	 are	 preferentially	 excited.	 In	 the	 excited	 state,	 the	
fluorophore	rotates	due	to	Brownian	motion.	The	degree	of	rotation	before	emission	depends	of	
rotation	 correlation	 time	 and	 fluorescence	 lifetime.	 Emission	 occurs	 with	 an	 electric	 vector	
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parallel	 to	 the	 emission	 dipole	 of	 the	 fluorophore.	 Hence,	 the	 emitted	 light	 of	 a	 fast	 rotating	
fluorophore	 is	 less	 polarized	 and	 the	molecule	 has	 a	 lower	 anisotropy	 than	 the	 emission	 of	 a	
slowly	rotating	fluorophore.	For	globular	proteins,	the	rotation	correlation	time	θ	depends	on	the	
molecular	weight	as	described	by	the	Perrin	equation.	
	
ߠ ൌ ߟ	 ∙ ܯܴܶ 	ሺ̅ݒ ൅ 	݄ሻ	
	
Where	θ	is	the	rotation	correlation	time,	η	is	the	viscosity	of	the	sample	(0.01	poise	for	water,	
0.011	poise	for	10	%	sucrose),	M	is	the	molecular	weight,	R	is	the	gas	constant,	T	represents	the	
temperature,	vത	is	the	specific	volume	(typically	near	0.73	ml/g)	and	h	is	the	hydration	(typically	
near	0.23	mg	H2O	per	mg	of	protein).	The	theory	of	anisotropy	explained	above	shows	that	binding	
of	a	small	fluorescent	ligand	to	a	protein	causes	an	increase	in	anisotropy.	
Measurements	 were	 taken	 with	 a	 Varian	 Cary	 Eclipse	 equipped	 with	 polarizer	 wheels	 and	 a	
peltier	element.	Unless	specified	otherwise,	the	sample	volume	was	60	µl	in	3	mm	cuvettes	and	
readings	were	averaged	over	5	minutes	at	20	°C	with	the	parameters	stated	in	table	2.26.		
	
Table	2.26	Parameters	used	for	anisotropy	measurements.	
Parameter	 Atto488	 Atto594 Rhodamine Tryptophan	 Anthranilic	acid
Excitation	wavelength 501	nm	 601 nm 555 nm 280 nm 320	nm	
Emission	wavelengths 523	nm	 627 nm 582 nm 340 nm 420	nm	
Excitation	slit	width	 10	nm	 20 nm 5 nm 10 nm 20	nm	
Emission	slit	width	 20	nm	 20 nm 10 nm 20 nm 20	nm	
PMT	voltage	 400	V	 400 V 500 V 600 V 600	V	
Average	time	 5	s	 5 s 5 s 5 s 5	s	
Temperature	 20	°C	 20 °C 20 °C 20 °C 20	°C	
G	factor	 1.6724	 2.1338 1.9587 0.6537 1.1373	
Concentration	 1	µM	 1 µM 500 nM 10 µM 1	µM	
	
G	 factors	 were	 applied	 to	 compensate	 different	 transmission	 efficiency	 of	 the	 polarizers	 for	
horizontally	 and	 vertically	 polarized	 light.	 To	 obtain	 these	 values,	 the	 emission	 of	 every	
fluorophore	used	was	recorded	consecutively	with	polarizers	oriented	horizontally	and	vertically	
and	 the	 ratio	 of	 the	 intensities	 yielded	 the	G	 factor.	 The	 samples	were	 excited	with	 vertically	
polarized	light	and	emission	intensities	of	horizontally	(IH)	and	vertically	(IV)	polarized	light	were	
recorded	separately.	With	these	values	the	anisotropy	(r)	was	calculated.	
	
ݎ ൌ 	 ܫ௏ െ 	ܩ	 ∙ ܫுܫ௏ ൅ 	2ܩ	 ∙ ܫு	
	
The	increase	in	anisotropy	was	plotted	against	ligand	concentration	and	binding	constants	were	
derived	from	nonlinear	curve	fitting	using	Prism	software	[115]	with	an	equation	for	saturation	
binding.	
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Δݎ ൌ ݎ௠௔௫ 	 	∙ ሾ݈݅݃ܽ݊݀ሿܭௗ 	൅	ሾ݈݅݃ܽ݊݀ሿ 	
	
Where	Δr	 is	 the	 increase	 in	 anisotropy,	 rmax	 is	 the	 increase	 in	 anisotropy	 at	 saturating	 ligand	
concentrations	and	Kd	is	the	dissociation	constant.	
	
2.5.3 Binding	detected	with	microscale	thermophoresis	
Thermophoresis	 is	 the	directed	movement	of	particles	due	to	a	 temperature	gradient.	 In	most	
cases,	this	movement	occurs	from	hot	to	cold	and	depends	on	the	hydration	shell,	charge	and	size	
of	the	molecules.	If	binding	of	another	molecule	changes	any	of	these	three	parameters,	this	can	
be	 detected	 by	 microscale	 thermophoresis	 (MST;	 NanoTemper,	 Munich).	 The	 temperature	
gradient	 is	 generated	 by	 an	 infrared	 laser	 and	 the	movement	 of	 the	molecules	 is	 followed	by	
change	in	local	fluorescence	intensity	inside	a	capillary.	
Binding	 of	 Taspase	 to	 nanoparticles	 was	 assessed	 in	 standard	 glass	 capillaries	 with	 a	
Monolith	NT.115	during	 a	MST	demonstration	 course.	 Taspase	was	 labeled	with	Atto488	 and	
50	 nM	 labeled	 protein	 was	 added	 to	 a	 16‐step	 serial	 dilution	 of	 nanoparticles,	 ranging	 from	
200	µg/ml	to	12	ng/ml.	To	avoid	adsorption	of	Taspase	to	the	capillary	walls,	0.1	%	Tween	was	
added	to	a	buffer	containing	50	mM	NaH2PO4,	450	mM	NaCl,	1	mM	DTT,	pH	8.0	in	a	final	volume	
of	 40	 µl.	 Binding	 of	 the	 peptidic	 Taspase	 inhibitor	 Comp9	 was	 assessed	 under	 label‐free	
conditions,	 using	 intrinsic	 tryptophan	 fluorescence	 for	 detection	 with	 a	 Monolith	
NT.115LabelFree.	1	µM	of	Taspase	was	added	to	a	serial	dilution	of	400	µM	to	12	nM	Comp9	in	
50	mM	NaH2PO4,	450	mM	NaCl,	1	mM	DTT,	0.1	%	Tween,	pH	8.0.	Data	analysis	and	determination	
of	Kd	values	was	performed	with	the	software	tools	 implemented	 in	the	NanoTemper	Analysis	
software.	
	
2.5.4 Determination	of	inhibitor	stability	with	fluorescence	anisotropy	
Fluorescence	 anisotropy	 is	 sensitive	 to	 changes	 in	 the	 hydrodynamic	 radius,	 as	 explicated	 in	
section	2.5.2.	Therefore,	it	can	be	used	as	a	measure	for	the	cleavage	of	fluorescent	substrates.	The	
stability	of	the	peptidic	rhodamine‐labeled	inhibitor	was	assayed	in	the	presence	of	1	µM	Taspase	
and	 compared	 to	 the	 regular	 fluorescent	 substrate	 (section	 2.5.1)	 as	 positive	 control.	
Measurements	were	taken	in	200	µl	of	50	mM	NaH2PO4,	450	mM	NaCl,	1	mM	DTT,	pH	8.0	in	3	mm	
cells.	Inhibitor	or	substrate	concentrations	amounted	to	8	µM	and	readings	were	performed	with	
a	Varian	Cary	Eclipse	fluorescence	spectrometer	using	the	settings	listed	in	table	2.27.	
	
	
	
	
	
Table	2.27	Parameters	used	to	measure	inhibitor	stability	with	anisotropy.	
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Parameter	 Substrate	 Inhibitor
Excitation	wavelength 320	nm	 495 nm
Emission	wavelength	 420	nm	 582 nm
Excitation	slit	width	 20	nm	 20	nm
Emission	slit	width	 20	nm	 20	nm
PMT	voltage	 600	V	 600 V
Average	time	 5	s	 5 s
Interval	 10	min	 10 min
Temperature	 20	°C	 20 °C
G	factor	 1.1373	 1.9640
	
	
Curves	were	fitted	to	a	model	for	mono‐exponential	decay	with	GraphPad	Prism:	
	
ݎ ൌ ሺݎ௜௡௧௔௖௧ െ ݎ௖௟௘௔௩௘ௗሻି௄∙௧ ൅	ݎ௖௟௘௔௩௘ௗ	
	
where	r	represents	the	anisotropy,	rintact	is	the	anisotropy	value	of	the	uncleaved	state,	rcleaved	is	
the	anisotropy	value	in	the	cleaved	state,	t	is	the	time	and	K	the	rate	constant.	The	half‐life	t0.5	can	
be	calculated	as	
ݐ଴.ହ ൌ ݈݊2ܭ 	
2.5.5 CD	spectroscopy	
CD	spectra	and	melting	curves	were	recorded	with	a	Jasco	J‐710	CD	spectropolarimeter	(Jasco,	
Gross‐Umstadt).	Far‐UV	spectra	were	recorded	in	0.1	cm	cuvettes	(Hellma	Analytics,	Müllheim).	
For	Taspase	and	Taspase	mutants	the	buffer	contained	50	mM	potassium	phosphate	buffer	at	pH	
6.5,	while	the	synthetic	loop	peptide	was	dissolved	in	50	mM	potassium	phosphate,	pH	6.0.	The	
protein	 concentration	 was	 determined	 precisely	 and	 200	 µl	 of	 a	 0.2	 mg/ml	 solution	 were	
measured	with	the	parameters	given	in	table	2.28.	
To	correct	the	y‐drift	of	the	device,	all	spectra	were	shifted	so	that	the	ellipticity	between	250	and	
260	nm	was	zero.	From	each	protein	spectrum	a	buffer	spectrum	was	subtracted	and	the	mdeg	
units	were	converted	to	molar	ellipticity	using	path	length	and	protein	concentration.	
߰௦௣௘௖ ൌ ݈߰௖௠ 	 ∙ ܿ௠௚/௠௟	
where	ψspec	is	the	specific	ellipticity	in	deg	cm3	dm‐1	per	gram	of	amino	acid,	ψ	is	the	observed	
ellipticity	in	mdeg,	l	is	the	path	length	in	cm	and	c	is	the	concentration	in	mg/ml.	
These	spectra	show	if	the	purified	protein	is	folded	and	allow	an	estimation	of	helix,	sheet,	turn	
and	random	coil	content.	For	the	estimation	of	secondary	structure	content	by	deconvolution,	the	
CDSSTR	algorithm	[125]	was	used.	
Melting	 curves	 were	 recorded	 in	 a	 1	 cm	 cuvettes	 sealed	 with	 a	 stopper	 (Hellma	 Analytics,	
Müllheim)	with	0.05	mg/ml	protein	in	50	mM	potassium	phosphate	buffer	at	pH	6.5.	The	set	of	
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parameters	used	 to	obtain	 the	melting	curves	 is	 listed	 in	 table	2.28.	Nonlinear	curve	 fitting	 to	
obtain	 melting	 temperatures	 was	 performed	 with	 the	 Jasco	 Spectra	 Manager	 2.0	 software	
package.	
	
Table	2.28	Parameters	used	to	record	far‐UV	CD	spectra	with	a	Jasco	J‐710.	
Far‐UV	spectra	 Melting	curves
Parameter	 Value	 Parameter value
Start	 260	 Wavelength 225 nm
End	 200	 Temperature	slope 1 °C/min	
Scanning	mode	 Continuous	 Delay	time 180 s
Response	time	 0.5	s	 Response	time 8 s
Bandwidth	 2 nm	 Bandwidth 1 nm
Data	pitch	 0.2	nm	 Data	pitch 0.1 °C
Temperature	 21	°C	 Temperature 20‐85 °C	
Accumulations	 20	
Scanning	speed	 100	nm/min	
	
2.5.6 Fluorescence	melting	curves	
For	fluorescence	melting	curves	of	Taspase,	the	solvatochromism	of	tryptophan	is	exploited.	The	
emission	 maximum	 of	 tryptophan	 depends	 on	 the	 polarity	 of	 the	 environment,	 because	 two	
different	electron	transitions	can	occur	when	the	fluorescent	indole	ring	absorbs	a	photon.	These	
two	perpendicular	electronic	transitions	are	referred	to	as	1La	and	1Lb	and	differ	in	their	energy	
levels.	For	a	tryptophan	in	the	protein	core,	1Lb	has	lower	energy	than	1La	and	is	the	predominant	
transition.	Since	the	1La	transition	is	directed	through	the	ring‐NH	group,	it	can	have	dipole‐dipole	
interactions	with	polar	solvent	molecules	and	is	therefore	the	lowest	energy	transition	for	surface	
exposed	tryptophans.	As	emission	from	1Lb	occurs	from	a	higher	energy	level	than	emission	from	
1La,	the	tryptophan	emission	undergoes	a	bathochromic	shift	during	protein	unfolding.	
Accurate	determination	of	the	emission	maximum	to	one	nanometer	is	challenging,	because	of	the	
broad	emission	spectrum	of	tryptophan.	In	order	to	increase	the	accuracy	of	the	measurement,	
the	intensity	at	two	wavelengths	with	considerable	changes	in	intensity	during	unfolding	were	
observed	 during	 unfolding.	 This	 procedure	 also	 allowed	 a	 mathematical	 elimination	 of	 the	
thermal	quenching	occurring	during	the	measurement	via	division	by	the	sum	of	the	intensities.	
Measurements	were	taken	in	3	mm	quartz	cuvettes	with	a	Varian	Cary	Eclipse	spectrofluorimeter	
equipped	with	a	peltier	element.	10	µM	of	Taspase	in	200	µl	was	assayed	to	determine	the	effect	
of	 buffer	 composition	 and	 nanoparticle	 binding.	 After	 excitation	 at	 280	 nm,	 the	 fluorescence	
emission	intensities	at	334	and	376	nm	were	recorded,	while	the	temperature	was	increased	from	
20	to	95	°C.	The	detailed	settings	for	this	assay	can	be	found	in	table	2.29.	
Table	2.29	Parameters	used	for	recording	of	fluorescence	melting	curves.	
Parameter	 Value	
Excitation	wavelength 280	nm	
Emission	wavelengths 334	nm	and	376 nm
Excitation	slit	width	 20	nm	
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Emission	slit	width	 10	nm	
PMT	voltage	 480	V	
Average	time	 5	s	
Hold	time	 180	s	
Temperature	slope	 0.5	°C/min
Data	interval	 0.1	°C	
Temperature	range	 20‐95	°C	
	
	
The	intensities	measured	at	334	nm	(I334)	and	376	nm	(I376)	were	converted	to	arbitrary	folding	
units	(F)	using	the	following	formula.	
	
ܨ ൌ ܫଷଷସ െ	ܫଷ଻଺ܫଷଷସ ൅	ܫଷ଻଺	
These	values	were	normalized	on	a	scale	from	0	to	1	using	the	values	of	the	folded	and	unfolded	
states	as	references.	The	fraction	of	unfolded	protein	(U)	at	a	temperature	(T)	is	defined	as	
	
ܷሺܶሻ ൌ 1 െ ܨሺܶሻ െ	ܨ௨௡௙௢௟ௗ௘ௗܨ௙௢௟ௗ௘ௗ െ	ܨ௨௡௙௢௟ௗ௘ௗ	
where	F(T)	represents	the	value	of	the	folding	value	(as	defined	above)	at	temperature	T,	while	
Funfolded	and	Ffolded	represent	folding	value	of	the	unfolded	and	native	protein,	respectively.	
	
2.5.7 NMR	spectroscopy	
For	NMR	spectra	of	Taspase,	the	buffer	was	changed	to	50	mM	NaH2PO4,	300	mM	NaCl,	1	mM	DTT,	
pH	7.9	by	repeated	dilution	and	concentration	in	a	Centricon	and	measurements	were	taken	at	
30	°C,	unless	specified	otherwise.	Sample	concentrations	ranged	between	400	and	600	µM	and	to	
all	samples	2	%	(v/v)	deuterium	oxide	was	added	as	frequency	lock,	and	50	µM	DSS	(2,2‐dimethyl‐
2‐silaptane‐5‐sulfonate)	to	allow	a	calibration	of	1H	chemical	shifts.	The	final	sample	volume	of	
600	µl	was	transferred	into	a	5	mm	thin‐wall	NMR	tube.	
NMR	spectra	were	recorded	with	a	Bruker	Ultrashield	700	NMR	spectrometer	with	inverse	triple	
resonance	cryoprobe	(Bruker	Biospin,	Rheinstetten)	with	constant	transmitter	frequencies	(1H	:	
700,22	MHz;	15N:	70.952676	MHz;	13C:	176,070459	MHz).	Recording	and	processing	of	NMR	
spectra	was	executed	with	the	Topspin	3.0	software	package	(Bruker	Biospin,	Rheinstetten)	using	
the	parameters	specified	in	supplemental	table	7.1,	table	7.2,	and	table	7.3.	All	pulse	programs	
used	were	taken	from	the	Bruker	standard	library.	
	
2.5.8 Recording	and	processing	of	NMR	spectra	
Free	induction	decays	were	Fourier	transformed	in	every	dimension	(command	“xfb”	for	2D	or	
“tf3;	tf2;	tf1”	for	3D)	and	π/4	shifted	sine	filter	functions	were	used	for	apodization.	A	fifth	degree	
polynomial	was	subtracted	for	baseline	correction	in	every	dimension	(commands	“abs2.water;	
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abs1”	for	2D	or	“tabs3;	tabs2;	tabs1”	for	3D).	Spectra	were	phase	corrected,	with	imaginary	data	
added	to	2D	planes	of	3D	spectra	by	Hilbert	transformation	(command	“xht2;	xht1”)	to	allow	a	
phase	correction	of	3D	spectra.	For	the	evaluation	and	peak	assignment,	CCPN	suite	2.3	was	used.	
	
2.5.9 Assignment	theory	
The	 principle	 of	 backbone	 atom	 assignment	 and	 identification	 of	 sequential	 amino	 acids	 is	
explained	here	using	simplified	example	spectra	(figure	2.5).	The	assignment	was	based	on	a	1H‐
15N	HSQC,	which	can	be	regarded	as	 the	 fingerprint	of	a	protein.	This	spectrum	shows	all	H‐N	
correlations,	which	 are	mainly	 backbone	 amide	 groups	 (figure	 2.5b),	 but	 also	 side‐chain	 H‐N	
groups	 of	 tryptophans,	 asparagines	 and	 glutamines	 are	 visible.	 Essentially,	 every	 amino	 acid	
(except	 for	 the	N‐terminal	one	and	prolines)	 causes	one	peak	 in	 this	 spectrum.	With	only	 the	
	
	
Figure	2.5	Schematic	spectra	and	information	for	NMR	backbone	assignment.	
a	1H‐15NHSQC	spectrum	showing	three	amino	acids	labeled	“a”,	“b”	and	“c”.	b	Naming	convention	for	amino	
acid	atoms,	shown	for	alanine	 in	a	polypeptide	chain.	Heavy	atoms	are	displayed	 in	black,	hydrogens	 in	
white.	c	3‐dimensional	HNCaCb	spectrum	showing	the	carbon	resonances	of	the	amino	acids	“a”,	“b”	and	
“c”.	 Alpha	 carbon	 atoms	 are	 displayed	 in	 blue,	 beta	 carbon	 atoms	 in	 red.	d	 3	 dimensional	 CbCaCONH	
spectrum	showing	the	carbon	resonances	of	the	amino	acids	preceding	amino	acids	“a”,	“b”	and	“c”.	Alpha	
and	beta	carbon	atoms	are	 indistinguishable	 in	 this	spectrum.	e	Reference	chemical	shifts	 for	 the	alpha	
(blue)	and	beta	(red)	carbon	atoms	of	all	20	amino	acids.	Reference	chemical	shifts	were	extracted	from	
CCPN	and	are	based	on	the	RefDB	database	[126].	
H‐N	chemical	shifts,	it	is	not	possible	to	identify	which	type	of	amino	acid	the	signal	belongs	to.	
Hence,	these	peaks	are	arbitrarily	numbered.	This	is	shown	for	three	amino	acids	in	figure	2.5a.	
To	obtain	the	information	needed	for	an	assignment	of	the	amino	acid	type,	information	from	3D	
spectra	were	recorded.	In	HSQC‐based	3	dimensional	spectra,	a	third	axis	with	information	about	
the	chemical	shift	of	carbon	atoms	is	added.	In	the	spectrum	shown	in	figure	2.5c,	the	chemical	
shift	of	the	alpha	and	beta	carbon	atoms	is	recorded	and	can	be	visualized	in	columns	above	the	
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HSQC	spectrum,	because	the	chemical	shift	of	the	respective	H‐N	groups	is	also	included	in	this	
spectrum.	Alpha	and	beta	carbon	atoms	can	be	distinguished	due	to	 their	opposite	phase.	The	
chemical	shifts	of	the	carbon	alpha	and	beta	atoms	depend	strongly	on	the	amino	acid	type.	Since	
the	combination	of	Cα	and	Cβ	shift	values	is	unique	for	some	amino	acid	types	(figure	2.5e),	this	
allows	assigning	the	residue	type.	In	the	example	shown	in	figure	2.5,	residue	“a”	has	a	Cβ	with	a	
chemical	 shift	 higher	 than	 the	 Cα.	 As	 seen	 in	 figure	 2.5e,	 this	 is	 only	 the	 case	 for	 serine	 and	
threonine.	Consequently,	residue	“a”	is	probably	a	serine	or	threonine.	Residue	“b”	does	not	have	
a	Cβ,	but	only	a	Cα.	As	all	amino	acids	but	glycines	contain	a	Cβ	atom,	residue	“b”	must	be	a	glycine.	
The	Cβ	shift	of	residue	“c”	is	with	20	ppm	remarkably	low.	This	is	typical	for	alanines,	indicating	
that	residue	“c”	is	most	likely	an	alanine.	
Proteins	usually	contain	an	amino	acid	type	more	than	once,	which	prevents	an	assignment	of	the	
position	in	the	polypeptide	chain	with	the	information	of	HSQC	and	HNCaCb	spectra.	This	means,	
it	 is	possible	 to	determine	 that	 the	HSQC	peak	 labeled	as	 residue	 “b”	 is	 a	glycine,	but	 it	 is	not	
possible	to	determine	which	glycine	in	the	protein	caused	this	peak.	Furthermore,	the	order	of	the	
three	amino	acids	cannot	be	derived	from	these	spectra.	
Information	 about	 the	 sequential	 arrangement	 of	 the	 amino	 acids	 can	be	 obtained	with	 pulse	
programs,	in	which	the	magnetization	is	transferred	from	the	carbon	atoms	to	the	H‐N	group	of	
the	succeeding	amino	acid	(i+1).	Figure	2.5d	shows	such	a	spectrum	(called	CbCaCONH),	in	which	
the	Cα	and	Cβ	chemical	shift	information	of	the	preceding	amino	acid	(i‐1)	is	recorded	with	the	N‐
H	shifts	of	 the	amino	acid	considered.	This	means	that	 the	columns	above	the	HSQC	spectrum	
(figure	2.5d)	now	represent	the	chemical	shifts	of	the	preceding	amino	acid.	
Looking	at	the	CbCaCONH	spectrum	(figure	2.5d)	of	residue	“b”,	it	is	noticeable	that	the	chemical	
shift	values	in	C	dimension	are	identical	to	those	of	residue	“a”	in	the	HNCaCb	spectrum	(figure	
2.5c).	As	explained	above,	this	can	only	be	the	case,	if	residue	“a”	precedes	residue	“b”.	Residue	“a”	
has	only	one	single	peak	in	the	CbCaCONH	spectrum	(figure	2.5d),	which	has	the	same	chemical	
carbon	shift	as	 the	Cα	of	 residue	“c”	 (figure	2.5c).	Hence,	 residue	“c”	precedes	residue	“a”.	The	
CbCaCONH	peaks	of	residue	“c”	indicate	the	carbon	shifts	of	the	amino	acid	preceding	residue	“c”.	
With	these	three	spectra	(HSQC,	HNCaCb,	CbCaCONH)	the	order	of	the	three	residues	could	be	
determined	as	Gly	(residue	“c”)	–	Ser/Thr	(residue	“a”)	–	Ala	(residue	“b”).	This	procedure	is	called	
chain	tracing.	
In	many	cases,	it	is	possible	to	localize	this	short	fragment	in	the	protein	sequence.	If	the	protein	
has	 both	Gly‐Ser‐Ala	 and	Gly‐Thr‐Ala	 in	 its	 sequence,	 or	 the	motif	 occurs	multiple	 times,	 it	 is	
necessary	 to	 assign	 longer	 fragments,	 before	 it	 can	be	unambiguously	 assigned	 to	 the	protein	
sequence.	Other	 spectra	 reveal	 information	 about	 the	 chemical	 shifts	 of	 side	 chain	 hydrogens	
and/or	hydrogens	of	 the	preceding	 amino	 acids.	These	 values	 are	helpful	 both	 to	 identify	 the	
amino	acid	type	and	sequential	order.	
It	should	be	mentioned	that	spectra	are	never	as	perfect	as	in	the	example	explained	above.	In	the	
HNCaCb	spectrum,	the	carbon	shifts	of	the	preceding	amino	acid	are	frequently	visible	in	addition	
to	the	carbon	shifts	of	the	amino	acid	itself.	Furthermore,	usually	not	all	peaks	are	clearly	visible	
due	to	overlap,	insufficient	signal‐to‐noise	ratio,	too	high	or	too	low	correlation	times,	or	terminal	
degradation.	Additionally,	small	shift	differences	between	two	spectra	are	commonly	observed,	
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because	of	slight	conformational	changes	or	minor	deviations	in	sample	preparation.	If	two	stable	
conformations	 exist,	which	 is	 often	 observed	 as	 cis/trans	 conformations	 for	 amino	 acids	 near	
prolines,	 both	 conformations	 are	 visible	 with	 their	 signal	 intensity	 corresponding	 to	 the	
abundance	of	the	respective	conformation.	
	
2.5.10 Lactate	dehydrogenase	activity	assay	
As	a	control	for	nanoparticle	inhibition,	lactate	dehydrogenase	(LDH)	was	used.	The	conversion	
of	 NADH	 to	 NAD+	 during	 the	 reduction	 of	 pyruvate	 to	 lactate	 was	 followed	 by	 absorbance	
spectroscopy.	The	reaction	was	followed	in	1	cm	cuvettes	at	340	nm	wavelength	in	a	Varian	Cary	
100	spectrophotometer	equipped	with	a	peltier	element.	Measurements	were	performed	with	a	
spectral	band	width	of	1	nm	and	5	seconds	average	time	at	20	°C.	Prior	to	each	measurement,	the	
blank	rate	of	250	µM	NADH	and	1	mM	pyruvate	in	100	mM	sodium	phosphate	buffer	pH	7.4	was	
measured	for	2	minutes.	To	start	the	reaction,	100	ng/ml	LDH	were	added	and	the	linear	decrease	
of	absorbance	was	followed	over	several	minutes.	With	a	molar	extinction	coefficient	for	NADH	of	
6220	 M‐1	 cm‐1,	 the	 NADH	 consumption	 per	 minute	 was	 calculated	 and	 the	 blank	 rate	 was	
subtracted.	 To	 test	 for	 inhibition	 by	 nanoparticles,	 Amsil8	 and	 Amsil125	 nanoparticles	 were	
added	to	the	final	reaction	volume	of	300	µl	and	incubated	briefly,	before	the	activity	was	assayed.	
	
2.5.11 Chymotrypsin	activity	assay	
Another	protease	tested	for	inhibition	by	nanoparticles	was	the	serine	protease	chymotrypsin.	As	
substrate,	the	peptide	Succ‐Ala‐Ala‐Pro‐Phe‐pNA	was	used,	where	Succ	is	succinic	acid	and	pNA	
is	p‐nitroaniline.	Chymotrypsin	cleaves	the	substrate	between	Phe	and	pNA.	Free	pNA	exhibits	a	
strong	absorbance,	which	can	be	followed	by	UV/Vis	spectroscopy.	Measurements	were	taken	at	
20	°C	with	300	µl	of	50	mM	NaH2PO4,	10	%	sucrose,	450	mM	NaCl,	1	mM	DTT,	pH	8.0	in	1	cm	
cuvettes	with	 a	 Varian	 Cary	 100.	 In	 this	 assay,	 the	 blank	 rate	 of	 150	µM	 substrate	 peptide	 in	
presence	or	absence	of	nanoparticles	was	followed	at	390	nm	for	2	minutes,	before	the	reaction	
was	started	by	addition	of	350	nM	chymotrypsin.	After	baseline	subtraction,	the	comparison	of	
the	 increase	 in	 absorbance	 with	 and	 without	 nanoparticles	 allowed	 a	 determination	 of	 the	
inhibitory	effect.	
	
2.5.12 MALDI‐TOF	mass	spectrometry	
Mass	spectra	of	proteins	were	recorded	with	an	Autoflex	speed	MALDI‐TOF	mass	spectrometer	
(Bruker	 Daltonics,	 Bremen).	 The	 matrix	 solution	 was	 created	 by	 dissolving	 7.6	 mg	 of	 2’,5’‐
dihydroxyacetophenone	 in	 375	 µl	 analytical	 ethanol	 and	 adding	 it	 to	 125	 µl	 of	 an	 18	mg/ml	
aqueous	solution	of	ammonium	hydrogen	citrate.	Proteins	were	desalted	with	the	help	of	Supel‐
Tips	C18	(Sigma‐Aldrich,	Seelze)	and	eluted	in	2	µl	of	a	50:50‐mixture	(v/v)	of	acetonitrile	and	
0.1	%	trifluoroacetic	acid.	2	µl	of	2	%	TFA	and	2	µl	of	matrix	solution	were	added	to	the	eluted	
protein.	 0.5	 µl	 of	 this	mixture	was	 spotted	 on	 an	MTP	 384	 ground	 steel	 target	 plate	 (Bruker	
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Daltonics,	Bremen)	and	allowed	to	dry.	Samples	were	mounted	onto	a	target	frame	and	analyzed	
with	the	standard	methods	LP_20‐50kDa	or	RP_5‐20kDa	from	the	Bruker	library.	
	
2.5.13 LC‐MS	ESI‐TOF	mass	spectrometry	
Liquid	 chromatography‐mass	 spectrometry	 electrospray	 ionization	 time‐of‐flight	 mass	
spectrometry	(LC‐MS	ESI‐TOF	MS)	measurements	were	taken	with	an	LCQ	Fleet	ESI	spectrometer	
(Thermo	Scientific,	Darmstadt)	equipped	with	an	Eclipse	XDB‐C18	column	(Agilent,	Böblingen).	
Chromatography	 was	 performed	 with	 5	 mM	 ammonium	 acetate	 and	 linear	 gradient	 from	
acetonitrile	to	water	was	applied	over	10	ml.	The	flow	rate	was	set	to	1	ml/min	and	absorbance	
was	detected	at	210	nm.	
	
2.6 Bioinformatic	methods	
2.6.1 Generation	of	Taspase	models	and	preparation	for	docking	
Missing	 parts	 of	 the	 Taspase	 crystal	 structure	 were	 added	 by	 homology	 modeling	 using	 the	
available	structure	(PDB	2a8j)	as	template.	For	homology	modeling	with	YASARA,	sequence	and	
structure	were	subjected	to	the	implemented	algorithm	with	the	parameters	given	in	table	2.30.	
	
Table	2.30	Parameters	for	homology	modeling	in	YASARA.	
Parameter	 Value	
PsiBLASTs	 1	
EValue	Max	 0.5	
Templates	Total	 5	
Templates	SameSeq	 1	
OligoState	 4	
Alignments	 5	
LoopSamples	 50	
TermExtensions	 90	
Speed	 slow	
	
For	homology	models	created	with	Swiss‐Model	[122],	the	automated	modeling	mode	was	used	
with	default	parameters	and	2a8i	as	template.	
As	YASARA	and	Swiss‐Model	do	not	support	heterodimer	modeling,	the	model	of	cleaved	Taspase	
was	 generated	 in	 a	 stepwise	 approach.	 First,	 homology	models	 of	 the	 α‐	 and	 β‐subunit	 were	
computed	 independently.	 Subsequently,	 both	models	were	 aligned	 to	 the	 full‐length	 structure	
2a8i,	to	reconstitute	the	active	αβ‐dimer.	This	dimer	was	refined	in	an	energy	minimization	and	
1	ns	molecular	dynamics	(MD)	simulation	using	YASARA.	
The	structures	were	prepared	for	docking	using	UCSF	chimera	[112]	and	programs	of	the	DOCK	6	
suite	 [114].	 In	chimera,	solvent	molecules	were	deleted,	for	alternative	atom	locations	only	the	
highest	 occupancy	 was	 kept	 and	 charges	 were	 calculated.	 Next,	 cavities	 on	 the	 surface	 were	
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identified	 using	 sphgen	 [127]	 and	 the	 active	 site	was	 selected	 as	 target	 area	 for	 docking.	 The	
overlapping	spheres	are	used	later	in	the	docking	process.	As	third	step,	a	square	box	with	50	Å	
edge	length	was	built	around	the	active	site.	In	this	box,	two	energy	grids	were	computed	using	
grid	 [128]	with	 the	 input	parameters	 listed	 in	 table	2.31.	The	bump	grid	 contains	 information	
necessary	to	identify	steric	overlap	of	ligand	and	receptor.	The	energy	grid	is	used	for	scoring	and	
holds	information	about	the	van	der	Waals	and	electrostatic	interactions.	
	
Table	2.31	Parameters	to	calculate	the	energy	grid	for	docking.	
Parameter	 Value	
grid_spacing	 0.3	Å	
energy_cutoff_distance 9999	Å	
atom_model	 a	(all	atoms,	including	H)
attractive_exponent	 6	
repulsive_exponent	 12	
dielectric_factor	 4	
bump_overlap	 0.75	
	
2.6.2 Compound	database	for	virtual	docking	
Compounds	for	the	in	silico	virtual	screen	were	obtained	from	the	ZINC	database	[129].	To	reduce	
the	 amount	 of	 structures	 and	 still	 cover	 a	maximum	 of	 different	 features,	 compounds	with	 a	
similar	 structure	were	 discarded.	 For	 this,	 the	 structures	were	 converted	 to	 chemical	 hashed	
fingerprints	with	ChemAxon	 [130],	 the	 fingerprints	of	 the	 structures	were	 compared	and	only	
compounds	that	differ	from	all	others	by	more	than	60	%	were	selected.	For	this,	the	compounds	
were	compared	pairwise.	Both	compounds	were	checked	for	the	presence	or	absence	of	certain	
structural	features	and	the	portion	of	shared	features	was	calculated.	This	is	additionally	done	for	
longer	 fragments,	 branching	 points	 and	 cyclic	 patterns.	 The	 structures	 of	 this	 subset	 were	
downloaded	from	the	ZINC	database	in	mol2	file	format.	
	
2.6.3 Virtual	Docking	
Two	docking	methods	were	used	consecutively.	First,	the	compounds	were	screened	in	a	flexible	
docking	process,	and	then	compounds	similar	to	the	best	fitting	compounds	were	obtained	and	
docked	using	an	AMBER	force	field	[131].	
Flexible	 docking	 was	 performed	 with	 the	 Anchor‐and‐Grow	 method	 on	 4	 processors.	 This	
algorithm	partitions	the	compound,	which	is	to	be	docked,	into	rigid	segments.	These	segments	
contain	only	bonds	with	double	bonds	or	partial	double	bond	character.	The	largest	rigid	fragment	
is	used	as	anchor	and	oriented	in	the	active	site.	This	is	done	by	matching	the	heavy	atoms	of	the	
fragment	with	the	spheres	generated	with	sphgen	(see	section	2.6.1)	and	subsequent	energetic	
optimization.	 This	 process	 is	 repeated	 500	 times	 and	 100	 orientations	with	 the	 best	 docking	
scores	are	used	for	growth.	In	the	growth	stage,	the	flexible	parts	of	the	compounds	are	added	one	
by	one	and	only	the	conformations	with	the	best	binding	energies	are	used	for	the	next	growth	
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step.	After	the	last	cycle,	all	the	fragments	are	combined	and	the	original	compound	is	docked	in	
the	active	site.	A	final	energy	calculation	is	performed	to	allow	a	ranking	of	all	the	compounds	that	
are	docked.	Parameters	used	for	this	step	are	listed	in	table	2.32.	
All	structures	with	a	docking	score	below	an	arbitrarily	defined	cut‐off	(‐40	kJ/mol)	were	selected	
for	the	following	step.	For	the	selected	structures,	similar	structures	were	searched	and	used	for	
the	next	docking	round.	This	second	docking	round	was	performed	with	 the	same	parameters	
used	for	the	first	round	(table	2.32)	on	8	processors.	The	docked	conformations	were	processed	
with	the	prepare_amber	script	of	the	DOCK	suite,	which	adds	hydrogens,	AMBER	force	field	atom	
types,	charges,	topology	and	coordinates.	31	structures	containing	cyclobutane	moieties	could	not	
be	parameterized	correctly	and	thus	were	excluded	from	the	set.	The	amber	input	files	were	used	
for	the	final	docking	round	with	AMBER	scoring.	In	this	docking	process,	all	26	amino	acids	within	
5	Å	around	the	active	site	were	treated	as	flexible.	The	ligand‐receptor‐complex	was	subjected	an	
energy	 minimization	 with	 200	 conjugate	 gradient	 steps,	 followed	 by	 a	 10	 picoseconds	 MD	
simulation	and	another	energy	minimization.	These	calculations	were	performed	on	8	processors	
with	the	input	variables	given	in	table	2.33.	
	
Table	2.32	Parameters	used	for	flexible	Anchor‐and‐Grow	docking.	
Parameter	 Value
automated_matching	 yes
max_orientations	 500
min_anchor_size	 40	
pruning_max_orients	 100
pruning_clustering_cutoff	 100
simplex_anchor_max_iterations	 500
simplex_growth_max_iterations	 500
atom_model	 a	(all	atoms)
	
Table	2.33	Parameters	used	for	AMBER	score	docking.	
Parameter	 Value
amber_score_movable_distance_cutoff 5 Å
amber_score_before_md_minimization_cycles 200
amber_score_after_md_minimization_cycles 200
amber_score_md_steps 10000
amber_score_temperature	 300 K
amber_score_nonbonded_cutoff	 18 Å
2.6.4 Generation	of	Taspase	loop	models	
Two	models	 of	 the	 isolated	 Taspase	 loop	were	 generated.	 The	 first	model	was	 obtained	with	
conventional	homology	modeling,	as	described	for	the	full‐length	protein	(section	2.6.1).	Starting	
point	for	the	second	model	was	a	linear	peptide	chain.	After	energy	minimization	and	100	ns	MD	
simulation,	the	structure	reached	an	energetic	minimum,	which	was	considered	as	stable	state.
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3 Results	
3.1 Cloning	and	purification	of	Taspase	protein	
The	DNA	for	Taspase	proteins	was	cloned	in	expression	vectors	and	transformed	in	competent	
bacterial	expression	strains.	The	conditions	for	protein	expression	were	individually	optimized	
for	wild	type	Taspase,	the	active	mutant	and	the	loop	peptide.	Affinity	tags	allowed	a	purification	
of	 heterologously	 expressed	 protein	 in	 the	milligram	 scale.	 The	 pure	 proteins	 were	 used	 for	
biochemical	characterization	in	in	vitro	assays.	
	
3.1.1 Cloning	of	Taspase	and	its	mutants	
Isolation	of	the	cDNA	of	human	Taspase	from	SEM	cells	and	cloning	into	a	pET‐22b	vector	with	C‐
terminal	 His‐tag	 was	 performed	 by	 Jens	 Rabenstein	 [82].	 The	 bicistronic	 construct	 for	 active	
Taspase	 with	 shortened	 loop	 (figure	 2.3)	 was	 designed	 in	 silico.	 The	 DNA	 was	 synthesized	
(GeneArt,	Regensburg)	and	subsequently	cloned	via	NdeI/XhoI	restriction	sites	into	a	modified	
pET‐41b	 vector	 [132,132].	 The	 catalytically	 inactive	 mutant	 D233A/T234A	 was	 created	 by	
QuikChange	according	to	manufacturer’s	instructions	using	the	construct	for	wild	type	Taspase	
as	 template.	 Vector	maps	 of	 all	 bacterial	 expression	 constructs	 can	 be	 found	 in	 supplemental	
figure	7.1.	
	
 
Figure	3.1	Agarose	gel	after	PCR	amplification	of	the	Taspase	loop.	
PCR	was	performed	with	wild	type	Taspase	as	template.	The	visible	band	exhibits	the	expected	size	of	the	
Taspase	loop	of	168	bp.	
 
For	cloning	of	the	Taspase	loop,	the	full	length	Taspase	construct	was	used	as	template	with	the	
primer	 pair	 given	 in	 table	 2.13.	 After	 PCR	 amplification,	 the	 PCR	 product	was	 analyzed	 in	 an	
agarose	gel	(figure	3.1).	A	band	at	approximately	150	bp	can	be	detected,	which	corresponds	to	
the	expected	size	of	168	bp	for	the	Taspase	loop.	This	band	was	cut	from	the	gel	and	the	DNA	was	
isolated.	Subsequently,	both	 the	 insert	 (PCR	product)	and	 the	vector	 (pET‐41b)	were	digested	
separately	with	ApaI	and	XhoI.	Insert	and	vector	were	purified	again,	before	they	were	ligated	(3	
to	 1	 ratio)	 using	 T4	 ligase.	 After	 transformation	 of	 the	 ligation	 product	 into	 shox	 cells	 and	
incubation	over	night,	ten	clones	were	tested	in	a	colony	PCR	and	the	result	was	again	controlled	
in	an	agarose	gel	(figure	3.2).	
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Figure	3.2	Agarose	gel	after	colony	PCR	for	verification	of	positive	clones.	
Ten	clones	were	selected	after	ligation	of	Taspase	loop	and	modified	pET‐41b	vector.	Comparison	to	a	PCR	
with	wild	type	Taspase	plasmid	(Ctrl)	shows	that	all	clones	except	for	clone	6	exhibit	a	band	at	the	size	of	
the	Taspase	loop	(168	bp).	
 
All	clones	except	for	clone	6	showed	a	band	at	the	size	of	the	positive	control	(168	bp).	Clones	1	
and	3	were	selected	arbitrarily	for	DNA	isolation	and	sequencing.	Both	clones	tested	possessed	
the	 correct	 sequence	 and	 the	 DNA	 of	 clone	 1	 was	 transformed	 into	 the	 expression	 strain	
BL21(DE3)T1r.	
	
3.1.2 Expression	test	of	wild	type	Taspase	
 
Figure	3.3	SDS‐PAGE	gels	of	expression	test	for	wt	Taspase.	
Expression	of	wild	type	Taspase	was	tested	in	E.	coli	BL21(DE3)T1r	cells	(BL21)	and	Rosetta2	cells	(Ros)	
at	18	°C,	24	°C	and	30	°C	after	3	h,	6	h	and	over	night	(o.n.).	Supernatant	(S)	and	pellet	fractions	(P)	were	
compared	 to	 a	 sample	 before	 IPTG‐induction	 (‐IPTG).	 The	 expected	 sizes	 of	 full‐length	 Taspase	 (fl),	 α‐
subunit	(α)	and	β‐subunit	(β)	are	indicated	with	arrows.	Optimum	expression	conditions	are	achieved	in	
Rosetta2	cells	after	6	h	at	30	°C. 
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Heterologous	expression	of	the	His‐tagged	wild	type	Taspase	protein	in	E.	coli	was	tested	in	two	
different	strains	(BL21(DE3)T1r	and	Rosetta2)	at	three	different	temperatures	(18	°C,	24	°C	and	
30	°C)	and	for	three	different	expression	times	(3	h,	6	h,	over	night)	in	TB	medium.	The	amount	of	
overexpressed	protein	was	compared	to	the	protein	content	before	addition	of	IPTG.	After	lysis	
and	ultracentrifugation,	pellet	and	supernatant	proteins	were	investigated	with	SDS‐PAGE	(figure	
3.3).	
Under	most	conditions,	the	major	fraction	of	Taspase	can	be	found	in	the	pellet,	while	only	a	small	
fraction	 is	present	 in	the	supernatant.	The	 largest	amount	of	soluble	Taspase	 is	achieved	after	
expression	for	6	h	at	30	°C	in	Rosetta2	cells.	Consequently,	 these	conditions	were	used	for	the	
expression	of	wild	 type	Taspase,	 as	well	 as	 for	 the	 expression	of	 the	 inactive	Taspase	mutant	
(D233A/T234A	mutant).	
	
3.1.3 Purification	of	wild	type	Taspase	and	inactive	Taspase	
In	figure	3.4,	the	chromatograms	and	gels	for	the	purification	of	wild	type	Taspase	are	displayed.	
The	corresponding	figures	for	the	inactive	mutant	can	be	found	in	supplemental	figure	7.4.		
After	expression	in	2	l	under	optimized	conditions	(section	3.1.2),	bacteria	were	resuspended	in	
phosphate	buffer	and	lysed	by	incubation	with	lysozyme,	followed	by	sonification.	After	cell	debris	
and	insoluble	proteins	had	been	removed	by	ultracentrifugation	and	sterile	 filtration,	a	NiNTA	
affinity	chromatography	was	performed	and	the	purity	of	the	eluted	fractions	was	controlled	by	
SDS‐PAGE	(figure	3.4).		
	
Figure	3.4	NiNTA	affinity	purification	of	wild	type	Taspase.	
The	 upper	 panel	 shows	 the	 chromatogram	 of	 the	 NiNTA	 affinity	 purification	 including	 the	 gradient	 of	
elution	buffer.	Samples	for	SDS‐PAGE	were	taken	from	the	supernatant	before	NiNTA	purification	(S)	and	
from	 elution	 fractions	 indicated	 with	 arrows.	 The	 corresponding	 gel	 (lower	 panel)	 reveals	 fractions	
containing	full‐length	Taspase	(fl),	α‐subunit	(α)	and	β‐subunit	(β).	Fractions	highlighted	in	blue	were	pure	
enough	for	gel	filtration,	while	the	impure	fractions	highlighted	in	green	were	applied	to	another	NiNTA	
affinity	chromatography.	
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The	first	elution	peak	(green	in	figure	3.4)	emerges	at	low	imidazole	concentrations	(~35	mM)	
and	contains	significant	amounts	of	Taspase	in	addition	to	severe	impurities	by	E.	coli	proteins.	
The	fractions	of	this	peak	were	diluted	to	100	ml,	reducing	the	imidazole	concentration	to	10	mM,	
and	applied	another	time	to	a	NiNTA	affinity	column.	The	chromatogram	of	this	purification	and	
the	respective	gel	filtration	can	be	found	in	supplemental	figure	7.5.	
The	second	elution	peak	at	125	mM	imidazole	(blue	in	figure	3.4)	contains	Taspase	with	only	few	
impurities	at	around	35	kDa.	This	peak	was	pooled	and	concentrated	to	2	ml,	before	the	protein	
was	subjected	to	gel	filtration	on	a	Superdex	200	column	for	further	purification	and	removal	of	
imidazole.	Two	peaks	are	visible,	which	were	analyzed	by	SDS‐PAGE	(figure	3.5).	
	
	
Figure	3.5	Preparative	gel	filtration	of	wild	type	Taspase.	
a	The	upper	panel	displays	the	gel	filtration	chromatogram.	The	two	peaks	were	analyzed	by	SDS‐PAGE	
(lower	panel),	showing	that	the	second	peak	(highlighted	in	blue)	contains	pure	full‐length	Taspase	(fl),	α‐
subunit	(α)	and	β‐subunit	(β).	b	The	corresponding	gel	for	the	inactive	Taspase	mutant	(D233A/T234A)	
shows	only	one	band	near	45	kDa,	corresponding	to	the	full‐length	enzyme.	
	
	
The	 first	 peak	 at	 50	 ml	 corresponds	 to	 the	 void	 volume	 and	 contains	 large	 complexes	 or	
aggregates.	For	wild	type	Taspase,	the	major	peak	(blue	in	figure	3.5a)	contains	almost	exclusively	
the	proenzyme	of	full	length	Taspase	or	the	active	form	consisting	of	α‐	and	β‐subunits.	For	the	
inactive	mutant,	 only	 the	 proenzyme	was	 found	 (figure	 3.5b).	 This	 peak	was	 concentrated	 to	
18	mg/ml	and	stored	in	aliquots	at	‐20	°C.	The	overall	protein	yield	amounted	25	mg	per	liter	of	
bacteria	culture.	
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3.1.4 Purification	of	active	Taspase	mutant	
To	 express	 a	 cleaved	 Taspase	 variant,	 the	 two	 subunits	 were	 co‐expressed	 in	 E.	 coli	 with	
shortened	Taspase	loop.	This	variant	is	subsequently	referred	to	as	active	Taspase.	The	bicistronic	
construct	for	active	Taspase	comprises	the	amino	acids	1	to	206	(His‐tagged	α‐subunit)	and	amino	
acids	234	to	420	(β‐subunit;	figure	2.3).	Expression	tests	indicated	maximum	protein	expression	
after	6	hours	at	37	°C	(see	supplemental	section	7.6).	The	low	amount	of	overexpressed	protein	
could	partially	be	compensated	by	increasing	the	expression	culture	size	to	6	liter.	Cell	lysis	and	
NiNTA	affinity	purification	were	performed	as	described	for	the	wild	type	Taspase	(section	3.1.3).	
Although	only	the	α‐subunit	is	His‐tagged,	the	β‐subunit	can	be	co‐purified	due	to	dimerization	of	
the	subunits.	The	chromatograms	of	 the	NiNTA	affinity	chromatogram	and	the	subsequent	gel	
filtration	are	displayed	in	figure	3.6.	
	
	
Figure	3.6	Purification	of	active	Taspase	by	affinity	chromatography	and	gel	filtration.	
a	NiNTA	affinity	purification	of	active	Taspase.	The	His‐tagged	α‐subunit	and	the	untagged	β‐subunit	were	
co‐purified.	The	top	panel	shows	the	chromatogram	including	the	elution	gradient.	The	SDS	gel	of	protein	
containing	elution	fractions	is	shown	in	the	lower	panel.	The	second	peak	(highlighted	in	blue)	contains	α‐
subunit	(α)	and	β‐subunit	(β)	with	few	impurities	and	was	used	for	subsequent	gel	filtration.	b	Gel	filtration	
of	active	Taspase.	The	upper	panel	displays	 the	chromatogram.	The	SDS‐PAGE	gel	of	protein	containing	
fractions	is	shown	in	the	lower	panel.	The	third	peak	(highlighted	in	blue)	contains	pure	active	Taspase.	
	
The	 first	 elution	 peak	 of	 the	 NiNTA	 column	 (figure	 3.6a)	 between	 275	 and	 300	 ml	 contains	
Taspase,	but	also	a	significant	amount	of	impurities.	Hence,	only	the	second	elution	peak	(blue	in	
figure	3.6a)	was	concentrated	and	used	for	gel	filtration.	The	gel	filtration	chromatogram	(figure	
3.6b)	exhibits	three	prominent	peaks.	The	left	peak	corresponds	to	the	void	volume	and	contains	
aggregated	protein.	The	middle	peak	contains	Taspase	with	impurities	of	larger	proteins	and	the	
right	 peak	 (blue	 in	 figure	 3.6b)	 contains	 Taspase	with	 some	 impurities	 below	 20	 kDa.	 These	
proteins	were	probably	degradation	products	and	could	be	successfully	removed	by	using	a	filter	
with	 30	 kDa	 cut‐off	 for	 final	 concentration	 to	 15	mg/ml.	 The	 overall	 yields	 of	 active	 Taspase	
ranged	from	1	to	2	mg	per	liter	of	bacteria	culture.	
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3.2 Characterization	of	Taspase	and	its	mutants	
With	purified	wild	type,	active	and	inactive	Taspase	available,	a	detailed	biochemical	comparison	
and	characterization	was	accomplished.	Dimerization	was	assessed	by	analytical	 gel	 filtration,	
while	 CD	 as	 well	 as	 fluorescence	 spectroscopy	 gave	 insight	 into	 the	 stabilization	 by	 sodium	
chloride.	 Possible	 posttranslational	 modifications	 could	 be	 excluded	 with	 the	 help	 of	 mass	
spectrometry,	 and	 the	 autocatalytic	 processing	 was	 followed	 by	 SDS‐PAGE	 and	 NMR	
spectroscopy.	 Furthermore,	 first	 structural	 information	 about	 the	 loop	 region,	 which	 is	 not	
resolved	in	the	crystal	structures,	was	obtained	by	NMR	and	CD	spectroscopy.	
	
3.2.1 CD	spectroscopic	studies	
In	 order	 to	 analyze	 the	 secondary	 structure	 of	 the	 Taspase	mutants,	 far‐UV	 CD	 spectra	were	
recorded	(figure	3.7a).	
	
Figure	3.7	Far‐UV	CD	spectra	of	Taspase.	
a	Far‐UV	CD	spectra	of	wild	type	Taspase	(wt),	active	Taspase	(with	shortened	loop)	and	inactive	Taspase	
(D233A/T234A)	indicate	a	similar	secondary	structure	composition	of	all	three	proteins.	The	shape	of	the	
spectrum,	especially	the	minima	at	222	nm	and	208	nm	hint	at	a	helix‐rich	protein	with	beta‐stand	portions.	
b	 Secondary	structure	deconvolution	of	 the	wt	CD	spectrum	using	 the	CDSSTR	algorithm	confirm	55	%	
helix,	23	%	sheet,	11	%	turn	and	10	%	random	coil	elements.	Numbers	indicate	percent	values.	
	
All	three	CD	spectra	for	wild	type,	active	and	inactive	Taspase	are	similar	and	exhibit	minima	at	
220	nm	and	208	nm	with	the	220	nm	minimum	exhibiting	the	lowest	ellipticity.	Comparison	with	
a	reference	data	set	with	the	CDSSTR	algorithm	yielded	55	%	helix	and	23	%	sheet	content	(figure	
3.7b).	
	
3.2.2 Stability	of	Taspase	
Secondary	structure	is	lost,	when	proteins	are	unfolded.	Hence,	CD	spectroscopy	can	be	used	to	
monitor	 thermal	 unfolding	 of	 proteins	 (figure	 3.8a).	 To	 find	 suitable	 buffer	 conditions	 for	
subsequent	assays,	Taspase	stability	was	measured	 in	different	buffers.	As	CD	spectroscopy	 is	
limited	with	respect	to	chloride	and	sucrose	concentration,	tryptophan	unfolding	via	fluorescence	
spectroscopy	was	employed	as	orthogonal	method	(figure	3.8b).	
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Figure	3.8	Melting	curves	of	Taspase.	
a	CD	melting	curves	of	wild	type	Taspase	(wt	Taspase;	black;	Tm	=	59	°C),	active	Taspase	(blue;	Tm	=	60	°C)	
and	 inactive	Taspase	 (red;	Tm	=	63	 °C)	 in	50	mM	phosphate	buffer.	b	Tryptophan	 fluorescence	melting	
curves	show	that	wild	type	Taspase	in	50	mM	phosphate	buffer	(black;	Tm	=	56	°C)	can	be	stabilized	by	
addition	of	10	%	sucrose	(blue;	Tm	=	73	°C)	or	450	mM	NaCl	(red;	Tm	=	77	°C).	
	
CD	spectroscopy	in	phosphate	buffer	reveals	a	melting	temperature	(Tm)	of	59	°C	for	wild	type	
Taspase,	which	consists	of	α‐	and	β‐subunit	and	a	Tm	of	60	°C	for	the	active	Taspase	with	shortened	
loop.	 In	 contrast,	 the	 inactive	 mutant	 is	 made	 up	 of	 a	 continuous	 polypeptide	 chain	 and	 is	
somewhat	more	stable	with	a	melting	temperature	of	63	°C.	Fluorescence	spectroscopy	yielded	a	
melting	temperature	of	56	°C	for	wild	type	Taspase.	Khan	et	al.	[56]	used	chloride	and	sucrose	in	
their	buffers,	which	was	tested	here	for	a	stabilizing	effect.	Addition	of	10	%	sucrose	(292	mM)	
elevates	 the	melting	 temperature	by	17	 °C	 to	a	Tm	of	73	 °C.	A	 similar	 effect	 could	be	 seen	 for	
450	mM	NaCl,	which	stabilized	Taspase	by	21	°C	to	77	°C.	
	
3.2.3 MALDI‐MS	analysis	
Mass	spectrometry	allows	a	precise	determination	of	the	molecular	weight	of	proteins.	Spectra	
were	recorded	for	masses	between	15	and	50	kDa,	which	covers	the	mass	of	the	proenzyme,	as	
well	as	the	masses	of	the	subunits	(figure	3.9).	
For	the	wild	type	enzyme	(black	in	figure	3.9),	four	major	peaks	are	visible.	They	correspond	to	
the	proenzyme	(T2‐H428)	with	a	sodium	and	potassium	ion	as	adduct	(Δm/z	=	0.01	%),	the	α‐
subunit	(T2‐D233)	with	a	potassium	ion	as	adduct	(Δm/z	=	‐0.01	%)	and	the	β‐subunit	(T234‐
H428)	with	a	sodium	ion	as	adduct	(Δm/z	=	‐0.05	%).	The	double	charged	proenzyme	causes	the	
fourth	peak	at	exactly	half	the	mass	of	the	proenzyme	(22722	Da).	
The	 active	 Taspase	 (blue	 in	 figure	 3.9)	 exhibits	 two	main	 peaks	 in	 the	mass	 spectrum.	 They	
correspond	to	the	α‐subunit	(H1‐A212)	with	a	potassium	ion	as	adduct	(Δm/z	=	‐0.05	%)	and	the	
β‐subunit	(T234‐E420)	with	a	sodium	ion	as	adduct	(Δm/z	=	0.01	%).	
The	 inactive	 mutant	 (red	 in	 figure	 3.9)	 exhibits	 three	 major	 peaks,	 corresponding	 to	 the	
proenzyme	with	potassium	and	sodium	ions	as	adduct	(Δm/z	=	‐0.1	%),	as	well	as	the	double	and	
triple	charged	proenzyme.	
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Figure	3.9	MALDI‐TOF	mass	spectra	of	Taspase.	
Mass	 spectra	 of	wild	 type	 Taspase	 (top	 panel),	 active	 Taspase	 (middle	 panel)	 and	 15N‐labeled	 inactive	
Taspase	 (lower	 panel)	were	 recorded	 in	 the	 range	 of	 15	 to	 50	 kDa.	 The	 arbitrary	 intensity	 units	were	
rescaled.	Arrows	indicate	masses	of	the	respective	full‐length	protein	(fl),	α‐subunit	(α),	β‐subunit	(β),	and	
shortened	α‐subunit	(amino	acids	1‐206	or	1‐195).	For	improved	clarity,	double	and	triple	charged	masses	
are	not	labeled.	
	
3.2.4 Analytical	gel	filtration	
Analytical	gel	filtration	was	performed	to	test	for	Taspase	multimerization.	The	calibration	range	
covers	the	subunits	(22	kDa),	the	dimer	(45	kDa)	as	well	as	the	tetramer	(90	kDa)	and	can	be	
found	in	supplemental	figure	7.7.	Gel	filtration	runs	of	1	to	400	µM	Taspase	and	inactive	Taspase	
(D233A/T234A)	 in	 the	presence	of	450	mM	NaCl	on	a	Superdex	200	column	are	displayed	 in	
figure	3.10.	
Both	wild	type	Taspase	and	the	inactive	mutant	elute	in	the	range	of	a	tetramer	(90‐110	kDa;	gray	
area	 in	 figure	3.10)	 independent	of	 the	protein	 concentration.	The	expected	 range	 for	 the	αβ‐
dimer	(45‐55	kDa)	is	highlighted	in	green.	No	peak	can	be	detected	in	this	area	for	the	wild	type	
or	 the	 inactive	mutant.	 Consistent	with	 this,	 no	 peak	 for	 the	 separate	 α‐	 or	 β‐subunit	 can	 be	
detected	at	19	ml	retention	volume.	
The	result	is	essentially	the	same	at	lower	salt	concentrations	(100	mM	NaCl):	Wild	type	Taspase,	
active	and	inactive	Taspase	elute	as	tetramer	with	apparent	molecular	weights	around	100	kDa	
(supplemental	figure	7.8).	
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Figure	3.10	Analytical	gel	filtration	of	Taspase.	
Analytical	gel	filtration	chromatograms	of	a	calibrated	Superdex	200	column	reveal	that	wild	type	Taspase	
(a)	 and	 inactive	 Taspase	 (b)	 elute	 in	 the	 range	 of	 90‐110	 kDa	 (labeled	 T),	 corresponding	 to	 a	 hetero‐
tetramer.	At	the	expected	dimer	size	of	45‐55	kDa	(labeled	D),	no	peak	is	visible.	
	
3.2.5 Autocatalytic	processing	of	the	Taspase	proenzyme	
The	Taspase	proenzyme	undergoes	spontaneous	intramolecular	autocatalytic	processing.	In	this	
process,	the	polypeptide	chain	opens	between	Asp233	and	Thr234,	yielding	the	catalytic	active	
Thr234	with	 free	 hydroxyl	 group.	 This	 process	 is	 time	 dependent	 and	 can	 be	 visualized	 by	 a	
separation	of	the	subunits	by	SDS‐PAGE	(figure	3.11a).	
	
	
Figure	3.11	Autocatalytic	processing	of	Taspase.	
a	10	µM	wild	type	Taspase	was	incubated	in	gel	filtration	buffer	at	37	°C.	At	indicated	time	points,	samples	
were	taken	for	SDS‐PAGE.	The	expected	sizes	of	full‐length	Taspase	(fl),	α‐subunit	(α)	and	β‐subunit	(β)	are	
marked	with	arrows	in	the	15	%	SDS‐PAGE	gel.	b	No	autocatalytic	processing	was	observed	for	the	inactive	
Taspase	mutant	after	7	days.		
	
Six	hours	incubation	at	37	°C	caused	an	attenuation	of	the	band	for	the	full‐length	enzyme,	while	
the	bands	for	α‐	and	β‐subunit	gained	intensity.	After	one	day,	the	band	for	the	full‐length	enzyme	
is	 diminished,	 while	 both	 subunit	 bands	 became	 stronger.	 The	weak	 band	 for	 the	 full‐length	
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enzyme	is	visible	even	after	one	week.	In	contrast,	incubation	of	the	inactive	mutant	for	one	week	
resulted	in	a	single	band	for	the	full‐length	enzyme	(figure	3.11b).	
	
3.2.6 NMR	spectroscopic	analysis	of	Taspase	
For	the	first	time,	Taspase	was	analyzed	by	NMR	spectroscopy	in	this	project	to	gain	information	
about	the	flexible	parts,	which	are	not	resolved	in	the	crystal	structures.	A	1H‐15N	HSQC	spectrum	
of	15N‐labeled	wild	type	Taspase	was	recorded	at	30	°C	(figure	3.12a).	
	
	
Figure	3.12	1H‐15N	HSQC	spectrum	assignment.	
1H‐15N	HSQC	spectrum	of	wild	type	Taspase	after	one	week	at	30	°C	in	gel	filtration	buffer.	The	crowded	
region	 in	 the	 center	 of	 the	 spectrum	 (dashed	 lines)	 is	 magnified.	 For	 amino	 acids	 labeled	with	 letters	
without	numbers,	only	the	residue	type	could	be	determined	unambiguously.	
	
The	His‐tagged	protein	comprises	428	amino	acids,	including	15	prolines,	which	results	in	412	
backbone	 peaks	 theoretically	 visible	 in	 a	 1H‐15N	HSQC	 spectrum.	However,	 only	 56	 backbone	
peaks	are	visible	in	the	1H‐15N	HSQC	spectrum.	
These	 peaks	 were	 assigned	 to	 the	 corresponding	 amino	 acids	 using	 backbone	 (HNCaCb,	
CbCaCONH,	 HNCOCa)	 and	 side	 chain	 spectra	 (15N‐TOCSY‐HSQC,	 15N‐COSY‐HSQC,	 HbHaNH,	
HbHaCONH,	HCCH‐TOCSY)	recorded	with	15N	and	13C	labeled	protein	(supplementary	table	7.4).	
This	allowed	an	assignment	of	40	residue	types	(71	%),	of	which	32	(55	%)	could	be	assigned	to	
specific	amino	acid	positions.	Moreover,	a	spectrum	recorded	at	pH	6.5	(data	not	shown)	showed	
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only	marginal	shifts	and	the	same	number	of	peaks	compared	to	the	spectrum	at	pH	7.9	shown	in	
figure	3.12a.	
Another	striking	observation	was	a	time	dependent	appearance	of	peaks	in	the	HSQC	spectrum.	
The	 spectrum	 of	 a	 Taspase	 sample	 recorded	 immediately	 after	 purification	 exhibits	 only	 22	
backbone	NH	 peaks	 (supplemental	 figure	 7.9).	 The	 other	 34	 peaks	 become	 visible	 by	 and	 by	
during	the	incubation	for	five	to	seven	days.	A	spectrum	of	a	sample	incubated	for	30	days	(data	
not	 shown)	 still	 shows	 the	 56	 peaks	 seen	 after	 seven	 days	 and	 only	 few	 signs	 of	 terminal	
degradation,	 indicating	 that	 the	 underlying	process	 is	 completed	 after	 seven	days.	 The	 amino	
acids	initially	visible	in	the	HSQC	spectrum	could	be	assigned	to	the	N‐terminus	(5	residues),	the	
flexible	loop	(3	residues)	and	a	loop	near	the	active	site	(1	residue).	
The	inactive	mutant	lacking	the	ability	of	autocatalytic	activation	due	to	a	double	mutation	of	the	
active	 site	 (D233A/T234A)	was	 15N	 isotopic	 labeled	 and	 1H‐15N	HSQC	 spectra	were	 recorded	
(supplemental	figure	7.10)	under	the	same	conditions	used	for	wild	type	protein.	Both	proteins	
were	incubated	for	7	days	at	30	°C	before	spectra	were	recorded.	Compared	with	the	wild	type	
spectrum,	9	backbone	peaks	of	amino	acids	located	in	the	flexible	loop	(S222‐D233)	and	the	peak	
of	Glu34	in	the	N‐terminus	are	missing.	
	
3.2.7 Characterization	of	the	Taspase	loop	
In	silico	studies	
The	Taspase	loop	is	released	at	the	C‐terminal	end	by	an	autocatalytic	event,	which	creates	the	
catalytically	active	Thr234	at	the	N‐terminus	of	the	β‐subunit.	Suitable	algorithms,	such	as	JNet,	
CFSSP	or	the	YASARA	tool,	can	predict	the	secondary	structure	elements	of	the	loop	based	on	the	
amino	acid	sequence	(figure	3.13a).	
All	 three	 algorithms	 consistently	 predict	 a	 helical	 content	 around	 50	 %	 and	 the	 rest	 as	
unstructured.	Both	N‐	and	C‐terminus	are	predicted	as	random	coil	regions,	while	the	central	part	
(N185‐S223)	is	predicted	to	form	helices.	
To	investigate	if	the	loop	conformation	changes	after	the	autocatalytic	cleavage,	releasing	the	loop	
at	the	C‐terminus,	homology	models	of	the	proenzyme	and	active	Taspase	were	generated	(figure	
3.13c	and	d).	In	both	models,	the	loop	region	comprises	two	interacting	helices.	The	conformation	
of	the	loop,	however,	differs	between	the	proenzyme	and	active	Taspase.	While	in	the	proenzyme	
the	loop	is	attached	to	the	active	site	and	therefore	blocking	the	catalytic	center,	in	the	model	of	
active	Taspase	the	loop	is	located	outside	the	active	site,	rendering	the	catalytic	Thr234	accessible	
for	substrates.	
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Figure	3.13	Secondary	and	tertiary	structure	prediction	of	the	Taspase	loop.	
a	Primary	sequence	based	secondary	structure	prediction	of	the	loop	region	G178‐D233,	which	is	missing	
in	the	crystal	structure	of	active	Taspase	(PDB	2a8j).	The	algorithms	predict	a	stretch	of	helices	between	
N185	and	S223.	For	 the	YASARA	model	 and	 the	 JNet	prediction,	 cylinders	 represent	helical	areas,	 lines	
represent	 random	 coil	 and	 loops	 are	 represented	 as	 curves.	 Confidence	 (conf)	 values	 range	 from	 0	
(uncertain)	to	9	(confident).	Residues	predicted	as	buried	by	sol25	and	sol0	are	labeled	(B).	Note	that	the	
N‐terminal	GP	originates	 from	the	GST	tag.	b	 In	the	proenzyme,	 the	 loop	(red	and	orange)	 is	covalently	
attached	to	the	active	site	(green).	The	model	is	based	on	the	crystal	structure	of	the	proenzyme	(PDB	2a8i).	
The	loop	amino	acids	that	are	structured	in	the	crystal	structure	of	the	proenzyme,	but	not	in	the	processed	
protein	 are	 colored	 in	 orange.	 Newly	 modeled	 amino	 acids	 are	 displayed	 in	 red.	 c	 After	 autocatalytic	
activation,	the	loop	(red)	can	leave	the	active	site	(green).	The	model	is	based	on	the	structure	of	active	
Taspase	(PDB	2a8j).	
	
	
In	vitro	experiments	
Testing	this	in	silico	model	in	vitro	requires	purified	loop	peptide.	For	this,	the	56	amino	acid	loop	
fragment	was	obtained	by	recombinant	expression	in	E.	coli.	In	addition,	a	shorter	loop	fragment	
of	 42	 amino	 acids	 covering	 only	 the	 two	 helices	 was	 synthesized	 (CASLO	 ApS,	 Lyngby).	
Recombinant	 expression	 of	 the	 short	 fragment	 was	 considered	 ineffective,	 as	 short	 peptide	
fragments	are	typically	prone	to	degradation,	even	if	long	tags,	such	as	GST,	are	used.	
Expression	 tests	 of	 the	 long	 loop	 in	 E.	 coli	 (supplemental	 figure	 7.11)	 indicated	 optimum	
expression	conditions	of	25	°C	over	night	in	LB	medium	and	addition	of	1	%	Triton	X‐100	to	the	
buffer	in	which	the	pellet	was	resuspended.	The	GST	fusion	protein	was	purified	by	GSH	affinity	
chromatography	(figure	3.14a).	
	
RESULTS	 CHARACTERIZATION	OF	TASPASE	AND	ITS	MUTANTS	
	
78	
	
	
Figure	3.14	Purification	of	the	Taspase	loop.	
a	GSH	affinity	chromatogram	(top	panel)	and	the	SDS‐PAGE	gel	of	the	fractions	indicated	by	arrows.	The	
overexpressed	GST‐loop	 fusion	protein	 visible	 in	 the	 supernatant	 before	 affinity	 chromatography	 (S)	 is	
bound	to	the	column	and	thereby	removed	from	the	flow‐through	(first	lane).	After	washing,	the	GST‐loop	
is	eluted	and	concentrated	(‐PreSc).	PreScission	 (+PreSc)	 removes	 the	GST	 tag	and	removal	of	GST	 in	a	
10	kDa	cut‐off	Centricon	with	subsequent	concentration	of	the	flow‐through	yielded	pure	loop	protein.	b	
The	correct	size	of	the	loop	protein	(6621	Da)	was	confirmed	by	MALDI‐MS.	
	
The	supernatant	after	ultracentrifugation	with	the	overexpressed	GST‐loop	(S	in	figure	3.14a)	was	
applied	to	a	GSH	column.	Efficient	binding	to	the	column	is	confirmed	by	the	absence	of	the	target	
protein	in	the	flow‐through.	The	elution	fractions	contain	GST‐loop,	which	is	still	impurified	by	
additional	 proteins.	 The	 GST‐tag	was	 removed	 by	 PreScission	 protease	 treatment	 (+	 PreSc	 in	
figure	3.14a)	and	filtration	through	a	10	kDa	membrane	yielded	pure	loop	peptide	(C	in	figure	
3.14a).	 The	GST	 tag	 and	other	 impurities	were	 retained.	The	 correct	mass	of	 the	peptide	was	
confirmed	by	MALDI‐MS	(figure	3.14b).	With	the	two	variants	of	the	loop	peptide	available,	the	
secondary	structure	was	analyzed	by	CD	spectroscopy	(figure	3.15a).	
The	short	and	long	loop	differ	in	their	secondary	structure,	indicating	a	strong	influence	of	the	16	
additional	amino	acids	present	in	the	longer	loop	(5	N‐terminal;	11	C‐terminal).	The	spectrum	of	
the	short	 loop	peptide	exhibits	unambiguous	 features	of	an	unstructured	random	coil	protein,	
such	 as	 positive	 ellipticity	 at	 220	 nm	 and	 a	 minimum	 at	 200	 nm.	 In	 contrast,	 the	 long	 loop	
possesses	a	minimum	at	222	nm	and	 increasing	ellipticity	below	200	nm,	which	 is	 typical	 for	
helices.	Nevertheless,	the	minimum	at	200	nm	is	a	clear	sign	for	random	coil	regions	in	the	long	
loop.	Deconvolution	of	the	CD	spectra	(figure	3.15b)	yields	a	helix	content	of	58	%	for	the	long	
loop	and	only	19	%	for	the	short	loop.	
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Figure	3.15	Spectroscopic	analysis	and	MD	simulation	of	the	Taspase	loop.	
a	CD	spectra	of	the	short	(P183‐S222;	black)	and	long	Taspase	loop	(G178‐D233;	red)	show	more	helical	
structure	 for	 the	 long	 loop.	b	CD	spectrum	based	secondary	structure	deconvolution	using	CDSSTR	and	
CONTIN	confirm	a	higher	helical	content	(blue)	in	the	long	loop	compared	with	the	short	loop.	Numbers	are	
given	in	percent.	c	7	ns	molecular	dynamics	simulation	starting	with	a	linear	loop	indicates	formation	of	
transient	helices,	especially	around	Arg190.	
	
	
To	investigate	how	the	short	loop	peptide	behaves	in	solution,	a	7	nanoseconds	MD	simulation	
was	 performed	 (figure	 3.15c).	 Analysis	 of	 the	 adopted	 conformations	 over	 time	 reveals	 the	
formation	and	disorganization	of	short	helical	areas.	Most	prone	for	helix	formation	is	the	stretch	
around	 Arg190,	 while	 in	 the	 terminal	 regions	 and	 the	 central	 part	 around	 Lys202	 no	 helix	
formation	could	be	observed	during	the	simulation.	
	
3.3 Catalytic	activity	of	Taspase	
Qualitative	assays	of	Taspase	activity	have	been	published	before	 [56,63,69].	 In	 this	 thesis,	an	
improved	assay	is	presented.	It	allowed	quantification	of	the	specific	activity	for	the	first	time	and	
revealed	 different	 catalytic	 rates	 with	 respect	 to	 the	 two	 MLL	 cleavage	 sites.	 For	 this,	 the	
oppositional	role	of	sodium	chloride,	which	is	required	for	stability	but	inhibits	Taspase	activity	
[56],	had	to	be	overcome.	Furthermore,	a	modification	of	the	assay	facilitated	a	determination	of	
specific	Taspase	activity	in	cell	lysates.	
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3.3.1 Quantitative	Taspase	activity	assay	
The	catalytic	activity	of	Taspase	was	assayed	with	the	help	of	a	model	substrate	comprising	the	
Taspase	 target	 sequence.	 In	 the	 intact	 peptide,	 an	N‐terminal	 fluorophor	 is	 quenched	 by	 a	 C‐
terminal	dinitrophenol	moiety,	which	is	removed	upon	cleavage.	After	the	reaction	is	started	by	
addition	of	Taspase,	the	intensity	increases	linearly	as	long	as	saturating	substrate	concentrations	
are	present	(figure	3.16).	With	decreasing	substrate	concentrations,	the	reaction	rate	drops	until	
all	substrate	is	consumed	and	a	plateau	is	reached.	If	the	two	amino	acids	adjacent	to	the	cleavage	
site	of	the	substrate	peptide	are	substituted	by	alanines,	no	increase	in	fluorescence	intensity	is	
observed	after	addition	of	Taspase.	
	
	
Figure	3.16	Taspase	activity	assay.	
Emission	 of	 the	 fluorogenic	 substrate	 increases	 over	 time	 in	 presence	 of	 Taspase.	 The	 initial	 rate	 and	
plateau	at	substrate	depletion	increase	with	substrate	concentration.	Substrate	with	mutated	cleavage	site	
(red)	shows	no	increase	in	fluorescence.	
	
As	explicated	in	the	sections	above,	sodium	chloride	stabilizes	Taspase	and	prevents	precipitation.	
However,	chloride	inhibits	Taspase	activity	with	an	IC50	value	of	68	±	7	mM	(supplemental	figure	
7.12).	Hence,	chloride	was	omitted	from	the	buffer	and	all	activity	measurements	were	taken	in	
10	%	sucrose.	
Wild	 type	Taspase	was	 incubated	 in	a	buffer	with	10	%	sucrose	at	37	 °C	and	 the	activity	was	
measured	after	different	incubation	times	to	test	for	a	potential	loss	of	activity	(figure	3.17).	
	
	
Figure	3.17	Loss	of	Taspase	activity	over	time.	
Incubation	of	wild	type	Taspase	at	37	°C	in	measurement	buffer	containing	10	%	sucrose	shows	a	loss	of	
activity	over	time.	Nonlinear	fit	yields	a	half‐life	around	2.5	hours.	
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After	 24	 hours,	 the	 residual	 activity	 of	 Taspase	 is	 less	 than	 10	 %	 compared	 to	 the	 activity	
immediately	after	thawing.	The	calculated	half‐life	of	Taspase	activity	is	near	2.5	hours.	Although	
sucrose	and	salt	show	a	similar	increase	of	the	melting	temperature	(figure	3.8b),	incubation	for	
24	hours	in	a	buffer	with	450	mM	NaCl	resulted	in	no	detectable	loss	of	activity	(data	not	shown).	
To	overcome	the	instability	in	measurement	buffer,	fresh	Taspase	aliquots	were	thawed	for	each	
assay.	This	approach	enabled	a	reproducible	quantitative	measurement	of	Taspase	activity.	
	
	
Figure	3.18	Activity	of	the	Taspase	variants.	
Specific	 activity	 of	 wild	 type	 Taspase	 (wt,	 black,	 0.086	 ±	 0.0009	 µmol	 *	 min‐1	 *	 mg‐1),	 active	 Taspase	
(shortened	 loop,	 blue,	 0.063	 ±	 0.002	 µmol	 *	 min‐1	 *	 mg‐1),	 inactive	 Taspase	 (D233A/T234A	 mutant,	
0.00003	µmol	*	min‐1	*	mg‐1)	and	buffer	control	(no,	0.00006	µmol	*	min‐1	*	mg‐1)	in	the	presence	of	8	µM	
substrate.	 For	 the	 inactive	mutant	 and	 the	 buffer	 control	 no	 activity	was	 observed.	 Error	 bars	 indicate	
standard	deviations.	
	
Wild	type	Taspase,	active	Taspase	and	the	inactive	mutant	were	used	in	equal	concentrations	of	
300	nM	for	activity	assays	with	8	µM	substrate	(figure	3.18).	The	active	mutant	exhibits	75	%	of	
the	 activity	measured	 for	wild	 type	 Taspase.	 In	 contrast,	 the	 inactive	 Taspase	mutant	 has	 no	
catalytic	activity,	which	also	applies	to	the	buffer	control	without	Taspase.	
3.3.2 Cleavage	sequence	specificity	of	Taspase	
A	natural	 substrate	of	Taspase	 is	 the	MLL	protein.	Taspase	 cleaves	MLL	at	 two	cleavage	sites,	
called	CS1	and	CS2.	50	%	of	the	amino	acids	are	identical	for	the	two	sequences	(table	3.1).	Here,	
kinetic	constants	for	CS1	(GKGQVDGADDK)	and	CS2	(KISQLDGVDDK)	peptides	are	reported	for	
the	first	time	(figure	3.19).	
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Figure	3.19	Substrate	specificity	of	Taspase.	
Michaelis‐Menten	plots	at	37	°C	for	the	two	Taspase	peptides	with	the	cleavage	sites	CS1	(blue	squares)	and	
CS2	(black	circles)	of	the	MLL	protein.	Catalytic	parameters	obtained	by	nonlinear	fitting	can	be	found	in	
table	3.1.	
	
Taspase	has	an	affinity	in	the	low‐micromolar	range	for	both	target	sequences,	with	a	sevenfold	
higher	affinity	for	the	CS2	peptide	(18	µM),	compared	to	the	CS1	peptide	(2.7	µM).	Furthermore,	
the	maximum	reaction	velocity	(vmax)	and,	hence,	also	the	turnover	number	(kcat)	differs	between	
the	two	substrates.	Both	values	are	about	3	times	higher	for	CS2	than	for	CS1	(CS1:	vmax	=	0.03	±	
0.003	µmol	min‐1	mg‐1,	kcat	=	0.0274	s‐1;	CS2:	vmax	=	0.11	±	0.002	µmol	min‐1	mg‐1,	kcat	=	0.083	s‐1).	A	
significant	 difference	 can	 be	 seen	 if	 the	 specificity	 constants	 (kcat/Km)	 are	 compared.	 Here,	
cleavage	of	the	CS2	peptide	is	more	than	20‐fold	more	efficient	than	CS1	cleavage.	
	
Table	3.1	Catalytic	parameters	of	Taspase	target	sequences	at	37	°C.	
	 CS1	
[Mca]‐GKGQVDGADDK‐[DNP]	
CS2
[Abz]‐KISQLDGVDDK‐[DNP]	
Km	(µM)	 18.4	±	2.8 2.7 ±	0.1
vmax	(µmol	min‐1	mg‐1) 0.03	±	0.003 0.11	±	0.002	
kcat	(s‐1)	 0.0274	 0.083
kcat/Km	(l	mol‐1	s‐1)	 1487	 31190
[Mca]:	7‐amino‐4‐methylcoumarin;	[DNP]:	dinitrophenol;	[Abz]:	anthranilic	acid	
	
3.3.3 Taspase	activity	in	human	cell	lysates	
Taspase	levels	in	eukaryotic	Hela,	HEK	and	HCT	116	cells	are	low	and	therefore	below	detection	
levels	 the	 western	 blots	 performed	 in	 this	 project	 (supplemental	 figure	 7.13).	 Consequently,	
Taspase	 levels	had	to	be	 increased	by	overexpression.	To	allow	a	subsequent	quantification	of	
Taspase	concentration,	a	GFP	tag	was	added,	which	does	not	impair	the	catalytic	activity	[70].	This	
approach	yielded	Taspase	concentrations	of	370	nM	in	Hela	cell	lysates.	Additionally,	the	assay	
temperature	had	to	be	lowered	from	37	°C	to	30	°C	to	prevent	precipitation	of	the	lysis	buffer	after	
supplemented	with	PMSF.	To	compare	the	activity	of	Hela	 lysates	with	overexpressed	Taspase	
and	Taspase	isolated	from	E.	coli,	measurements	were	taken	under	identical	conditions	(figure	
3.20).	
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Figure	3.20	Specific	activity	of	eukaryotic	Taspase.	
Specific	activity	at	30	°C	in	the	presence	of	8	µM	substrate	of	Hela	lysates	with	overexpressed	Taspase‐GFP	
fusion	protein	(transfected)	and	purified	Taspase	after	heterologous	bacterial	expression	(bacterial).	Both	
Taspase	species	show	a	similar	specific	activity.	
	
Hela	 lysates	 and	Hela	 controls	 transfected	with	 an	 empty	 PC3	 vector	 showed	 no	measurable	
Taspase	activity	(data	not	shown).	In	contrast,	the	lysate	with	overexpressed	GFP‐Taspase	is	able	
to	cleave	the	substrate	peptide.	Compared	with	bacterially	expressed	and	purified	Taspase,	the	
specific	activity	of	overexpressed	Taspase	in	Hela	lysates	is	nearly	identical.	
	
3.3.4 Taspase	inhibition	test	using	NSC48300	
With	this	assay	in	hands,	the	only	available	Taspase	inhibitor	NSC48300	described	by	Chen	et	al.	
[63],	which	has	been	controversially	discussed	[133],	could	be	tested	(figure	3.21).		
	
Figure	3.21	Inhibition	test	with	the	reported	Taspase	inhibitor	NSC48300.	
a	The	reported	Taspase	inhibitor	NSC48300	exhibits	no	inhibitory	activity	at	concentrations	up	to	333	µM,	
compared	to	DMSO	controls.	Note	that	the	reported	Ki	is	4.22	µM.	b	Structure	of	NSC48300.	
	
In	 the	 in	 vitro	 activity	 assay,	 the	 inhibitory	 effect	 observed	 by	 Chen	 et	 al.	 [63]	 could	 not	 be	
confirmed.	NSC48300	yielded	no	decrease	in	catalytic	activity,	even	at	concentrations	of	333	µM,	
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which	 exceeds	 the	 reported	Ki	more	 than	70‐fold.	 The	presence	 and	purity	 of	NSC48300	was	
confirmed	by	ESI‐LC‐MS	analysis	(supplemental	figure	7.14).		
	
3.4 Exploration	of	Taspase	inhibitors	by	virtual	docking	
In	this	project,	different	approaches	were	followed	to	find	novel	Taspase	inhibitors.	One	of	these	
approaches	was	 a	 virtual	 docking	 of	 a	 large	 compound	 library.	 Subsequently,	 the	 top	 binding	
candidates	were	purchased	and	tested	for	inhibition	in	vitro.	All	tested	candidates	failed	to	exhibit	
an	inhibitory	effect.	
	
3.4.1 Model	preparation	
Virtual	docking	basically	requires	two	molecules,	termed	ligand	and	receptor.	As	receptor,	two	
different	states	of	Taspase	were	used:	On	the	one	hand	the	proenzyme,	where	binding	of	a	small	
molecule	could	interfere	with	the	autocatalytic	activation	process	and,	thereby,	keep	Taspase	in	
the	 inactive	proenzyme	state	and	on	the	other	hand	the	active	Taspase	protein,	where	a	small	
molecule	could	inhibit	the	catalytic	activity	by	blocking	the	active	site.	
In	a	first	step,	the	missing	loop	areas	were	added	to	the	monomers	of	the	crystal	structures	(figure	
3.22a)	to	include	the	N‐terminus	(M1‐R40),	the	Taspase	loop	(A206‐S229)	and	a	short	loop	in	the	
β‐subunit	(S352‐Q362).	The	corresponding	model	quality	statistics	can	be	found	in	supplemental	
figure	7.15.	
	
	
Figure	3.22	Preparation	of	Taspase	models	for	virtual	docking.	
a	Model	of	wild	type	Taspase	proenzyme	based	on	PDB	2a8i	with	missing	loops	(red)	modeled.	YASARA	
homology	modeling	was	used	to	add	the	N‐terminus	(M1‐R40),	the	Taspase	loop	(A206‐229)	and	a	short	
loop	 in	 the	 β‐subunit	 (S352‐Q362).	 These	 residues	were	 not	 defined	 in	 the	 crystal	 structure.	b	 Sphere	
cluster	(blue)	generated	by	sphgen.	The	cluster	covers	the	catalytic	Thr234	(red).	c	The	active	site	(green)	
was	surrounded	with	a	cube	(yellow),	in	which	the	energy	grids	were	precomputed.	In	this	area,	the	space	
was	performed.	
	
Partial	 charges	 were	 calculated	 with	 the	 help	 of	 Chimera	 [112]	 and	 suitable	 target	 areas	 for	
docking	were	identified	by	the	sphgen	algorithm	(figure	3.22b).	The	area	covering	the	site	was	
selected	 as	 ligand	binding	 site	 and	 in	 a	 cube	with	30	Å	 edge	 length	 the	energy	grids	 for	 rigid	
docking	were	precomputed	(figure	3.22c).	
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For	the	ligand	database,	a	large	variety	of	compounds	and	availability	of	the	compounds	for	 in	
vitro	use	was	required.	The	ZINC	database	[129]	met	both	criteria,	with	12	million	purchasable	
compounds	available.	To	reduce	the	number	of	compounds	to	a	reasonable	amount	for	docking	
and	 still	 cover	 a	 maximum	 of	 different	 conformations,	 chemically	 different	 molecules	 were	
selected	with	the	help	of	the	SUBSET	algorithm	[130].	Only	molecules	which	differ	from	all	other	
by	 at	 least	 60	%	were	 used	 for	 docking.	With	 this	 approach,	 the	 number	 of	 compounds	was	
reduced	from	12	million	to	15865.	
	
3.4.2 Virtual	docking	of	ZINC	database	compounds	
As	a	first	step,	the	compounds	of	the	ZINC	database	were	treated	as	flexible	and	docked	with	an	
anchor‐and‐grow	algorithm	(section	2.6.3).	Taspase	residues	within	5	Å	of	the	active	site	were	
regarded	as	flexible,	as	well.	This	allowed	a	fast	and	yet	sufficiently	accurate	exploration	of	several	
hundred	different	binding	conformations	for	each	compound.	The	free	binding	energy	for	the	top	
pose	of	each	ligand	was	computed	with	a	precomputed	grid,	which	includes	van	der	Waals	and	
electrostatic	components.	A	distribution	of	the	binding	energies	is	shown	in	figure	3.23.	
	
Figure	3.23	Energy	distribution	of	the	docked	compounds.	
a+b	15865	compounds	of	the	ZINC	database	were	docked	on	the	proenzyme	(a)	or	active	Taspase	(b)	with	
an	anchor‐and‐grow	algorithm.	A	ranking	of	the	free	binding	energies	follows	a	Gaussian	distribution	(black	
lines).	For	compounds	with	binding	energy	below	40	kcal/mol	(red),	similar	compounds	were	searched.	
c+d	These	similar	compounds	were	docked	in	a	second	round	on	the	proenzyme	(c)	or	active	Taspase	(d)	
and	an	AMBER	scoring	function	was	used	for	ranking	after	a	short	MD	simulation.	
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The	 sample	 size	 of	 15865	 compounds	was	 large	 enough	 to	 obtain	 a	 Gaussian	 distribution	 of	
binding	scores	(figure	3.23a	and	b)	with	a	mean	binding	energy	of	26	kcal/mol	for	the	proenzyme	
and	 30	 kcal/mol	 for	 the	 active	 Taspase.	 The	 best	 binding	 compounds	 were	 used	 for	 the	
subsequent	docking	round.	As	threshold,	twice	the	standard	deviation	was	used,	which	resulted	
in	a	cut‐off	binding	energy	of	40	kcal/mol.	This	criterion	was	met	by	1	%	of	the	proenzyme	dataset	
and	2	%	of	the	active	Taspase	dataset.	
Since	a	filtered	dataset	was	used,	in	which	only	compounds	that	differ	from	each	other	by	at	least	
60	%	were	present,	the	data	set	of	the	top	compounds	was	expanded	by	the	inclusion	of	similar	
molecules.	For	this,	the	ZINC	database	was	searched	for	compounds	with	at	least	70	%	similarity	
to	 the	 top	compounds.	This	approach	 increased	the	number	of	compounds	to	1925	(from	363	
compounds	for	the	proenzyme)	and	7313	(from	1817	compounds	for	active	Taspase)	and	ensured	
that	derivatives	of	the	top	compounds	were	included	in	the	next	docking	round.	
To	increase	the	reliability	of	the	binding	score,	an	energy	minimization	and	short	MD	simulation	
was	performed	for	each	compound	after	docking,	before	the	binding	energy	was	calculated	using	
an	AMBER	force	field	scoring.	The	scoring	distributions	for	the	proenzyme	and	active	Taspase	are	
shown	 in	 Figure	 3.23c	 and	 d,	 respectively.	 Again,	 a	 Gaussian	 distribution	 is	 almost	 obtained	
indicating	a	sufficient	sample	size.		
	
3.4.3 Inhibition	tests	with	compounds	obtained	by	virtual	docking	
For	 both	 datasets	 (proenzyme	 and	 active	 Taspase),	 the	 top	 poses	 of	 the	 modeled	 Taspase‐
inhibitor‐complexes	were	inspected,	 the	respective	compounds	were	reviewed	for	toxicity	and	
availability.	Figure	3.24a	and	b	shows	the	docked	conformations	of	two	top	candidates	found	for	
the	proenzyme,	referred	to	as	ZINC52513265	and	ZINC19323748,	respectively.	Both	compounds	
block	 the	 catalytic	 Thr234	 (cyan	 in	 figure	 3.24a	 and	 b)	 and	 have	 contact	 to	 the	 surrounding	
residues	(pale	orange	in	figure	3.24a	and	b).	
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Figure	3.24	Docked	conformation	and	inhibition	test	of	putative	proenzyme	inhibitors.	
a+b	Docked	poses	of	ZINC52513265	(a)	and	ZINC19323748	(b)	with	the	proenzyme.	The	catalytic	Thr234	
is	highlighted	in	cyan	and	interacting	Taspase	residues	in	pale	orange.	c+d	Addition	of	ZINC52513265	(c)	
or	 ZINC19323748	 (d)	 shows	 no	 significant	 inhibition	 of	 Taspase	 activity.	 The	 structures	 of	 the	 two	
compounds	are	inserted.	
	
A	shared	feature	of	these	two	compounds	is	the	sulfate	group,	which	interacts	with	the	Thr234.	
An	overlay	of	the	docked	poses	of	the	top	ten	compounds	reveals	that	this	interaction	of	a	sulfate	
group	with	the	Thr234	is	a	shared	feature	among	these	compounds	(figure	3.25).	
	
Figure	3.25	Shared	features	among	top	candidates.	
a	An	overlay	of	the	ten	compounds	with	best	binding	scores	reveals	common	features.	b	Additionally	to	a	
central	sulfate	moiety,	two	aromatic	rings	(5‐	and	6‐membered)	are	present	in	most	structures.	
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This	common	framework	is	diversified	by	different	moieties	at	the	aromatic	rings	and	different	
linkers	from	the	sulfate	moiety	to	the	rings.	For	this	reason,	two	compounds	were	selected,	which	
contain	a	central	sulfate	group	but	differ	in	most	of	the	other	moieties.	These	compounds	were	
purchased,	incubated	at	a	concentration	of	200	µM	with	Taspase	for	6	h	to	allow	an	inhibition	of	
the	autocatalytic	activation,	and	were	tested	in	the	fluorogenic	assay.	However,	the	proteolytic	
Taspase	 activity	 is	 not	 inhibited	 in	 presence	 of	 up	 to	 1	mM	 ZINC52513265	 (figure	 3.24c)	 or	
600	µM	ZINC19323748	(figure	3.24d).	
Evaluation	 of	 the	 best	 binding	 compounds	 in	 the	 dataset	 for	 active	 Taspase	 showed	 a	 more	
heterogeneous	group	of	inhibitors	than	the	proenzyme	dataset.	A	sulfate	group	is	present	in	some	
inhibitors,	as	well,	but	an	overlay	of	the	top	inhibitors	revealed	no	striking	common	framework.	
Hence,	 three	 compounds	 (ZINC63428205,	 ZINC21096526,	 and	 ZINC21096535)	were	 selected	
randomly	for	in	vitro	analysis	(figure	3.26a‐c).	
	
	
Figure	3.26	Docked	conformation	and	inhibition	of	putative	active	Taspase	inhibitors.	
a‐c	 Structures	 of	 ZINC63428205	 (a),	 ZINC21096526	 (b)	 and	 ZINC21096535	 (c).	 d‐f	 Docked	 poses	 of	
ZINC63428205	(d),	ZINC21096526	(e)	and	ZINC21096535	(f)	with	active	Taspase.	The	catalytic	Thr234	is	
highlighted	in	cyan,	interacting	Taspase	residues	in	pale	orange	and	the	chloride	ion	in	green.	g	All	three	
ZINC	compounds	exhibit	no	inhibitory	effect	in	the	Taspase	activity	assay.	
	
All	three	compounds	cage	the	chloride	ion	in	the	active	site	and	do	not	directly	interact	with	the	
catalytic	Thr234	(figure	3.26d‐f).	Interestingly,	the	compounds	shown	in	figure	3.26e	and	f	cage	
the	 chloride	 ion	 at	 different	 positions,	 despite	 their	 close	 structural	 similarity.	 In	 the	Taspase	
activity	assay,	however,	all	 three	compounds	exert	no	 inhibitory	effect	 in	concentrations	up	to	
600	µM	(figure	3.26g).	
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3.5 Inhibition	of	Taspase	by	nanoparticles	
Recent	 studies	 disclosed	 binding	 of	 serum	 proteins	 to	 nanoparticles	 [99].	 Furthermore,	 silica	
nanoparticles	can	inhibit	the	proteasome,	the	only	other	N‐terminal	nucleophile	(Ntn)	threonine	
protease	 (Shirley	 Knauer,	 personal	 communication).	 Hence,	 binding	 of	 Taspase	 to	 silica	
nanoparticles	 and	 their	 effect	 on	 the	 proteolytic	 activity	 was	 tested.	 Three	 different	 sizes	 of	
nanoparticles	 inhibited	Taspase	at	 low	nanomolar	concentrations,	while	 the	activities	of	 three	
control	enzymes	were	not	impaired.	
3.5.1 Nanoparticles	bind	and	inhibit	Taspase	in	vitro	
Binding	of	Taspase	 to	silica	nanoparticles	was	observed	 in	a	preliminary	experiment	during	a	
microscale	 thermophoresis	 (MST)	 demonstration	 course.	 Here,	 Taspase	 was	 added	 to	
nanoparticles	with	8	or	125	nm	diameter,	and	binding	was	observed	label‐free	in	solution	(figure	
3.27a).	
	
	
Figure	3.27	Nanoparticles	bind	Taspase.	
a	Microscale	thermophoresis	(MST)	titrations	reveal	binding	of	Taspase	to	nanoparticles.	For	8	nm	(Amsil8)	
and	 125	nm	 (Amsil125)	 silica	 nanoparticles	 EC50	 values	 of	 35	 nM	±	 0.5	 nM	 and	10	 pM	±	 0.4	 pM	were	
obtained.	b	Fluorescence	anisotropy	titrations	with	1	µM	Atto488‐labeled	Taspase	yield	a	stoichiometry	of	
some	 10	 µmol/mg	 nanoparticles.	 This	 corresponds	 to	 roughly	 5000	 Taspase	 molecules	 per	 Amsil125	
nanoparticle	and	6	Taspase	molecules	per	Amsil8	nanoparticle.	
	
Both	 sizes	 of	 nanoparticles	 were	 able	 to	 bind	 Taspase	 with	 high	 affinity.	 The	 obtained	 EC50	
concentrations	were	in	the	nanomolar	range	for	Amsil8	(35	nM	±	0.5	nM)	and	in	the	picomolar	
range	for	Amsil125	(10	pM	±	0.4	pM).	Active	site	fluorescence	anisotropy	titrations	with	Atto488‐
labeled	Taspase	confirmed	the	ranges	of	binding	affinities	detected	by	MST	and	displayed	a	higher	
change	 in	 anisotropy	upon	binding	 for	Amsil125	 than	 for	Amsil8	due	 to	 the	higher	molecular	
weight.	 Based	 on	 these	 data,	 a	 stoichiometry	 of	 roughly	 10	 nmol	 per	 mg	 nanoparticles	 was	
calculated	for	both	Amsil8	and	Amsil125	(figure	3.27b).	This	corresponds	to	approximately	six	
Taspase	molecules	bound	per	Amsil8	nanoparticle	and	5000	Taspase	molecules	per	Amsil125	
nanoparticle.	To	explore	possible	 consequences	of	nanoparticles	 for	Taspase	activity,	 this	was	
tested	in	an	in	vitro	assay	(figure	3.28).	
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Figure	3.28	Nanoparticles	inhibit	Taspase	activity	noncompetitively.	
a	 Silica	 nanoparticles	 with	 8	 nm	 (Amsil8)	 20	 nm	 (Amsil20)	 and	 125	 nm	 (Amsil125)	 diameter	 inhibit	
Taspase	activity.	EC50	values	of	41	±	9	nM,	1.4	±	0.3	nM	and	119	±	21	pM	were	calculated	for	Amsil8,	Amsil20	
and	 Amsil125,	 respectively.	 b	 Fluorescence	 anisotropy	 of	 Atto488‐labeled	 changes	 in	 the	 presence	 of	
Amsil125,	 while	 the	 anisotropy	 of	 the	 fluorogenic	 substrate	 and	 the	 Atto488‐labeled	 control	 protein	
parvalbumin	alters	only	marginally.	c	The	change	in	anisotropy	upon	addition	of	Amsil125	nanoparticles	is	
the	same	for	wild	type	Taspase	(wt)	and	the	 inactive	Taspase	mutant	(red),	 indicating	that	they	bind	to	
nanoparticles	in	the	same	manner.	Wild	type	and	inactive	Taspase	proteins	were	labeled	with	Atto488.	d	
Titrations	 with	 Amsil125	 at	 different	 substrate	 concentrations	 pinpoint	 a	 noncompetitive	 inhibition	
mechanism	(R2	=	0.98).	A	Ki	value	of	380	±	55	pM	was	calculated.	
	
All	three	sizes	of	silica	nanoparticles	tested	(8,	20	and	125	nm	diameter)	inhibited	the	Taspase	
activity	 already	 at	 low	 concentrations.	 As	 observed	 for	 binding	 to	 nanoparticles,	 the	 EC50	
concentrations	are	negatively	correlated	with	the	nanoparticle	diameter.	Hence,	Amsil125	has	the	
highest	 affinity	 with	 119	 ±	 21	 pM,	 while	 Amsil20	 and	 Amsil8	 bind	 Taspase	 at	 nanomolar	
concentrations	(EC50	=	1.4	±	0.3	nM	and	41	±	9	nM,	respectively).	
However,	 nanoparticles	 would	 artificially	 lower	 Taspase	 activity,	 if	 they	 bind	 the	 fluorescent	
substrate	and	render	it	unavailable	for	Taspase	cleavage.	To	this	end,	binding	of	the	substrate	to	
Amsil125	 nanoparticles	 was	 analyzed	 by	 fluorescence	 anisotropy	 and	 compared	 to	 Taspase	
binding	 (figure	 3.28b).	 Since	 only	 the	 anisotropy	 of	 Taspase	 changed	 in	 the	 presence	 of	
nanoparticles,	while	the	anisotropy	of	the	substrate	remained	virtually	constant,	binding	of	the	
substrate	to	nanoparticles	can	be	excluded	as	an	explanation	for	the	inhibition	of	Taspase	activity.	
Interestingly,	 the	proenzyme	binds	 to	Amsil125	comparably	 to	 the	wild	 type	enzyme.	For	 this	
experiment,	 the	titration	was	performed	with	Atto488‐labeled	 inactive	Taspase	mutant	(figure	
3.28c).	Furthermore,	the	constant	anisotropy	of	the	Atto488‐labeled	control	protein	parvalbumin	
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excludes	an	Atto488‐dependent	binding	to	nanoparticles.	Only	at	high	concentrations,	a	binding	
of	parvalbumin	to	nanoparticles	could	be	observed	(supplementary	 figure	7.16).	However,	 the	
EC50	 value	 of	 3	 ±	 0.8	 µM	 determined	 for	 this	 interaction	 is	 300	000‐fold	 higher	 compared	 to	
Taspase.	
To	 gain	 a	 first	 insight	 into	 the	 inhibitory	mechanism,	 the	 inhibition	 type	was	 determined	 for	
Amsil125	 by	 a	 variation	 of	 both	 substrate	 and	 nanoparticle	 concentrations	 (figure	 3.28d).	
Nonlinear	fitting	reveals	a	reversible	noncompetitive	inhibition	with	a	Ki	value	of	380	±	55	pM.	
One	 possible	 explanation	 for	 the	 observed	 inhibition	 is	 a	 destabilization	 of	 Taspase	 by	
nanoparticles,	 which	 causes	 unfolding	 and	 thereby	 reduces	 the	 activity.	 Hence,	 the	 impact	 of	
nanoparticles	on	the	secondary	and	tertiary	structure	of	Taspase	was	analyzed.	To	this	end,	CD	
spectra	were	recorded	to	assess	the	secondary	structure	(figure	3.29a).		
	
	
Figure	3.29	Nanoparticles	do	not	alter	secondary	structure	or	stability.	
a	CD	spectra	in	the	presence	of	nanoparticles	with	8	nm	(Amsil8)	20	nm	(Amsil20)	and	125	nm	(Amsil125)	
diameter	show	no	change	in	secondary	structure	content	of	Taspase.	b	Tryptophan	fluorescence	melting	
curves	reveal	no	alteration	of	Taspase	stability.	Melting	points	in	phosphate	buffer	without	NaCl	(solid	lines)	
are	near	56	°C	and	with	450	mM	NaCl	near	77	°C	(dashed	lines),	both	in	the	presence	and	absence	of	100	
µg/ml	nanoparticles	with	8	nm	(Amsil8)	20	nm	(Amsil20)	and	125	nm	(Amsil125)	diameter.		
The	 obtained	 spectra	 in	 the	 presence	 and	 absence	 of	 nanoparticles	 are	 indistinguishable,	
indicating	 that	 neither	 nanoparticle	 type	 caused	 a	 change	 in	 secondary	 structure	 content	 at	
inhibitory	 concentrations	 of	 40	 µg/ml.	 However,	 a	 change	 in	 the	 tertiary	 structure,	 such	 as	 a	
movement	or	torsion	of	a	whole	subunit,	cannot	be	excluded	by	these	data.	
Consequently,	 fluorescence	 tryptophan	 melting	 curves	 were	 recorded	 to	 get	 insight	 into	 the	
tertiary	structure,	as	well	as	the	overall	folding	state	and	stability	of	Taspase	(figure	3.29b).	As	
explicated	 in	 section	3.2.2,	Taspase	has	 a	melting	 temperature	near	56	 °C	and	77	 °C	 in	buffer	
without	 and	with	 450	mM	NaCl,	 respectively.	 These	 values	 do	 not	 change	 in	 the	 presence	 of	
100	µg/ml	nanoparticles	(=	266	nM	Amsil8;	16	nM	Amsil20;	204	pM	Amsil125).	
Taken	together,	these	data	argue	against	changes	in	secondary	or	tertiary	structure	and	indicate	
that	the	inhibition	by	nanoparticles	is	not	caused	by	a	destabilization	of	Taspase.	
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3.5.2 Enzyme	inhibition	is	no	general	feature	of	nanoparticles	
So	 far,	 inhibition	 of	 enzyme	 activity	 could	 be	 not	 only	 restricted	 to	 Taspase,	 but	 instead	 be	 a	
general	 feature	 of	 nanoparticles.	 To	 test	 the	 hypothesis	 of	 a	 general	 inhibitory	 effect	 of	
nanoparticles	 on	 enzyme	 activity,	 three	 control	 enzymes	 were	 studied	 in	 activity	 assays,	
measuring	either	lactate	formation	by	lactate	dehydrogenase	(LDH)	or	proteolytic	activity	of	the	
serine	endopeptidase	chymotrypsin	and	of	the	serine	endo‐	and	exopeptidase	proteinase	K	(figure	
3.30).	
	
	
Figure	3.30	LDH,	chymotrypsin	and	proteinase	K	are	weakly	inhibited	by	nanoparticles.	
a	 Lactate	 dehydrogenase	 (LDH)	 activity	was	 assayed	 in	 the	 presence	 of	 silica	 nanoparticles	with	 8	 nm	
(Amsil8)	 20	 nm	 (Amsil20)	 and	 125	 nm	 (Amsil125)	 diameter.	 Amsil8	 shows	 weak	 inhibition	 at	 high	
concentrations	(3	mg/ml).	Amsil20	inhibits	the	activity	by	up	to	25	%	with	a	nanomolar	EC50.	Amsil125	
reduces	the	activity	by	up	to	15	%.	b	Chymotrypsin	activity	 is	not	 inhibited	by	nanoparticles	with	8	nm	
(Amsil8)	20	nm	(Amsil20)	and	125	nm	(Amsil125)	diameter.	c	Proteinase	K	activity	is	not	influenced	in	the	
presence	of	100	µg/ml	Amsil8.	For	concentrations	between	0.05	and	50	µg/ml	proteinase	K,	the	digestion	
pattern	does	not	change	in	the	presence	of	nanoparticles.	fl,	α	and	β	represent	the	size	of	full‐length	Taspase,	
α‐	and	β‐subunit,	respectively.	
	
Amsil125	 inhibits	LDH	activity	by	up	 to	15	%	at	 low	nanomolar	 concentrations	 (figure	3.30a;	
blue).	Higher	concentrations	cause	no	further	reduction	of	LDH	activity.	For	Amsil20,	inhibition	is	
not	seen	in	the	picomolar	range,	where	Taspase	is	already	significantly	inhibited.	However,	higher	
concentrations	can	reduce	LDH	activity	by	up	to	25	%.	Similarly,	micromolar	concentrations	of	
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Amsil8	are	required	to	inhibit	LDH	activity	by	10	%,	which	is	two	orders	of	magnitude	more	than	
for	Taspase	with	an	EC50	value	of	41	nM.	
Concerning	 the	 second	 control	 enzyme	 chymotrypsin,	 the	 enzymatic	 activity	 is	 not	 altered	by	
nanoparticles	(figure	3.30b).	Neither	of	the	nanoparticles	could	reduce	the	proteolytic	activity,	
even	if	the	concentrations	exceeded	the	EC50	of	Taspase	by	two	orders	of	magnitude.	
To	assay	the	activity	of	the	third	control	enzyme	proteinase	K,	the	Taspase	digestion	pattern	was	
analyzed	 by	 SDS‐PAGE	 after	 limited	 proteolysis	 by	 proteinase	 K	 (figure	 3.30c).	 The	 digestion	
bands	below	both	the	full‐length	enzyme	and	the	two	subunits	indicate	that	high	concentrations	
of	proteinase	K	can	degrade	all	three	Taspase	species.	A	comparison	of	the	degradation	pattern	in	
the	 presence	 and	 absence	 of	 100	 µg/ml	 Amsi8	 reveal	 no	 inhibition	 for	 all	 11	 proteinase	 K	
concentrations	tested.	
	
3.5.3 Nanoparticles	inhibit	Taspase	in	cell	lysates	and	in	cells	
Studies	with	three	control	enzymes	indicated	that	inhibition	of	enzyme	activity	seemed	to	be	no	
general	 feature	 of	 nanoparticles.	 Hence,	 the	 selective	 inhibition	 of	 Taspase	 activity	 by	
nanoparticles	could	also	be	possible	in	cell	lysates.	This	hypothesis	was	tested	in	Hela	cell	lysates	
with	overexpressed	GFP‐Taspase	(figure	3.31).	
	
	
Figure	3.31	Nanoparticles	inhibit	Taspase	activity	in	cell	lysates.	
Taspase	activity	was	assayed	in	Hela	cell	lysates	in	the	presence	of	nanoparticles	with	8	nm	(Amsil8)	20	nm	
(Amsil20)	and	125	nm	(Amsil125)	diameter.	Nonlinear	fitting	yielded	EC50	values	of	80	±	34	µg/ml	(=	213	
±	90	nM)	for	Amsil8,	251	±	24	µg/ml	(=	40	±	4	nM)	for	Amsil20	and	42	±	15	µg/ml	(=	86	±	31	pM)	for	
Amsil125.	
	
One	striking	finding	is	that	nanoparticles	reduce	Taspase	activity	only	by	up	to	50	%	in	lysates.	
Moreover,	 the	 EC50	 values	 (40‐250	 µg/ml)	 are	 somewhat	 higher	 than	 for	 pure	 Taspase	 (8‐
60	µg/ml),	which	additionally	reduces	the	inhibitory	effect	in	cell	lysates.	
However,	the	inhibitory	concentrations	in	lysates	were	still	in	the	nanomolar	and	sub‐nanomolar	
range.	Since	nanoparticles	can	be	taken	up	by	cells	[99],	the	consequent	experiment	was	to	test	
the	 effect	 of	 nanoparticles	 on	 cellular	 Taspase	 activity.	 This	 endeavor	 required	 a	 cell‐based	
activity	assay,	in	which	a	fluorescent	reporter	substrate,	called	BioTasp	[71],	with	nuclear	import	
and	export	sequences	was	used	(figure	3.32a).	
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Figure	3.32	Cellular	Taspase	activity	assay.	
a	The	BioTasp	reporter	substrate	comprises	an	N‐terminal	nuclear	localization	signal	(NLS)	eGFP	(green),	
glutathione	S‐transferase	(GST),	Taspase	cleavage	sites	(red;	scissors)	and	a	reverse	nuclear	export	signal	
(NES).	b	BioTasp	(green;	second	column)	is	found	equally	distributed	in	nucleus	and	cytoplasm	in	Hela	cells	
without	 Taspase	 (first	 row)	 and	 Hela	 cells	 transfected	 with	 inactive	 Taspase	 (second	 row)	 due	 to	 the	
presence	of	both	nuclear	localization	and	export	signal	(NLS	and	NES,	respectively).	Nuclei	were	stained	
with	Hoechst	(blue;	first	column).	In	the	presence	of	wild	type	Taspase	(wt	Taspase;	third	row),	the	nucleus	
export	signal	(NES)	is	cleaved	and	the	nuclear	localization	signal	(NLS)	causes	an	accumulation	of	BioTasp	
in	the	nucleus.	c	Statistical	analysis	shows	no	significant	(ns)	difference	in	the	nucleus	to	cytoplasm	ratio	
(N/C)	of	BioTasp	between	untransfected	cells	and	cells	with	inactive	Taspase.	In	contrast,	the	N/C	ratio	is	
significantly	higher	in	cells	with	wild	type	Taspase.	50	cells	from	3	independent	experiments	were	counted.	
***	indicate	p‐values	<	0.001.	
	
BioTasp	contains	a	green	fluorescent	protein	(GFP)	fused	to	a	GST	to	prevent	passive	diffusion	
through	the	nuclear	pores.	The	sensor	shuttles	between	nucleus	and	cytoplasm	by	its	NLS	and	
NES.	Due	to	a	well‐considered	combination	of	signal	strength,	the	steady	state	of	the	sensor	is	an	
even	 distribution	 throughout	 the	 cell	 (figure	 3.32b).	 The	 localization	 of	 BioTasp	 changes,	 if	
Taspase	is	overexpressed.	Taspase	cleaves	BioTasp	at	the	integrated	CS2	cleavage	site	from	MLL	
and	removes	the	NES,	which	leads	to	an	accumulation	of	BioTasp	in	the	nucleus.	Controls	with	
overexpressed	inactive	Taspase	show	a	distribution	similar	to	cells	without	Taspase.	Statistical	
evaluation	confirmed	a	significantly	increased	nuclear	localization	in	cells	with	wild	type	Taspase	
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compared	to	cells	with	inactive	or	no	Taspase	(figure	3.32c;	N/C	ratios	for	no	Taspase:	1.25	±	0.03,	
inactive	Taspase:	1.03	±	0.03,	wild	type	Taspase:	2.81	±	0.1).	
With	this	assay,	the	silica	nanoparticles	of	8,	20	and	125	nm	diameter	were	tested.	For	this,	cells	
were	 challenged	 with	 200	 µg/ml	 nanoparticles	 3	 hours	 after	 transfection.	 The	 presence	 of	
nanoparticles	 had	 no	 visible	 effect	 on	 the	 cell	 viability	 or	morphology	 (supplementary	 figure	
7.17).	The	BioTasp	localization	was	analyzed	after	18	hours	incubation	(figure	3.33).	
	
	
Figure	3.33	Nanoparticles	inhibit	Taspase	activity	in	cells.	
a	Hela	cells	transfected	with	Taspase	(red;	mCherry)	and	the	BioTasp	reporter	substrate	(green;	GFP)	were	
stained	with	Hoechst	(blue)	after	treatment	with	200	µg/ml	Amsil8	(first	row),	Amsil20	(second	rwo)	or	
Amsil125	(third	row)	for	18	h.	The	equal	distribution	of	the	green	BioTasp	reporter	substrate	indicates	low	
Taspase	activity	in	presence	of	nanoparticles.	Hoechst,	GFP	and	mCherry	channels	are	displayed	separately	
in	columns	1‐3,	respectively,	and	merged	in	column	4.	b	Statistical	analysis	of	the	nuclear	to	cytoplasm	ratio	
(N/C)	 shows	 a	 significantly	 reduced	N/C	 ratio	 in	 the	presence	 of	 nanoparticles	 compared	 to	 untreated	
controls.	50	cells	from	3	independent	experiments	were	counted.	***	indicate	p‐values	<	0.001.	
	
Figure	3.33a	shows	an	even	distribution	of	BioTasp	throughout	the	whole	cell	after	nanoparticle	
challenge.	The	red	fluorescence	confirms	the	successful	overexpression	of	wild	type	Taspase	and	
its	 perfect	 overlap	 with	 the	 Hoechst	 staining	 indicates	 an	 exclusively	 nuclear	 localization.	
Statistical	evaluation	reveals	that	all	three	types	of	nanoparticles	significantly	reduce	the	nuclear	
localization	of	BioTasp	to	a	level	midway	between	cells	with	wild	type	and	inactive	Taspase	(figure	
3.33b).	Since	the	control	cells	with	wild	type	Taspase	can	be	regarded	as	100	%	activity	and	the	
cells	with	inactive	Taspase	as	0	%	activity,	nanoparticles	reduce	the	Taspase	activity	in	cells	by	
roughly	50	%	at	200	µg/ml.	Furthermore,	the	inhibitory	effect	of	Amsil125	seems	to	be	somewhat	
lower	compared	to	Amsil8	and	Amsil20.	
In	 summary,	 inhibition	 of	 Taspase	 activity	 in	 cell	 lysates	 and	 cells	was	 observed	 for	 all	 three	
nanoparticles	at	nanomolar	concentrations.	
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3.6 Inhibition	of	Taspase	by	peptidyl‐succinimidyl	peptides	
Besides	 nanoparticles	 and	 compounds	 obtained	 by	 virtual	 docking,	 substrate	 analog	 Taspase	
inhibitors	 designed	 by	 Prof.	Markus	Kaiser	were	 tested	 in	 this	 project.	 Starting	 point	 for	 this	
endeavor	 was	 the	 proteolytic	 cleavage	 mechanism	 proposed	 by	 the	 Bogyo	 group	 [69].	 This	
mechanism	 involves	 the	 formation	 of	 a	 succinimide‐hydrate	 intermediate	 (figure	 3.34),	which	
facilitates	the	peptide	bond	transfer	of	 the	protein	backbone	to	the	aspartate	side	chain	of	 the	
substrate.	
	
	
Figure	3.34	Design	of	the	peptidyl‐succinimidyl	peptide.	
In	the	proposed	cleavage	mechanism	[69],	the	aspartate	side	chain	attacks	the	following	glycine	(red	arrow).	
This	reaction	yields	a	succinimide‐hydrate	intermediate	(top	panel;	succAsp	hydrate),	which	was	used	as	
starting	point	for	substrate	analog	Taspase	inhibitors.	The	potential	inhibitor	motif	peptidyl‐succinimidyl	
(succAsp)	is	shown	in	the	top	right	panel.	In	the	test	compound	Comp2	(bottom	panel),	the	Leu	at	P2	was	
substituted	 by	 Val	 to	 reduce	 the	 polarity.	 The	 Fmoc	 protection	 group	 was	 left	 for	 detection	 by	 UV	
absorption.	This	figure	was	taken	from	[134].	
	
The	novel	 class	of	 substrate	analog	 inhibitors	developed	 for	 this	 thesis	 features	a	 succinimide	
moiety	 (figure	 3.34).	 Optimization	 of	 the	 initial	 inhibitors	 yielded	 the	 most	 potent	 Taspase	
inhibitor	so	far	with	a	Ki	of	0.4	±	0.1	µM	in	vitro.	Moreover,	this	compound	was	active	in	cell	lysates,	
albeit	the	affinity	is	30‐fold	attenuated.	Furthermore,	the	developed	inhibitors	can	enter	the	cell,	
however,	the	achieved	intracellular	concentrations	were	too	low	for	a	measurable	inhibition	of	
Taspase	 activity.	 This	 project	 was	 accomplished	 in	 cooperation	 with	 the	 Kaiser	 group,	 who	
designed	and	synthesized	the	compounds.	
	
3.6.1 Peptidyl‐succinimidyl	peptides	inhibit	Taspase	in	vitro.	
The	peptidyl‐succinimidyl	peptides	were	synthesized	by	the	Kaiser	group	using	Fmoc/tBu	solid	
phase	peptide	synthesis.	Leaving	 the	N‐terminal	 fluorenylmethyloxycarbonyl	 (Fmoc)	group	on	
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the	final	product	allowed	an	exact	spectroscopic	determination	of	the	concentration.	However,	
this	additional	aromatic	moiety	could	change	the	inhibitory	properties	of	the	compound.	To	rule	
out	an	inhibition	by	the	Fmoc	group,	the	inhibitory	effect	of	Fmoc‐valine	(Comp1)	was	tested	in	
the	 in	 vitro	 assay	 (supplemental	 figure	 7.18a).	 This	 titration	 resulted	 in	 a	 negligible	 effect	 on	
Taspase	activity,	even	at	high	Fmoc‐Val	concentrations.	
In	the	next	step,	the	designed	inhibitor	(figure	3.34)	as	well	as	eight	derivatives	were	titrated	to	
determine	IC50	and	Ki	values	(table	3.2	and	supplemental	figure	7.18).	
	
Table	3.2	Inhibitory	potential	of	the	succinimidyl	peptides	and	their	derivatives.	
Deviations	from	the	common	inhibitor	scaffold	are	highlighted	in	yellow.	
Compound	 Sequence*	 IC50 [µM]	 Ki	[µM]
Comp1		 Fmoc‐Val	 >	1000	 n.d.
Comp2		 Fmoc‐Gln‐Val‐succAsp‐Gly‐Val‐Asn‐Asp‐NH2 38.7	±	12.1	 4.3	±	1.3
Comp3		 Fmoc‐Gln‐Val‐piperidineAsp‐Gly‐Val‐Asn‐Asp‐NH2 30.1	±	10.6	 3.3	±	1.2
Comp4		 Fmoc‐Gln‐Val‐allocAsp‐Gly‐Val‐Asn‐Asp‐NH2 143	±	39	 15.9	±	4.3
Comp5		 Fmoc‐Gln‐Val‐succAsp‐βAla‐Val‐Asn‐Asp‐NH2 61	±	9.5	 6.8	±	1.1
Comp6		 Fmoc‐Gln‐Val‐succGlu‐Gly‐Val‐Asn‐Asp‐NH2 14.4	±	2.8	 1.6	±	0.3
Comp7		 Fmoc‐Gln‐Val‐Asp‐Gly‐Val‐Asn‐Asp‐NH2 >	1000	 n.d.
Comp8		 Fmoc‐Gln‐Val‐isoAsp‐Gly‐Val‐Asn‐Asp‐NH2 424	±	58	 47	±	6.4
Comp9		 Fmoc‐Prg‐Bpa‐Gln‐Val‐succAsp‐Gly‐Val‐Asn‐Asp‐NH2 3.6	±	0.8	 0.4	±	0.09
Comp10		 Rhd‐Gln‐Val‐succAsp‐Gly‐Val‐Asn‐Asp‐NH2 373	±	23	 41	±	2.6
*	Fmoc:	fluorenylmethyloxycarbonyl;	succAsp:	succinimide;	piperidineAsp:	Asp	with	piperidine	protection	
group;	 allocAsp:	 Asp	 with	 alloc	 protection	 group;	 βAla:	 β‐alanine;	 succGlu:	 glutarimide;	 isoAsp:	
isoaspartate;	Prg:	propargyl	glycine;	Bpa:	benzophenone	alanine;	Rhd:	rhodamine	B	
	
Comp2	exhibited	a	promising	inhibitory	effect	in	the	low	micromolar	range	(Ki	=	4.3	±	1.3	µM).	To	
ensure	that	the	inhibitor	was	not	simply	used	as	competitive	substrate	and	cleaved	by	Taspase,	
the	succinimide	moiety	was	omitted,	yielding	a	peptidic	Taspase	substrate	(Comp7	in	table	3.2).	
In	contrast,	this	compound	was	degraded	without	a	reduction	of	Taspase	activity.	This	indicates	
that	Comp7	is	degraded	rapidly,	while	the	succinimide	moiety	in	Comp2	truly	acts	as	an	inhibitor	
and	cannot	be	degraded	by	Taspase.	
During	synthesis,	a	side	product	with	an	LC‐MS	mass	equivalent	to	a	piperidine	addition	product	
could	 be	 isolated	 (Comp3).	 Although	 not	 further	 analyzed,	 this	 compound	 was	 presumably	
generated	by	an	addition	of	piperidine	to	the	succinimide	residue.	The	Ki	and	IC50	values	of	Comp3	
are	similar	to	those	of	Comp2	(Ki	=	3.3	±	1.2	µM).	Another	side	product	occurring	during	synthesis	
displayed	 an	 LC‐MS	 mass	 corresponding	 to	 a	 compound	 with	 alloc‐protected	 Asp	 (Comp4).	
However,	compared	with	Comp3,	the	inhibitory	effect	of	Comp4	was	fivefold	lower	(Ki	=	15.9	±	
4.3	µM).	
In	the	proposed	cleavage	mechanism	[69],	the	protein	backbone	of	the	substrate	is	transferred	to	
the	aspartate	side	chain,	forming	an	isoaspartate	intermediate	(figure	3.35).	
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Figure	3.35	Isoaspartate	intermediate	during	proteolysis.	
In	the	proposed	catalytic	mechanism,	the	succinimide‐hydrate	intermediate	(succAsp	hydrate)	is	used	to	
transfer	 the	protein	backbone	 to	 the	aspartate	side	chain.	This	yields	an	 isoaspartate	 (isoAsp),	which	 is	
needed	for	Taspase	cleavage.	
	
To	test	if	isoaspartate	can	truly	be	cleaved	by	Taspase	or	inhibits	the	reaction,	a	substrate	with	
isoaspartate	instead	of	aspartate	was	synthesized	(Comp8).	This	compound	exhibited	a	tenfold	
weaker	inhibition	of	Taspase	than	the	succinimide	compound	Comp2	(IC50	=	424	±	58	µM),	which	
excluded	isoaspartate	as	inhibitory	moiety	for	Taspase.	
For	 further	 improvement	of	 the	binding	affinity,	 the	role	of	 the	S’	 site	of	Taspase	 for	 inhibitor	
binding	was	explored.	To	this	end,	the	P’	residue	glycine	was	replaced	by	β‐alanine	(Comp5).	This	
small	structural	change	caused	a	minor	reduction	of	the	binding	affinity	(Ki	=	6.8	±	1.1	µM).	
For	an	extension	of	the	5‐membered	succinimide	ring	to	a	6‐membered	ring,	the	succinimide	was	
replaced	by	 a	 glutarimide	 (Comp6).	This	 change	 slightly	 improved	 the	 affinity	 to	 a	Ki	 of	 1.6	±	
0.3	µM.	
The	 most	 promising	 compound	 was	 the	 photoreactive	 inhibitor	 Comp9,	 which	 possesses	 an	
additional	 N‐terminal	 benzophenone	 as	 well	 as	 a	 propargyl	 glycine	 group.	 With	 a	 Ki	 in	 the	
nanomolar	range	(0.4	±	0.09	µM)	this	compound	showed	a	tenfold	higher	inhibitory	potential	than	
the	 best	 published	 Taspase	 inhibitor.	 Binding	 of	 Comp9	 was	 confirmed	 by	 microscale	
thermophoresis	(MST)	as	alternative	method	(figure	3.36a).	
	
Figure	3.36	Binding	of	the	peptidyl‐succinimidyl	peptide	inhibitors.	
Binding	of	Comp9	was	verified	by	microscale	thermophoresis	(MST)	titrations.	A	Kd	value	of	22.1	±	0.6	µM	
was	obtained.		
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In	 contrast	 to	 the	 activity	 assay,	 MST	 allows	 the	 determination	 of	 binding	 constants	 in	 the	
presence	of	NaCl.	Hence,	the	MST	measurements	were	performed	in	the	presence	of	450	mM	NaCl	
to	maintain	Taspase	stability.	This	procedure	allows	inspecting	if	the	inhibitor	binds	in	the	active	
site	and	competes	with	the	chloride	ion,	which	was	found	in	the	active	site	[56].	
A	comparison	of	the	affinity	of	Comp9	in	the	presence	(22.1	±	0.6	µM;	MST)	and	absence	of	NaCl	
(0.4	±	0.09	µM;	activity	assay)	reveals	50‐fold	weaker	binding	in	the	presence	of	NaCl.	This	finding	
supports	 that	 binding	 is	 competitive	 with	 respect	 to	 chloride.	 This	 was	 also	 found	 for	 the	
substrate,	indicating	a	similar	binding	mode	of	substrate	and	inhibitor.	
	
3.6.2 Peptidyl‐succinimide	peptides	are	resistant	against	Taspase	cleavage	
To	 verify	 the	 competitive	 type	 of	 inhibition,	 Taspase	 inhibition	by	Comp2	was	 assayed	 in	 the	
presence	of	different	substrate	concentrations	(figure	3.37a).	Nonlinear	fitting	of	the	data	with	a	
model	 for	 competitive	 inhibition	 confirms	 that	 Comp2	 truly	 acts	 as	 a	 reversible	 competitive	
inhibitor.	
	
	
Figure	3.37	Stability	of	competitive	peptidyl‐succinimidyl	peptides.	
a	Competitive	inhibition	of	peptidyl‐succinimidyl	peptides	was	confirmed	with	Comp2.	A	Ki	of	2.5	±	2	µM	
was	obtained	by	nonlinear	fitting.	b	Rhodamine‐labeled	inhibitor	was	incubated	with	1	µM	Taspase	to	assay	
stability.	The	inhibitor	shows	no	decrease	in	anisotropy,	while	the	anisotropy	of	the	substrate	control	drops	
due	to	cleavage.	c	Taspase	was	incubated	with	and	without	63	µM	Comp2,	before	activity	was	assayed.	The	
calculated	 inhibition	reflects	the	ratio	of	the	activities	 in	the	presence	and	absence	of	the	 inhibitor	after	
certain	incubation	times.	Constant	inhibition	by	roughly	60	%	indicates	a	sufficiently	high	stability	of	the	
inhibitor	against	degradation.	Bars	indicate	standard	errors.	
	
Competitive	inhibition	of	a	protease,	however,	carries	the	risk	of	proteolytic	degradation	of	the	
inhibitor	due	to	its	substrate	analog	nature.	Hence,	the	stability	of	the	succinimide	motif	against	
Taspase	mediated	proteolysis	was	tested.	This	required	the	synthesis	of	a	fluorescent	derivative	
of	the	inhibitor	(Comp10).	Although	the	incorporation	of	a	bulky	rhodamine	dye	reduce	the	Ki	
twentyfold	 (Ki	 =	 41	 ±	 2.6	 µM),	 the	 affinity	 was	 still	 sufficiently	 high	 for	 stability	 tests.	 The	
fluorescent	dye	allowed	following	the	degradation	over	time	by	fluorescence	anisotropy	(figure	
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3.37b).	The	anisotropy	obtained	for	Comp10	in	the	presence	of	Taspase	was	constant	over	5	days.	
In	contrast,	the	anisotropy	of	the	substrate	drops	rapidly	due	to	proteolytic	cleavage.	
To	exclude	an	influence	of	the	fluorescent	dye	attached	to	Comp10,	Taspase	was	incubated	with	
63	µM	Comp2,	and	the	activity	was	assayed	after	defined	times	(figure	3.37c).	The	initial	inhibition	
by	 roughly	 60	%	 remained	 constant	 even	 after	 incubation	 for	 24	 hours.	However,	 the	 overall	
Taspase	activity	was	reduced	over	time	due	to	the	instability	of	Taspase	in	the	assay	buffer	(see	
section	3.2.2).	
Altogether,	 these	 experiments	 demonstrate	 the	 stability	 of	 peptidyl‐succinimide	 inhibitors	
against	proteolytic	cleavage	by	Taspase.	
	
3.6.3 Peptidyl‐succinimide	peptides	bind	and	inhibit	Taspase	in	cell	lysates	
The	next	step	towards	in	vivo	experiments	was	to	test	the	inhibitory	potential	of	the	developed	
peptidyl‐succinimide	peptides	in	cell	lysates.	To	this	end,	Hela	cell	lysate	was	supplemented	with	
recombinant	Taspase	and	incubated	with	the	photoreactive	compound	Comp9.	Irradiation	with	
UV	light	cross‐linked	the	inhibitor	with	the	bound	protein.	A	subsequent	addition	of	a	rhodamine	
azide	via	click	reaction	allowed	visualization	by	fluorescence	imaging	(figure	3.38).	
	
Figure	3.38	Photolabeling	and	lysate	inhibition	with	peptidyl‐succinimide	peptides.	
a	Taspase	(5	µM)	was	added	to	Hela	cell	lysates	and	subsequently	cross‐linked	with	5	µM	of	the	UV‐reactive	
Comp9	inhibitor.	A	click	reaction	with	rhodamine	amide	allowed	detection	via	fluorescence.	The	α‐subunit	
and	the	band	for	the	full‐length	(fl)	Taspase	are	visible	in	the	gel,	but	not	the	β‐subunit.	Cross‐linking,	click	
reaction	and	fluorescence	gel	imaging	was	performed	by	Susanne	Zweerink,	Kaiser	group.	b	Comp9	inhibits	
the	activity	of	overexpressed	Taspase	in	Hela	lysates	with	an	IC50	of	111	±	30	µM.	
	
The	fluorescent	bands	at	45	kDa	and	28	kDa	correspond	to	full‐length	Taspase	and	the	α‐subunit,	
respectively.	 This	 indicates	 that	 the	 inhibitor	 binds	 to	 the	 α‐subunit	 of	 Taspase,	 while	 no	
interaction	with	 the	 β‐subunit	 is	 visible.	 Furthermore,	 no	 interaction	 above	 background	with	
other	 proteins	 in	 the	 lysate	was	 observed.	 However,	 the	 comparatively	 high	 concentration	 of	
recombinant	Taspase	(5	µM)	added	to	the	lysates	should	be	considered	in	the	interpretation	of	
this	finding.	
The	inhibitory	potential	was	assayed	in	Hela	lysates	transfected	with	GFP‐Taspase.	The	assay	was	
performed	 in	 lysis	 buffer	 containing	 150	 mM	 NaCl.	 Under	 these	 conditions,	 the	 inhibition	 is	
roughly	30‐times	weaker	(IC50	=	111	±	30	µM)	than	for	recombinant	Taspase	in	the	in	vitro	assay.	
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3.6.4 Peptidyl‐succinimidyl	peptides	enter	the	cell	
Although	the	molecular	weight	of	the	peptidyl‐succinimide	peptides	of	nearly	1	kDa	is	rather	large	
to	enter	 the	 cell,	 their	 ability	 to	 cross	 the	 cell	membrane	was	 tested.	 For	 this,	Hela	 cells	were	
treated	with	the	fluorescent	compound	Comp10.	After	defined	incubation	times,	the	cells	were	
washed	 and	 the	 intracellular	 fluorescence	 was	 used	 as	 a	 measure	 for	 cellular	 uptake	 of	 the	
compound	(figure	3.39a‐c).	
	
	
Figure	3.39	The	peptidic	inhibitors	enter	the	cell	but	exhibit	no	Taspase	inhibition.	
a	The	fluorescence	labeled	peptidic	inhibitor	can	enter	Hela	cells.	The	intracellular	fluorescence	intensity	is	
increased	after	1	h	(middle	panel)	and	5	h	(right	panel)	compared	to	the	background	intensity	(left	panel).	
b	Statistical	analysis	confirms	elevated	fluorescence	due	to	inhibitor	entry	after	1	and	5	hours.	The	inhibitor	
uptake	is	increased	by	incubation	in	the	absence	of	serum.	c	Hela	cells	treated	with	50	µM	Comp9	for	20	h	
show	no	significant	(ns)	inhibition	of	Taspase	activity	in	comparison	to	untreated	cells	(wt	Taspase).	In	this	
cellular	Taspase	activity	assay,	the	nucleus	to	cytoplasm	ratio	(N/C)	corresponds	to	the	Taspase	activity.	20	
(c)	or	50	(e)	cells	from	3	independent	experiments	were	evaluated.	***	indicate	p‐values	<	0.001.	
	
Untreated	Hela	cells	show	a	very	low	background	fluorescence	in	the	RFP	channel	(figure	3.39a).	
After	treatment	 for	5	hours	with	the	peptide,	 the	cells	show	a	distinct	red	fluorescence	evenly	
distributed	throughout	the	cell,	indicating	a	cellular	uptake	of	the	fluorescent	inhibitor.	Statistical	
evaluation	of	 the	samples	reveals	 that	 the	 increase	 in	 fluorescence	 is	highly	significant	 (figure	
3.39b).	Even	after	incubation	for	1	hour,	the	cells	display	an	increased	fluorescence,	which	is	not	
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visible	by	eye	(figure	3.39a).	Notably,	the	incubation	in	serum‐free	medium	increased	the	uptake	
of	 the	 inhibitor	 more	 than	 twofold	 in	 the	 samples	 treated	 for	 5	 hours.	 With	 fluorescence	
microscopy,	a	determination	of	the	intracellular	concentration	of	the	inhibitor	was	not	possible.	
Therefore,	the	uptake	could	only	be	confirmed	qualitatively.	
Nevertheless,	the	inhibitory	effect	of	the	peptidyl‐succinimide	inhibitor	was	tested	in	Hela	cells	
using	a	cell‐based	activity	assay	(section	3.5.3).	To	this	end,	Hela	cells	were	treated	with	50	µM	
Comp9	for	18	hours,	before	cells	were	fixated	and	the	localization	of	the	reporter	substrate	was	
evaluated	(figure	3.39c).	However,	cells	treated	with	Comp9	displayed	the	same	Taspase	activity	
as	untreated	cells.	
In	summary,	the	peptidyl‐succinimide	peptides	successfully	inhibited	recombinant	Taspase	and	
cell	lysates,	but	showed	no	inhibitory	effect	in	the	cellular	activity	assay	despite	cellular	uptake	of	
the	compounds.	
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4 Discussion	
Proteolytic	activation	is	a	common	regulatory	mechanism	for	various	cellular	processes.	In	the	
case	of	 a	 t(4;11)	 translocation,	Taspase	 is	 the	key	enzyme	 for	 the	proteolytic	activation	of	 the	
oncogenic	 MLL	 protein.	 Consequently,	 inhibition	 of	 Taspase	 could	 prevent	 the	 malignant	
transformation	of	cells	with	t(4;11)	translocation	and	probably	also	solid	tumors.	
For	the	development	of	new	inhibitors,	a	detailed	understanding	of	the	biochemical	properties,	
the	 catalytic	 mechanism	 and	 the	 structure	 of	 the	 target	 enzyme	 are	 of	 tremendous	 value.	
Therefore,	 Taspase	 was	 subjected	 to	 extensive	 biochemical	 characterization	 with	 respect	 to	
structure,	 stability,	 autocatalytic	 activation,	 posttranslational	 modification	 and	 substrate	
specificity.	With	this	knowledge,	novel	Taspase	inhibitors	were	evaluated	in	vitro,	in	cell	lysates	
and	in	cells.	This	approach	yielded	two	novel	classes	of	Taspase	inhibitors:	Silica	nanoparticles	
and	substrate	analog	succinimide	peptides.		
	
4.1 Taspase	is	a	unique	protease	and	requires	unique	inhibitors	
Taspase	belongs	to	the	type	II	asparaginase	family	and	shares	the	typical	αββα	asparaginase	fold,	
an	autocatalytic	activation	process,	as	well	as	an	N‐terminal	nucleophile	(Ntn)	at	the	β‐subunit.	
However,	despite	these	similarities,	Taspase	differs	from	other	type	II	asparaginases	in	some	key	
properties,	which	were	analyzed	in	detail.	
	
4.1.1 Catalytic	constants	of	Taspase	
The	MLL	protein	possesses	two	similar	Taspase	cleavage	sites	(CS1	and	CS2;	table	3.1)	with	CS2	
being	more	conserved	and	optimal	for	cleavage	[57].	With	a	quantitative	activity	assay	in	hand,	
this	cleavage	site	specificity	could	be	quantified	for	the	first	time	(figure	3.19).	Although	the	CS1	
and	CS2	model	substrates	used	for	the	in	vitro	assay	differ	slightly	in	the	fluorescent	dyes	attached	
at	the	N‐terminus,	the	effect	on	the	catalytic	activity	is	expected	to	be	negligible	due	to	sufficient	
distance	to	the	cleavage	site.	The	resulting	catalytic	constants	revealed	low	micromolar	affinities	
of	the	CS1	and	CS2	substrates	(Km	=	18	and	3	µM,	respectively),	which	is	in	good	agreement	with	
the	previously	published	affinity	for	CS1	(12	µM;	[56]).	The	turnover	numbers	for	CS1	and	CS2	
cleavage	were	quantified	 for	 the	 first	 time	(0.03	and	0.08	s‐1,	 respectively)	and	are	rather	 low	
compared	 to	 other	 asparaginases,	 for	 example	 from	 the	 enterobacterial	 Pectobactrium	
carotovorum	 (120	 s‐1;	 [135]),	 from	 Yersinia	 pseudotuberculosis	 (0.22	 s‐1;	 [136]),	 or	 from	 the	
hyperthermophilic	Pyrococcus	furiosus	(888	s‐1	at	80	°C;	[137]).	The	resulting	specificity	constant	
confirms	a	twentyfold	higher	cleavage	preference	of	CS2	over	CS1.	
Post‐translational	modifications	are	a	common	mechanism	for	the	regulation	of	enzyme	activity	
and	have	also	been	speculated	for	Taspase	[71].	For	Taspase	protein	expressed	heterologously	in	
E.	coli,	post‐translational	modifications	could	not	be	detected	by	MALDI‐MS	(figure	3.9).	While	
methylation	 and	 acetylation	 have	 been	 described	 for	 E.	 coli	 [138],	 enzymatic	 regulation	 by	
phosphorylation	is	common	in	eukaryotes,	but	rarely	observed	in	E.	coli.	However,	the	fact	that	
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Taspase	expressed	in	bacteria	and	eukaryotic	cells	exhibit	the	same	specific	activity	(figure	3.20),	
suggests	 that	 Taspase	 activity	 does	 not	 need	 activation	 by	 post‐translational	modifications	 in	
eukaryotic	cells.	However,	modifications	under	stress	conditions	such	as	phosphorylation	cannot	
be	excluded	with	these	data.	Note	that	the	GFP‐tag	needed	for	this	experiment	is	reported	to	have	
no	influence	on	the	activity	[71].	
Moreover,	these	data	rule	out	the	hypothesis	that	bacterially	expressed	Taspase	displays	only	an	
attenuated	activity	[71].	Additionally,	the	enzyme/substrate	ratio	required	for	efficient	substrate	
cleavage	 is	 below	 1:500,	 which	 is	 more	 than	 two	 orders	 of	 magnitude	 more	 efficient	 than	
published	 [71].	 One	 plausible	 explanation	 that	 the	 catalytic	 activity	 in	 vitro	 is	 higher	 than	
published	 before	 refers	 to	 the	 instability	 of	 Taspase	 in	 the	 assay	 buffer.	 In	 this	 regard,	 the	
requirement	 of	 salt	 for	 stability	 was	 pinpointed	 (figure	 3.8)	 and	 NaCl	 concentrations	 below	
450	 mM	 caused	 precipitation	 of	 Taspase	 (data	 not	 shown).	 To	 avoid	 inhibition	 by	 chloride,	
Taspase	was	stabilized	by	sucrose	for	activity	measurements	and	it	was	demonstrated	for	the	first	
time	that	albeit	sucrose	stabilizes	Taspase,	the	half‐life	is	still	only	near	2.5	hours.	Hence,	Taspase	
requires	fast	purification	with	high	salt	concentrations	and	short	incubation	times	to	maintain	its	
catalytic	activity.	Insufficient	consideration	of	any	of	these	requirements	was	found	to	result	in	a	
dramatic	loss	of	activity	(figure	3.17	and	figure	3.8).	
	
4.1.2 Autocatalytic	processing	of	Taspase	takes	several	days	
While	 the	 general	 principle	 of	 autocatalytic	 processing	 of	 a	 proenzyme	 is	 shared	 among	
asparaginases,	 the	 kinetics	 of	 the	 activation	 rates	 varies	 significantly	 between	 different	
asparaginases	(table	4.1).	For	instance,	activation	of	E.	coli	asparaginase	takes	less	than	one	day	
[62],	contrary	to	the	fivefold	slower	activation	of	Flavobacterium	meningosepticum	asparaginase	
[139].	 The	 slowest	 activation	 rate	 was	 reported	 for	 human	 asparaginase	 with	 90	 days.	 For	
Taspase,	the	only	reported	value	is	that	it	takes	longer	than	6	hours	[63].	
	
Table	4.1	Properties	of	Taspase‐homolog	proteins.	
Protein	
Homology
sequence	 structure	
Oligomeric	state
Xtal	 solution	 Autocatalysis	
Taspase	 100	%	 0	Å dimer dimer 3	days
Asparaginase	 36	%	 0.9	Å dimer dimer	+	monomer	 90	days
F.	m.	Glycoamidase	 27	%	 1.1	Å dimer monomer <	5	days
E.	c.	Asparaginase	 21	%	 1.5	Å dimer dimer <	1	days
Proteasome	 14	%	 4.7	Å heptamer heptamer α‐SU‐dependent
	
	
A	detailed	study	of	 the	autocatalytic	process	provided	 for	 the	 first	 time	 information	about	 the	
Taspase	 activation	 rate.	 Separation	 of	 the	 active	 subunits	 from	 the	 proenzyme	 by	 SDS‐PAGE	
indicates	that	the	activation	process	takes	approximately	one	day	(figure	3.11).	Importantly,	the	
activation	of	Taspase	does	not	begin	at	the	start	of	the	assay,	but	already	during	the	purification	
process	of	the	protein.	This	becomes	clear	by	comparison	of	the	SDS	gels	of	the	bacterial	lysate	
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(figure	 3.3;	 almost	 only	 proenzyme),	 after	 affinity	 purification	 (figure	 3.4;	 predominantly	
proenzyme)	and	after	gel	filtration	(figure	3.5;	ca.	50	%	proenzyme).	Hence,	the	two	days	needed	
for	protein	purification	have	to	be	added	to	the	activation	time	determined	in	the	assay,	yielding	
a	total	activation	time	of	three	days.	Moreover,	the	high	amount	of	proenzyme	in	the	bacterial	
lysates	after	expression	over	night	could	hint	at	a	lower	processing	in	cells	compared	to	buffer	
conditions.	
Interestingly,	the	band	for	the	proenzyme	loses	intensity	over	time,	but	does	not	disappear	even	
after	seven	days.	Two	explanations	are	possible	for	this	phenomenon.	Either	a	fraction	of	Taspase	
is	still	in	the	proenzyme	form,	or	the	band	is	caused	by	an	SDS‐resistant	dimer	of	the	two	subunits.	
Since	 the	 autocatalytic	 processing	 is	 an	 irreversible	 spontaneous	 event	 and	 no	 equilibrium	
reaction,	a	stagnation	of	this	process	is	unlikely.	Additionally,	the	presence	of	an	SDS‐resistant	αβ‐
dimer	is	in	agreement	with	the	high	affinity	of	the	subunits	discussed	below.	
Moreover,	Nomme	and	colleagues	reported	an	acceleration	of	the	human	asparaginase	activation	
process	by	addition	of	glycine	[66].	However,	Taspase	activation	was	independent	of	glycine,	salt,	
sucrose	or	malate	(data	not	shown).	
To	gain	further	insight	into	this	activation	process,	time‐dependent	NMR	studies	were	applied.	
With	 this	 technique,	 the	 activation	 can	 be	 followed	more	 detailed	 than	with	 SDS‐PAGE	 at	 the	
atomic	 level.	 The	 NMR	 peak	 intensities	 of	 the	 amino	 acids	 in	 the	 fragment	 released	 by	 the	
autocatalytic	activation	event	(referred	to	as	Taspase	loop)	increased	over	time	(supplemental	
figure	 7.9).	 Since	 the	 assigned	 peaks	 in	 the	 1H‐15N‐HSQC	 spectrum	 of	 Taspase	 correspond	 to	
flexible	 loop	 regions	 and	 disordered	 regions	 (see	 section	 4.1.4	 for	 detailed	 explanation),	 the	
appearance	of	peaks	correlates	with	an	 increased	 flexibility	of	 the	corresponding	amino	acids.	
Therefore,	 the	 increasing	 flexibility	of	 the	 loop	 residues	 reflects	 the	autocatalytic	activation	of	
Taspase.	
The	peak	intensities	of	the	loop	residues	reach	their	maximum	after	approximately	seven	days,	
indicating	that	the	autocatalytic	activation	is	completed	after	this	period.	Hence,	compared	to	the	
SDS‐PAGE‐based	 analysis	 of	 the	 autocatalytic	 activation,	 the	 NMR	 experiments	 indicate	 a	
somewhat	 slower	 activation	 rate.	 This	 difference	 can	 presumably	 be	 attributed	 to	 the	 lower	
incubation	 temperature	 during	 the	 NMR	 experiment	 (30	 °C)	 compared	 to	 the	 SDS‐PAGE	
experiment	(37	°C),	as	the	probability	for	a	nucleophilic	attack,	which	is	needed	for	the	activation	
process,	is	usually	temperature	dependent	as	described	for	the	activation	of	other	Ntn‐hydrolases	
[139].	Additionally,	both	experiments	are	only	qualitative.	
In	summary,	these	first	data	of	the	Taspase	maturation	process	reveal	that	Taspase	activation	in	
vitro	 takes	 approximately	 three	 days,	which	 is	 significantly	 shorter	 than	 its	 closest	 structural	
homolog,	human	asparaginase	(90	days).	
	
4.1.3 Taspase	is	a	hetero‐tetramer	with	high	affinity	
After	 autoproteolysis,	 the	 subunits	of	 asparaginase	 type	 II	 family	proteins	 assemble	 to	 an	αβ‐
heterodimer.	 In	 Taspase,	 the	 αβ‐heterodimer	 displays	 a	 remarkably	 high	 stability.	 This	 high	
affinity	 of	 the	 subunits	 allowed	 a	 co‐purification	with	 a	His‐tag	 only	 present	 at	 the	 α‐subunit	
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(section	3.1.4).	Furthermore,	the	two	subunits	were	retained	by	a	30	kDa	filter	membrane	during	
purification,	although	each	subunit	is	small	enough	for	passage	(25	and	20	kDa).	Accordingly,	a	
FRET‐based	assay,	in	which	Atto488‐labeled	Taspase	was	mixed	with	Atto594‐labeled	Taspase,	
failed	 to	detect	 an	 exchange	of	 the	 subunits	 indicating	no	or	 slow	subunit	 exchange	 (data	not	
shown).	A	look	at	the	crystal	structure	reveals	that	the	high	affinity	of	the	subunits	is	based	on	a	
large	hydrophobic	interface	with	a	positively	charged	patch	of	the	α‐subunit	buried	in	a	negatively	
charged	groove	in	the	β‐subunit	(figure	4.1).	
	
	
Figure	4.1	Interface	of	the	two	Taspase	subunits.	
a	The	α‐subunit	possesses	a	positively	charged	patch	(blue)	at	the	interface	to	the	β‐subunit	(yellow).	b	
Conversely,	 the	β‐subunit	 shows	a	negatively	 charged	patch	 (red),	which	allows	 interaction	with	 the	α‐
subunit	(yellow).	Charges	were	mapped	on	a	model	based	on	PDB	2a8j.	
	
While	the	αβ‐dimer	is	generally	accepted	for	Taspase,	the	hetero‐tetrameric	oligomer	of	Taspase	
seen	 in	 all	 asparaginase‐like	 crystal	 structures	 [56,66,139,140]	 is,	 however,	 discussed	
controversially.	On	the	one	hand,	Taspase	unambiguously	adopts	a	hetero‐tetrameric	structure	
upon	crystallization	and	the	large	hydrophobic	interface	between	the	two	αβ‐dimers	suggests	a	
high	stability	of	the	complex	[56].	On	the	other	hand,	pull‐down	experiments	and	gel	filtrations	
indicated	 only	 a	 low	 affinity	 of	 the	 two	 αβ‐heterodimers	 in	 solution	 [68].	 Nevertheless,	 these	
contradictory	 experiments	 can	 be	 brought	 in	 line	 by	 a	 consideration	 of	 the	 Taspase	
concentrations.	At	high	concentrations	used	 for	 crystallography,	Taspase	 is	 a	hetero‐tetramer,	
whereas	the	low	concentrations	used	in	the	biochemical	assays	favor	the	αβ‐dimer.	Accordingly,	
also	the	homolog	F.	meningosepticum	glycosylasparaginase	is	a	dimer	in	solution,	despite	showing	
a	heterotetramer	in	the	crystal	structure	(table	4.1	and	[140]).	
For	the	first	time,	concentration	dependent	gel	filtrations	were	performed	with	Taspase	to	shed	
light	on	the	oligomeric	state	of	Taspase	in	solution.	For	concentrations	between	1	and	400	µM	
Taspase	was	exclusively	found	as	αββα‐heterotetramer	(section	3.2.4).	Cellular	concentrations	of	
Taspase	are	assumed	to	be	much	lower,	but	could	not	be	assessed	by	gel	filtration,	as	they	fall	
below	 the	 detection	 limit	 of	 the	UV	 detector	 [68].	 However,	 the	 fact	 that	 the	 90	 kDa	 Taspase	
hetero‐tetramer	can	pass	a	50	kDa	filter	membrane	(supplemental	figure	7.19)	indicates	that	the	
complex	is	not	as	stable	as	proposed	by	Khan	and	colleagues	based	on	the	dimer	interface	area	in	
the	crystal	structure	[56].	
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4.1.4 Structure	of	the	Taspase	loop	
In	the	previous	sections,	the	autocatalytic	maturation	of	the	Taspase	proenzyme	was	discussed.	
This	process	yields	a	C‐terminal	stretch	at	the	α‐subunit	of	all	Ntn‐hydrolases,	which	is	missing	in	
all	available	crystal	structures	due	to	a	lack	of	electron	density	for	this	region	(figure	4.3b).	In	the	
case	of	Taspase,	this	region	comprises	56	amino	acids	(G178‐D233)	and	is	referred	to	as	Taspase	
loop.	As	crystallography	failed	to	provide	information	about	this	part	of	the	protein,	NMR	and	CD	
spectroscopy	were	used	as	complementary	methods	to	gain	first	information	about	the	flexible	
Taspase	loop.	
The	first	striking	finding	was	that	the	1H‐15N	HSQC	spectrum	of	full‐length	Taspase	shows	low	1H	
signal	dispersion	of	0.8	ppm	(between	7.8	and	8.6	ppm),	which	is	typical	for	unstructured	regions	
[141–143].	To	map	these	residues,	the	respective	areas	in	the	model	were	added	by	homology	
modeling	(figure	4.2).	
	
	
Figure	4.2	Mapping	of	the	1H‐15N	HSQC	signals.	
Mapping	 of	 the	 assigned	 residues	 on	 a	 model	 of	 wild‐type	 Taspase	 based	 on	 the	 structure	 PDB	 2a8j.	
Assigned	residues	are	highlighted	in	red;	the	active	site	is	marked	in	green.	Most	of	the	assigned	residues	
can	be	found	in	the	flexible	N‐terminus	and	the	flexible	Taspase	loop.	
	
Indeed,	the	assigned	signals	in	the	spectrum	correspond	to	flexible	regions	in	the	N‐terminus	(15	
residues)	 or	 the	 Taspase	 loop	 (12	 residues),	 while	 the	 rigid	 parts	 with	 a	 defined	 secondary	
structure	 remain	 invisible.	Hence,	 the	missing	 regions	 of	 the	Taspase	 crystal	 structure	 can	be	
selectively	investigated	by	NMR	spectroscopy.	An	important	factor	for	the	signal	intensity	in	NMR	
spectroscopy	is	the	rotation	correlation	time	of	the	protein,	which	correlates	with	the	protein	size.	
This	 rotational	 correlation	 time	 is	 related	 to	 both	 the	 longitudinal	 (T1)	 and	 transversal	 (T2)	
relaxation	times.	Large	proteins	like	Taspase	exhibit	long	T1	and	short	T2	times,	which	results	in	
line‐broadening	in	the	resultant	NMR	spectrum	due	to	a	loss	of	magnetization	and	renders	the	
peaks	 invisible.	 However,	 the	 large	 loop	 regions	 of	 Taspase	 obviously	 behave	 like	 separate	
disordered	domains	with	 independent	rotational	correlation	 times.	Thus,	 the	rigid	core	region	
loses	its	magnetization	quickly,	while	the	flexible	regions	possess	lower	rotation	correlation	times	
and	the	signals	can	be	recorded	before	the	magnetization	is	lost.	Conversely,	the	inactive	mutant	
does	not	cleave	itself,	so	that	the	loop	retains	the	rotational	correlation	time	of	the	core	and	is	
therefore	invisible	in	the	NMR	spectra	of	inactive	Taspase	(figure	7.10).	
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Thus,	according	to	NMR	spectroscopic	studies	the	Taspase	loop	seems	to	be	flexible.	Furthermore,	
these	data	are	in	 line	with	the	helix‐turn‐helix	model	generated	by	homology	modeling	(figure	
3.13).	Essentially,	the	amino	acids	preceding	Ser222	were	not	visible	in	the	NMR	spectra,	whereas	
the	 region	 C‐terminal	 of	 Ser222	 was	 seen	 in	 the	 NMR	 spectra.	 This	 strongly	 supports	 the	
occurrence	of	a	more	rigid	secondary	structure	ending	at	Glu221.	
Based	on	these	data,	the	first	structural	model	was	generated	for	the	loop	region	missing	in	the	
crystal	structure	of	Taspase	and	all	other	asparaginases.	The	model	fulfils	the	criteria	mentioned	
above,	namely	a	central	region	of	discontinuous	helices,	as	well	as	a	defined	structure	C‐terminal	
of	Ser222.	
	
	
Figure	4.3	Proposed	structure	of	the	Taspase	loop.	
a	 The	 proposed	 structure	 is	 based	 on	 NMR	 and	 CD	 spectroscopy	 data	 as	 well	 as	 secondary	 structure	
prediction.	The	model	shows	a	helix‐turn‐helix	motif.	NLS	amino	acids	are	highlighted	in	orange,	critical	
NLS	residues	are	displayed	 in	red.	The	overlay	of	 two	possible	conformations	 indicates	 flexibility	of	 the	
termini.	b	Location	of	the	loop	in	the	Taspase	protein	(PDB	2a8j).	
	
The	 3D	 model	 generated	 by	 YASARA	 displays	 the	 proposed	 helix‐turn‐helix	 structure	 of	 the	
Taspase	loop	with	flexible	termini	(figure	4.3a).	Interestingly,	the	helix‐turn‐helix	motif	ends	at	
Glu221	and	allows	the	interaction	of	the	two	helices,	so	that	the	bipartite	basic	NLS	[74]	forms	a	
continuous	patch	(red	in	figure	4.3a).	Furthermore,	the	interaction	of	the	two	helices	agrees	with	
the	interface	visible	in	the	wheel	projections	(data	not	shown).	
As	mentioned	before,	all	other	type	II	asparaginases	comprise	a	flexible	loop	region	N‐terminal	of	
the	 catalytic	 site	 that	 is	 disordered	 in	 the	 crystal	 structures	 of	 human	 glycosylasparaginase,	
human	 asparaginase,	 plant	 asparaginase,	 E.	 coli	 asparaginase,	 and	 F.	 meningosepticum	
glycosylasparaginase.	Sequence‐based	models	of	the	loop	for	these	Taspase	homologs	(figure	4.4)	
reveal	that	only	the	Taspase	loop	is	predicted	to	be	predominantly	helical.	In	contrast,	the	other	
loops	 are	 predicted	 as	 pure	 random	 coil	 (human	 asparaginase,	 E.	 c.	 asparaginase,	 and	 F.	m.	
glycosylasparaginase)	 or	 random	 coil	 interspersed	 with	 short	 helices	 (human	
glycosylasparaginase	and	plant	asparaginase).	
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Figure	4.4	Asparaginase	type	II	loop	models.	
Modeled	structures	of	 the	Taspase	 loop	homologous	regions	 in	other	 type	 II	asparaginases.	The	 loop	of	
human	Taspase	(template	PDB	2a8i;	 loop	 length:	25	aa)	 is	predicted	as	predominantly	helical,	while	 for	
human	glycosylasparaginase	(template	PDB	1apy;	loop	length:	20	aa),	human	asparaginase	(template	PDB	
4pvs;	 loop	 length:	 14	 aa),	 plant	 asparaginase	 (template	 PDB	 2gez;	 loop	 length:	 33	 aa),	Escherichia	 coli	
asparaginase	 (template	 PDB	 2zal;	 loop	 length:	 17	 aa),	 and	 Flavobacterium	 meningosepticum	
glycosylasparaginase	(template	PDB	1ayy;	loop	length:	10	aa)	mainly	random	coil	elements	are	predicted.	
The	modeled	loop	regions	are	highlighted	in	red;	the	active	site	Thr234	is	highlighted	in	green.	
	
Although	 loops	 shorter	 than	 the	 25	 amino	 acids	 Taspase	 loop	 are	 unstructured	 (F.	 m.	
glycosylasparaginase:	 10	 amino	 acids;	 human	 asparaginase:	 14	 amino	 acids;	 human	
glycosylasparaginase:	20	amino	acids),	also	the	longer	plant	asparaginase	loop	(33	amino	acids)	
possesses	predominantly	random	coil	elements.	
Further	analyses	with	the	isolated	loop	protein	confirmed	the	helical	structure	of	the	Taspase	loop	
and	 revealed	 that	 the	 terminal	 loop	 region	 are	 required	 for	 helix	 formation	 (figure	 3.15a).	
Moreover,	MD	simulations	of	the	loop	without	the	termini	indicate	that	although	short	helices	can	
form,	they	are	only	transient	and	cannot	establish	a	defined	tertiary	structure	(figure	3.15c).	
	
4.1.5 Inhibition	strategies	for	Taspase	
Due	to	 the	key	role	of	Taspase	 in	 the	activation	of	 the	oncogenic	MLL	protein	associated	with	
t(4;11)	leukemias,	Taspase	inhibitors	are	of	high	demand.	However,	although	several	strategies	
have	been	followed	to	find	inhibitors,	a	breakthrough	is	still	awaited	and	novel	Taspase	inhibitors	
are	urgently	required.	
DISCUSSION	 TASPASE	IS	A	UNIQUE	PROTEASE	AND	REQUIRES	UNIQUE	INHIBITORS	
	
110	
	
In	contrast,	 inhibition	of	 the	homolog	enzyme	asparaginase	is	undesired	for	medical	purposes.	
Rather,	high	asparaginase	activity	is	desired	for	cancer	treatment,	since	asparagine	is	essential	for	
leukemic	 cells.	 Consequently,	 depletion	 of	 asparagine	 by	 asparaginase	 leads	 to	 inhibition	 of	
protein	 synthesis	 and	 subsequent	 cell	 death	 [144].	 Thus,	 asparaginase	 is	 successfully	 used	 as	
chemotherapeutic	 and	 was	 released	 as	 E.	 coli	 asparaginase	 (Elspar™),	 PEGylated	 E.	 coli	
asparaginase	(Oncaspar™),	or	Erwinia	chrysanthemi	asparaginase	(Erwinase™)	for	the	treatment	
of	childhood	ALL	[145].	
As	explicated	in	the	previous	sections,	Taspase	differs	from	all	other	type	II	asparaginases	in	its	
substrate	 specificity	 and	 the	 catalytic	 mechanism.	 This	 is	 assumed	 to	 be	 the	 reason,	 why	
commercial	 protease	 inhibitors,	 such	as	 the	 serine	protease	 inhibitor	PMSF	or	 the	 cOmplete™	
inhibitor	 cocktail,	 but	 also	 the	 threonine	 protease	 inhibitor	 bortezomib	 [63],	 do	 not	 inhibit	
Taspase.	However,	this	unique	position	of	Taspase	offers	various	ways	for	new	inhibitors,	some	
of	which	have	already	been	mentioned	in	the	introduction	(section	1.3.4):	
Compound	screening	yielded	an	allosteric	arsenic	inhibitor	(NSC48300)	with	a	Ki	of	4.2	µM	[63].	
However,	 this	 compound	 is	 not	 specific	 for	 Taspase	 and	 was	 initially	 identified	 as	 an	 anti‐
angiogenic	 drug.	 Besides	 the	 toxicity	 of	 the	 arsenic	 moiety,	 this	 compound	 has	 been	 under	
discussion,	 since	 inhibition	 could	 not	 be	 reproduced	 in	 a	 cellular	 assay	 [133].	 This	 lack	 of	
inhibition	by	NSC48300	was	here	confirmed	in	vitro	(figure	3.21),	which	questions	the	potential	
of	the	compound	even	more.	
Virtual	docking	 by	Knauer	and	colleagues	 resulted	 in	 two	compounds	 (CHC‐A4	and	DHC‐C1)	
with	weak	inhibitory	potential	[71].	The	authors	discussed	the	missing	parts	in	the	Taspase	crystal	
structure	and	limited	cell	entry	of	the	compounds	as	possible	causes	for	the	poor	screening	output.	
Furthermore,	the	comparatively	small	size	of	the	compound	database	might	also	have	lowered	
the	number	of	hits.	
For	these	reasons,	the	virtual	docking	was	repeated	with	an	improved	Taspase	model	including	
the	missing	loop	regions	and	a	fiftyfold	larger	compound	library	(section	3.4.2).	Additionally,	the	
hurdle	of	crossing	the	cell	membrane	was	eliminated	by	using	an	in	vitro	assay	for	the	readout.	
Nevertheless,	the	resulting	compounds	displayed	no	inhibition	of	Taspase	activity.	This	supports	
the	theory	that	Taspase	undergoes	a	structural	change	upon	substrate	binding,	which	would	limit	
the	value	of	the	crystal	structure	for	virtual	docking	approaches.	
Substrate	analogs	were	first	tested	by	Lee	and	colleagues	with	a	series	of	substrate‐derived	vinyl	
sulfone	and	vinyl	ketone	derivatives	 [69].	Despite	 the	moderate	 inhibitory	potential	 (IC50	near	
30	µM	for	the	best	compound	yzm18),	these	studies	proved	helpful	for	the	design	of	new	substrate	
analog	 compounds.	 These	 succinimide	 peptides	 tested	 in	 this	 thesis	 are	 discussed	 separately	
below	(section	4.3).	
Enforced	dimerization	by	the	fusion	of	Jun‐	and	Fos‐tags	to	the	C‐terminus	of	Taspase	resulted	
in	 a	 loss	 of	 catalytic	 activity	 [68].	 This	 finding	 seems	 to	be	 in	 contrast	 to	 the	 catalytic	 activity	
obtained	with	Taspase	 at	 concentration	where	 the	 dimer	 is	 the	 predominant	 oligomeric	 state	
(figure	3.37b).	A	simple	explanation	for	these	contradictory	findings	is	that	the	enforced	dimer	
adopts	a	different	conformation	than	the	natural	dimer.	Particularly,	 the	C‐terminally	attached	
dimer	tags	presumably	bring	the	C‐termini	in	close	proximity	in	the	enforced	dimer.	However,	the	
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C‐termini	 of	 the	 natural	 dimer	 are	more	 than	 60	Å	 apart	 on	 the	 opposite	 ends	 of	 the	 hetero‐
tetramer	(figure	7.20).	In	the	enforced	dimer,	a	steric	hindrance	could	therefore	prevent	substrate	
binding	 and	 thus	 abolish	 catalytic	 activity.	 Furthermore,	 the	 artificial	 generation	 of	 higher	
oligomeric	Taspase	species	by	Jun/Fos	mediated	dimerization	was	not	excluded,	which	might	be	
another	reason	for	the	missing	activity.	
Molecular	plugs	 are	 a	 comparatively	 new	mechanism	 to	 occlude	 the	 active	 site	 by	 artificial	
ligands.	 The	 Schmuck	 group	 achieved	 an	 inhibition	 of	 the	 serine	 protease	 β‐tryptase	 with	
nanomolar	Ki	using	a	four‐armed	ligand	to	block	the	active	site	noncompetitively	[146,147].	This	
approach	 could	 also	 be	 applicable	 to	 Taspase,	 if	 the	 compounds	 sterically	 prevent	 substrate	
binding.	Consequently,	41	of	these	molecular	plug	derivatives	were	obtained	from	the	Schmuck	
group	 and	 tested	 for	 Taspase	 inhibition.	 Although	 these	 compounds	 covered	 combinations	 of	
different	 charges,	 lengths	 and	 hydrophobicity,	 none	 of	 them	 was	 able	 to	 inhibit	 Taspase	
(supplemental	figure	7.21	and	figure	7.22).	
	
4.2 Nanoparticles	as	novel	inhibitors	
Owing	 to	 their	high	 surface	 to	volume	ratio,	nanoparticles	possess	a	high	 free	 surface	energy,	
which	 allows	 the	 adsorbance	 of	 other	molecules	 [148].	 The	 interaction	 of	 nanoparticles	 with	
biomolecules	is	already	used	for	a	broad	range	of	diagnostic	and	therapeutic	methods	in	medicine	
[149].	Recent	studies	revealed	that	the	proteasome,	the	only	other	Ntn‐type	threonine	protease,	
binds	to	silica	nanoparticles	(Shirley	Knauer,	unpublished	data).	For	this	reason,	Taspase	binding	
to	silica	based	nanoparticles	was	investigated.	
	
4.2.1 Taspase	binding	depends	on	nanoparticle	size	
Indeed,	microscale	thermophoresis	and	fluorescence	anisotropy	experiments	showed	binding	of	
Taspase	to	silica	nanoparticles	at	low	nanomolar	concentrations	(section	3.5.1).	Furthermore,	in	
contrast	to	Taspase,	the	control	protein	parvalbumin	showed	a	300	000‐fold	weaker	affinity.	To	
understand	 why	 some	 proteins	 bind	 to	 nanoparticles,	 while	 others	 are	 rejected,	 the	 protein‐
nanoparticle	 interface	 needs	 to	 be	 examined	 in	 more	 detail.	 However,	 the	 interactions	 of	
nanoparticles	with	biomolecules	are	still	not	fully	elucidated,	despite	extensive	research	in	recent	
years.	Nevertheless,	 some	concepts	 emerged	 from	 these	efforts,	which	help	 to	understand	 the	
influence	of	 nanoparticles	on	proteins	 [92].	 Some	of	 the	possible	 interactions	are	displayed	 in	
figure	4.5.	
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Figure	4.5	Interactions	of	proteins	with	nanoparticles.	
Binding	to	nanoparticles	(red)	is	dependent	on	protein‐specific	on/off	rates,	as	well	as	hydrophobicity,	size	
and	charge	of	the	particles	themselves.	The	green	circles	represent	various	proteins.	Modified	according	to	
[92].	
	
Obvious	factors	that	rule	the	interactions	are	charge	and	hydrophobicity	of	the	particle	and	the	
protein.	Surprisingly,	a	recent	study	revealed	that	negatively	charged	proteins	show	increased	
binding	to	nanoparticles,	irrespective	of	their	net	charge	[99].	Other	important	determinants	are	
the	size	and	curvature	of	the	nanoparticles	and	steric	factors.	The	protein	layer	surrounding	the	
nanoparticles	is	called	corona.	Due	to	the	parameters	outlined	in	figure	4.5,	this	corona	is	specific	
for	each	 type	of	nanoparticle	and	establishes	 rapidly.	Hence,	nanoparticles	 interact	 selectively	
with	only	some	proteins	and	do	not	bind	every	protein	[99,150].	This	is	in	agreement	with	the	
binding	of	Taspase	to	silica	nanoparticles,	while	parvalbumin	is	rejected	(section	3.5.1).	
For	 the	 interaction	of	Taspase	with	negatively	charged	amorphous	silica	particles	 (Amsil),	 the	
surface	area	and	curvature	 showed	a	great	 influence	on	Taspase	binding	affinity	and	 capacity	
(figure	 3.27).	 The	EC50	 of	 nanoparticles	with	125	nm	diameter	 (Amsil125)	 is	 3500‐fold	 lower	
compared	 with	 nanoparticles	 of	 8	 nm	 diameter	 (Amsil8).	 This	 is	 also	 reflected	 in	 the	
stoichiometry	of	roughly	5000	and	6	Taspase	molecule	per	Amsil125	and	Amsil8	nanoparticle,	
respectively,	which	is	in	good	agreement	with	the	stoichiometry	of	620:1	reported	for	HSA	with	
70	nm	NIPAM/BAM‐nanoparticles	[151].	Notably,	an	Amsil8	particle	binds	roughly	800	times	less	
Taspase	molecules	than	an	Amsil125	particle,	although	the	surface	area	is	only	roughly	250	times	
smaller	for	Amsil8.	This	is	probably	the	case	because	Taspase	is	able	to	bind	with	higher	density	
to	a	surface	with	low	curvature	(Amsil125)	compared	to	high	curvature	surfaces	(Amsil8).	
	
4.2.2 Possible	inhibitory	mechanisms	
Here,	for	the	first	time	silica	nanoparticles	were	found	not	only	to	bind,	but	also	to	inhibit	Taspase	
(figure	3.28).	Notably,	binding	and	inhibition	occur	at	similar	nanoparticle	concentrations	(figure	
3.27	and	 figure	3.28),	 indicating	 that	every	Taspase	molecule	bound	 to	nanoparticles	 loses	 its	
activity.	However,	the	inhibition	of	enzymes	by	nanoparticles	is	poorly	investigated	and	scarcely	
described.	One	example	is	the	inhibition	of	chymotrypsin	multi‐walled	carbon	nanotubes,	which	
were	 specifically	 imprinted	 to	 enable	 chymotrypsin	 binding	 [152],	 which	was	 also	 applied	 to	
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trypsin	by	an	independent	group	[153].	Another	study	investigated	the	influence	of	single‐walled	
carbon	 nanotubes	 on	 soybean	 peroxidase	 and	 chymotrypsin	 activity	 [109].	 They	 found	 an	
irreversible	 inhibition	 of	 chymotrypsin	 activity	 and	 more	 than	 90	 %	 inhibition	 of	 soybean	
peroxidase	 activity.	 For	 the	 inhibition	 mechanism	 of	 chymotrypsin,	 the	 authors	 suggested	 a	
denaturation	of	 the	protein,	while	 the	 inhibitory	mechanism	for	soybean	peroxidase	remained	
unresolved.	 Further	possible	models	 for	 enzyme	 inhibition	by	nanoparticles	 are	displayed	 for	
Taspase	in	figure	4.5	[92].	
	
	
Figure	4.6	Structural	changes	of	proteins	bound	on	nanoparticles.	
Interaction	with	nanoparticles	can	change	the	protein	structure	and	function.	The	green	circles	represent	
Taspase	subunits.	Models	for	Taspase	inhibition	by	nanoparticles	include	steric	occlusion	of	the	active	site	
after	 binding	 as	 hetero‐tetramer	 or	 dimer,	 separation	 of	 the	 subunits,	 as	 well	 as	 structural	 or	
conformational	changes,	crowding	effects,	fibrillation	and	oxidation.	Modified	according	to	[92].	
	
Structural	 changes	 have	 been	 described	 for	 the	 human	 β2‐microglubulin	 upon	 binding	 to	
copolymer	particles,	cerium	oxide	particles,	quantum	dots	and	nanotubes	[154].	In	the	case	of	β2‐
microglubulin,	nanoparticles	increase	the	probability	of	nucleation	of	protein	fibrils	and	thereby	
induce	amyloid	formation.	This	fibrillation	process	is	accompanied	by	a	transition	from	a	helix	to	
a	sheet	and	thus	significant	changes	in	the	protein	structure.	However,	the	secondary	structure	of	
Taspase	is	not	altered	upon	binding	to	nanoparticles	(figure	3.29a),	which	rules	out	fibrillation	as	
explanation	for	inhibition.	In	addition,	the	reversibility	of	the	inhibition	does	not	agree	with	an	
irreversible	fibrillation	and	aggregation	process.	
Moreover,	the	stability	of	enzymes	bound	to	nanoparticles	can	differ	from	the	enzyme	in	solution	
[109,155].	Interestingly,	this	effect	can	either	be	stabilizing	or	destabilizing,	depending	on	both	
the	nanoparticle	 and	 the	protein	 investigated.	 For	 instance,	 soybean	peroxidase	and	 subtilisin	
Carlsberg	 were	 stabilized	 by	 spherical	 nanoparticles	 such	 as	 C60	 fullerenes,	 silica	 or	 gold	
nanoparticles	 [155],	 while	 chymotrypsin	 unfolds	 upon	 binding	 to	 carbon	 nanotubes	 [109].	
Additionally,	the	storage	stability	of	glucose	oxidase	was	significantly	increased	after	binding	to	
silica‐encapsulated	 magnetic	 nanoparticles	 [156].	 Nevertheless,	 both	 stabilization	 and	
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destabilization	can	be	excluded	as	the	cause	for	Taspase	inhibition,	since	the	stability	is	not	altered	
by	nanoparticles	(figure	3.29).	
Another	mechanism	is	the	oxidation	of	biomolecules	catalyzed	by	nanoparticles,	which	has	been	
demonstrated	for	DNA	in	the	presence	of	TiO2	nanoparticles	[157],	but	can	also	affect	proteins	and	
other	biomolecules	[93,158].	Indeed,	Taspase	possesses	at	least	six	cysteins	and	two	methionines	
with	sufficient	solvent	accessibility	for	oxidation	and	especially	methionine	oxidation	was	found	
to	be	 important	 for	 inhibition	 for	example	 in	 the	case	of	catalase	 [159].	However,	oxidation	of	
Taspase	is	unlikely	due	to	the	highly	reducing	milieu	in	the	buffer	containing	10	mM	DTT.	
Moreover,	 binding	 of	 proteins	 to	 nanoparticles	 can	 greatly	 increase	 the	 local	 protein	
concentration	in	the	nanoparticle	corona	and	cause	layering	or	crowding	effects,	which	are	known	
to	promote	aggregation	[160,161].	Indeed,	the	stoichiometry	of	6	and	5000	Taspase	molecules	per	
Amsil8	 and	 Amsil125	 nanoparticle	 (figure	 3.27b),	 respectively,	 indicate	 high	 local	 Taspase	
concentrations.	 However,	 the	 CD	 spectra	 in	 the	 presence	 of	 nanoparticles	 contradict	 the	
aggregation	of	Taspase.	Moreover,	assuming	an	interface	size	of	35	x	42	Å	per	Taspase	monomer	
and	perfect	steric	packing,	the	surface	coverage	of	Amsil8	is	below	50	%	and	roughly	150	%	for	
Amsil125.	This	suggests	that	a	heavily	curved	surface	can	bind	less	Taspase	molecules	compared	
to	 flatter	 surfaces	 (figure	 4.7).	 However,	 a	 burying	 of	 Taspase	 by	 multiple	 layers	 in	 the	
nanoparticle	corona	is	probably	not	the	cause	for	the	reduced	activity.	
	
	
Figure	4.7	True‐to‐scale	model	of	Taspase	bound	to	nanoparticles.	
a	 Scaled	 model	 of	 Taspase	 bound	 to	 Amsil8	 nanoparticles	 (red)	 as	 αβ‐heterodimer	 (black	 and	 blue,	
respectively).	The	active	site	(green	circle)	is	occluded	in	the	bound	state.	The	calculated	stoichiometry	of	
6:1	is	displayed.	b	Size	comparison	of	Taspase	and	Amsil125.	
	
Hence,	Taspase	is	likely	to	bind	to	nanoparticles	in	a	single	layer	without	major	conformational	
changes.	For	this	it	is	important	to	consider	the	oligomeric	state	of	Taspase.	If	Taspase	binds	as	
hetero‐tetramer,	 the	 two	 active	 sites	 are	 located	 at	 opposite	 ends	 and	 cannot	 be	 covered	
simultaneously	by	one	nanoparticle.	As	inactivation	of	one	protomer	has	no	effect	on	the	other	
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protomer	[85],	one	protomer	is	likely	to	be	active	if	Taspase	binds	as	hetero‐tetramer,	unless	small	
conformational	changes	undetectable	by	CD	and	fluorescence	spectroscopy	occur.	
With	the	current	data,	the	most	plausible	explanation	for	Taspase	inhibition	by	nanoparticles	is	
binding	as	an	αβ‐dimer	in	a	single	layer	without	conformational	change	as	shown	in	figure	4.7a.	
This	 either	 results	 in	 noncompetitive	 inhibition	 (figure	 3.28)	 that	 is	 either	 allostery‐like	 or	
occludes	the	active	site.	However,	the	latter	mechanism	is	more	likely,	since	the	positively	charged	
active	 site	 is	 probably	 part	 of	 the	 binding	 interface	 for	 the	 strongly	 negatively	 charged	
nanoparticles.	As	a	result,	the	active	site	is	reversibly	occluded	and	inaccessible	for	the	substrate.	
Given	the	fact	that	the	inactive	mutant	can	still	bind	nanoparticles,	the	positively	charged	Taspase	
loop	(pI	=	9.8)	probably	supports	binding,	while	the	location	does	probably	not	influence	binding	
strength.	
Finally,	binding	of	only	one	subunit	and	separation	of	the	highly	affine	αβ‐dimer	can	be	ruled	out,	
as	this	would	result	in	free	α‐	or	β‐subunits,	which	again	can	be	excluded	since	neither	subunit	is	
found	after	filtration	through	a	30	kDa	membrane	(data	not	shown).	However,	a	separation	of	the	
two	subunits	and	binding	of	both	subunits	to	nanoparticles	is	another	plausible	explanation	for	
the	inhibitory	effect.	
Importantly,	 control	 experiments	with	 lactate	dehydrogenase,	 chymotrypsin	 and	proteinase	K	
showed	no	 or	 low	 inhibition	 of	 the	 respective	 enzyme	 activity	 at	 nanoparticle	 concentrations	
needed	 for	 Taspase	 inhibition	 (figure	 3.30).	 In	 summary,	 the	 nanoparticle	 concentrations	
required	for	LDH	inhibition	are	1‐2	orders	of	magnitude	higher	than	for	Taspase,	and	no	inhibitory	
effect	was	found	for	chymotrypsin	and	proteinase	K.	Moreover,	nanoparticles	cannot	reduce	LDH	
activity	by	more	than	25	%,	in	contrast	to	the	90	%	inhibition	seen	with	Taspase.	This	pinpoints	
that	silica	nanoparticles	do	not	inhibit	enzymes	in	general.	While	silica	nanoparticles	displayed	an	
inhibitory	effect	on	the	threonine	proteases	Taspase	and	the	proteasome,	they	failed	to	inhibit	the	
serine	 proteases	 chymotrypsin	 and	 proteinase	 K.	 This	 is	 in	 agreement	 with	 the	 finding	 that	
nanoparticles	bind	a	selective	set	of	proteins	[99].	However,	for	a	prediction	whether	an	enzyme	
is	inhibited	by	nanoparticles,	further	studies	are	required	to	gain	a	deeper	understanding	of	these	
interactions.	
	
4.2.3 In	vivo	effects	of	nanoparticles	on	Taspase	
In	contrast	to	in	vitro	assays	with	purified	protein,	nanoparticles	face	a	large	variety	of	different	
proteins	in	vivo.	Hence,	the	nanoparticle	corona	will	consist	of	a	diverse	mixture	of	proteins	that	
compete	 for	 binding.	 To	 test	 Taspase	 binding	 under	 such	 conditions,	 Hela	 cell	 lysates	 with	
overexpressed	 GFP‐Taspase	 were	 tested	 for	 Taspase	 activity	 in	 the	 presence	 of	 silica	
nanoparticles.	
While	nanoparticles	were	able	to	inhibit	Taspase	by	up	to	90	%	in	vitro,	the	maximum	inhibitory	
effect	 is	 limited	 to	50	%	 in	cell	 lysates	 (figure	3.31).	Consequently,	 the	nanoparticle	 surface	 is	
probably	partly	occupied	by	other	cellular	proteins,	which	reduce	the	inhibitory	potential	with	
respect	 to	 Taspase.	 Nevertheless,	 the	 nanomolar	 affinity	was	 still	 good	 enough	 to	 investigate	
Taspase	inhibition	in	cells.	
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Owing	 to	 their	 large	 size,	 nanoparticles	 cannot	 enter	 the	 cell	 passively,	 but	must	 be	 taken	up	
actively	by	the	cell.	However,	the	efficiency	of	this	cellular	uptake	again	depends	on	size	and	shape	
of	 the	 nanoparticle	 [162].	 The	 current	 model	 for	 the	 uptake	 mechanism	 involves	 energy‐
dependent	wrapping	of	the	nanoparticle	with	the	help	of	clathrin	and	the	cytoskeleton	[92].	In	a	
recent	study,	tissue‐specific	targeting	of	compounds	was	achieved	by	coating	nanoparticles	with	
a	lung‐targeting	peptide,	which	resulted	in	an	enrichment	of	these	nanoparticles	in	the	lung	after	
venous	injection	in	mice	[163].	Even	targeting	of	cellular	compartments	was	successfully	shown	
in	 living	 cells	 with	 nanoparticles	 conjugated	 to	 a	 small	 signal	 peptide.	 With	 this	 approach,	
fluorescent	nanocrystal	quantum	dots	accumulated	selectively	in	the	mitochondria	or	the	nucleus	
within	15	minutes	[164].	
Some	nanoparticles	pose	a	risk	to	cells	due	to	their	toxic	potential.	For	instance,	ZnO	nanoparticles	
were	 tested	 for	 cytotoxicity	 against	 human	 immune	 cells	 and	 monocytes	 were	 found	 to	 be	
particularly	 susceptible	 to	 the	 reactive	 oxygen	 species	 induced	 by	 the	 nanoparticles	 [165].	
Especially	 crystalline	 silica	 (SiO2)	 is	 known	 to	 induce	 chronic	 inflammation,	 fibrosis	 and	 lung	
cancer	 upon	 inhalation	 [166,167].	 In	 stark	 contrast	 to	 the	 high	 toxicity	 of	 crystalline	 silica,	
amorphous	 silica	 nanoparticles	 are	 regarded	 to	 be	 safe	without	 displaying	 chronic	 effects,	 as	
studied	 in	 rats	 [168].	 This	 is	 in	 agreement	 with	 the	 good	 viability	 of	 the	 cells	 after	 Amsil	
nanoparticle	challenge	with	normal	proliferation,	cell	size	and	morphology	(figure	3.33).	
Using	 fluorescently	 labeled	 nanoparticles,	 Tenzer	 and	 colleagues	 cold	 confirm	 that	 the	 silica	
nanoparticles	used	in	this	project	are	readily	taken	up	within	roughly	one	hour	[99].	Furthermore,	
the	 cellular	 uptake	 rate	 was	 increased	 in	 the	 presence	 of	 serum,	 compared	 to	 serum‐free	
incubation.	
Taspase	does	not	reside	in	the	cytoplasm,	but	is	located	mainly	inside	the	nucleus	[74].	Notably,	
this	nuclear	localization	is	not	static,	but	Taspase	shuttles	between	nucleus	and	cytoplasm	in	an	
importin‐α/nucleophosmin‐dependent	 manner	 [74].	 Importantly,	 the	 nuclear	 localization	 is	
retained	 in	 the	 presence	 of	 nanoparticles,	which	 are	 unlikely	 to	 be	 shuttled	 actively	 between	
nucleus	and	cytoplasm	(figure	3.33a).	This	finding	excludes	that	nanoparticles	bind	Taspase	in	the	
cytoplasm	and	prevent	the	nuclear	import,	as	this	would	be	reflected	in	a	distinct	accumulation	of	
Taspase	at	the	nuclear	envelope	and	in	the	cytoplasm.	Hence,	this	suggests	that	nanoparticles	have	
access	to	the	nucleus,	where	Taspase	binding	and	inhibition	occurs.	The	diameter	of	the	central	
channel	 of	 the	 nuclear	 pore	 complex	 (NPC)	 is	 with	 40	 nm	 large	 enough	 for	 the	 passage	 of	
nanoparticles	[169,170].	Indeed,	nanoparticles	can	enter	the	nucleus	[164],	which	was	also	shown	
for	silica	nanoparticles	[99].	Since	proteins	with	a	molecular	weight	above	60	kDa	cannot	pass	the	
pore	by	diffusion,	nanoparticles	are	probably	actively	imported.	
While	the	observed	inhibition	to	50	%	of	the	initial	activity	is	consistent	with	the	values	observed	
in	cell	lysates	for	Amsil8	and	Amsil20,	the	inhibitory	effect	of	the	larger	Amsil125	was	significantly	
lower	 in	cells	 (figure	3.33a).	This	outcome	 is	 in	agreement	with	 the	 finding	 that	 the	wrapping	
process	needed	for	cellular	uptake	is	optimal	for	nanoparticles	with	15‐30	nm	diameter	[92,162].	
Hence,	the	large	Amsil125	nanoparticles	are	taken	up	at	a	lower	rate	and	excluded	from	nuclear	
import	due	to	their	size,	which	results	in	a	lower	inhibitory	potential.	
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Altogether,	 the	 inhibition	 of	 Taspase	 by	 silica	 nanoparticles	 at	 nanomolar	 concentrations	
highlights	for	the	first	time	that	nanoparticles	are	able	to	qualitatively	inhibit	enzymes	in	vivo,	and	
thereby	 contributes	 to	 the	 comprehension	 of	 nanoparticle	 interactions	 in	 cells.	 Although	 the	
nature	of	silica	nanoparticles	does	not	suggest	a	selective	 inhibition,	 this	effect	does	not	affect	
proteases	in	general.	However,	possible	inhibitory	effects	of	nanoparticles	on	enzymes	need	to	be	
considered	in	future	studies	and	for	possible	medical	applications.	
	
4.3 Succinimide	peptides	inhibit	Taspase	competitively	
The	specific	consensus	sequence	of	Taspase	(Q‐[F,I,L,V]‐D	|	G‐X‐X‐D	or	Q‐[F,I,L,V]‐D	|	G‐X‐D‐X)	
facilitates	targeting	the	active	site	by	substrate‐derived	inhibitors	and	has	already	been	attempted	
by	the	Bogyo	group	in	2009	[69].	However,	these	vinyl	ketone	and	vinyl	sulfone	derivatives	only	
targeted	 the	 S‐site,	 but	 not	 the	 S’‐site	 and	displayed	 only	moderate	 inhibition	 (IC50	 =	 30	µM).	
Consequently,	 a	 new	 class	 of	 substrate	 analog	 inhibitors	 targeting	 both	 the	 S‐	 and	 S’‐site	was	
designed	and	tested	in	cooperation	with	the	Kaiser	group	for	chemical	biology.	
	
4.3.1 Implications	for	substrate	cleavage	and	binding	mode	
For	the	design	of	novel	inhibitors,	the	cleavage	mechanism	proposed	for	Taspase	was	analyzed	
(figure	 1.9;	 [69]).	 Concerning	 the	 high	 structural	 similarity	 of	 Taspase	 with	 other	 type	 II	
asparaginases	[66,139],	the	catalytic	mechanism	is	likely	to	show	some	similarities.	Nevertheless,	
asparaginases	hydrolyze	the	asparagine	side	chain,	while	Taspase	is	an	endopeptidase.	However,	
if	 the	 substrate	 undergoes	 a	 rearrangement	 via	 a	 succinimide‐hydrate	 intermediate,	 Taspase	
could	cleave	the	 isopeptide	bond	at	 the	asparagine	side	chain	(figure	1.9),	which	 is	again	very	
similar	 to	 the	 asparaginase	 cleavage	 mechanism	 [66].	 The	 fact	 that	 the	 compound	 with	
isoaspartate	(Comp8)	displayed	only	a	low	inhibitory	potential,	indicates	that	Taspase	can	indeed	
cleave	isopeptide	bonds.	In	contrast,	compounds	with	a	succinimide	moiety,	(Comp2,5,9,10)	could	
effectively	inhibit	Taspase.	
For	the	first	time,	conclusions	can	be	drawn	about	the	cleavage	mechanism	of	Taspase	based	on	
these	 experimental	 data.	 Indeed,	 these	 data	 strongly	 support	 the	 previously	 hypothesized	
substrate	 rearrangement	 via	 a	 succinimide‐hydrate	 to	 form	 an	 isopeptide	 bond	 between	
aspartate	and	glycine.	In	other	words,	the	protein	backbone	is	transferred	to	the	aspartate	side	
chain	before	the	final	cleavage	step	takes	place.	Hence,	Taspase	does	not	directly	hydrolyze	the	
peptide	bond,	but	the	newly	formed	isopeptide	bond	(figure	1.9).	Furthermore,	the	formation	of	
a	succinimide‐hydrate	intermediate	is	in	line	with	the	mandatory	presence	of	the	small	residue	
glycine	after	the	aspartate	to	allow	the	nucleophilic	attack	on	the	aspartate	side	chain.	
Moreover,	a	photoreactive	derivative	of	the	succinimide	inhibitor	was	used	to	shed	light	on	the	
binding	mode	of	the	substrate,	which	is	still	completely	enigmatic	due	to	missing	experimental	
data	and	a	lack	of	homologous	proteases.	For	this	critical	experiment,	the	photoreactive	cross‐
linker	was	located	at	the	P4	position	of	the	substrate.	After	cross‐linking,	the	inhibitor	was	found	
attached	to	the	α‐subunit,	but	not	the	β‐subunit	(figure	3.38).	As	both	subunits	contribute	to	the	
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active	site	located	between	them,	the	cross‐linking	experiment	allows	a	mapping	of	the	putative	
substrate	orientation	on	the	Taspase	structure	(figure	4.8).	
	
	
Figure	4.8	Proposed	substrate	orientation.	
The	suggested	binding	mode	derived	by	the	photolabeling	experiment	(see	main	text)	was	modeled	on	the	
dimer	of	Taspase	(PDB	2a8j).	a	The	substrate	(yellow)	is	proposed	to	bind	to	the	active	site	(red)	with	its	
P‐site	(green)	oriented	to	the	α‐subunit	(gray)	and	the	P’‐site	(green)	to	the	β‐subunit	(blue).	N‐	and	C‐
termini	of	the	substrate	are	labeled,	as	well	as	the	substrate	cleavage	site	and	the	Taspase	subunits.	b	The	
side	view	shows	the	catalytic	cleft	formed	by	both	subunits,	in	which	the	substrate	can	bind.	
	
Thus,	the	P‐site	of	the	substrate	is	likely	to	be	oriented	towards	the	α‐subunit,	which	in	turn	means	
that	the	P’‐site	is	probably	pointing	towards	the	β‐subunit.	Assuming	that	this	binding	mode	is	
correct,	the	groove	formed	by	both	α‐	and	β‐subunit	could	serve	as	binding	cleft	for	the	substrate	
as	 shown	 in	 figure	 4.8b.	 Although	 these	 experiments	 provide	 valuable	 first	 data	 about	 the	
substrate	binding,	detailed	information	about	the	substrate	binding	mode	cannot	be	derived	from	
these	preliminary	experiments.	Nevertheless,	the	developed	compounds	present	a	powerful	tool	
for	further	studies.	Possible	experiments	are	discussed	in	the	outlook	section.	
	
4.3.2 Scope	and	limits	of	the	succinimide	inhibitors	
In	vitro	applications	
The	 inhibition	 type	 of	 the	 newly	 designed	 peptidyl‐succinimide	 inhibitors	 is	 expected	 to	 be	
competitive,	as	this	is	usually	seen	for	substrate	analog	compounds.	Indeed,	the	substrate	could	
replace	the	inhibitor	(figure	3.36b).	Furthermore,	binding	of	the	inhibitor	to	Taspase	in	absence	
of	 the	 substrate	 was	 verified	 by	 microscale	 thermophoresis	 (figure	 3.36a)	 and	 excludes	
uncompetitive	 inhibition	 (i.e.	 binding	of	 the	 enzyme‐substrate	 complex).	Moreover,	 prolonged	
incubation	 times	 of	 enzyme	 and	 inhibitor	 did	 not	 result	 in	 increased	 inhibition,	 hinting	 at	 a	
reversible	 nature	 of	 the	 inhibition.	 However,	 unlike	 allosteric	 inhibitors,	 substrate	 analog	
protease	 inhibitors	are	prone	 to	cleavage	due	 to	 their	high	structural	 similarity	 to	 the	natural	
substrate.	In	the	case	of	Taspase,	a	degradation	of	the	succinimide	motif	could	be	ruled	out	and	
the	 inhibitory	 potential	 remained	 constant	 over	 time	 (figure	 3.37).	 Moreover,	 an	 artificial	
influence	 of	 the	 N‐terminal	 Fmoc	 protection	 group,	 which	 was	 used	 for	 photometric	
DISCUSSION	 SUCCINIMIDE	PEPTIDES	INHIBIT	TASPASE	COMPETITIVELY	
	
119	
	
determination	of	the	concentration,	was	excluded,	since	Fmoc‐valine	did	not	influence	Taspase	
cleavage.	
Since	Taspase	inhibitors	addressing	only	the	S‐site	of	Taspase	displayed	only	weak	inhibition	[69],	
the	role	of	 the	S’‐site	was	explored.	To	this	end,	 the	P’‐position	was	changed	from	glycine	to	a	
structurally	related	isoaspartate.	This	small	structural	change	 indeed	caused	a	twofold	weaker	
inhibition	 (Ki	=	6.8	±	1.1	µM),	which	pinpoints	 the	 importance	of	 the	S’‐site	 for	 tight	 inhibitor	
binding.	
Moreover,	derivatization	of	the	inhibitory	succinimide	motif	showed	that	an	extension	of	the	5‐
membered	 succinimide	motif	 (Ki	 =	 4.3	 ±	1.3	µM)	 to	 a	 6‐membered	 glutarimide	 ring	 yielded	 a	
compound	with	similar	inhibitory	potential	(Ki	=	1.6	±	0.3	µM).	However,	it	should	be	noted,	that	
although	glutarimide	is	the	most	probable	conformation	of	the	compound,	a	nucleophile	reaction	
of	the	glutamate	with	the	preceding	NH	backbone	group	cannot	be	excluded	by	the	LC‐MS	spectra.	
Surprisingly,	 the	 most	 potent	 inhibitor	 was	 a	 succinimide	 derivative	 with	 a	 photoreactive	
benzophenone	(Comp9;	Ki	=	0.4	±	0.09	µM).	This	compound	represents	the	most	potent	Taspase	
inhibitor	described	so	far.	Compared	with	the	next	best	published	inhibitor,	the	noncompetitive	
bisarsonic	acid	NSC48300	[63],	its	Ki	value	is	tenfold	better	and	it	does	not	rely	on	the	toxic	arsenic	
acid	moiety.	
Despite	 its	 promising	 inhibitory	 effect	 in	 vitro,	 the	 inhibitory	 effect	 in	 cell	 lysates	 with	
overexpressed	 GFP‐Taspase	 was	 30‐fold	 lower	 (IC50	 =	 111	 µM).	 Regarding	 this,	 the	 chloride	
concentration	of	150	mM	NaCl	in	the	lysis	buffer	is	to	be	considered,	which	was	not	present	in	the	
in	 vitro	 assay.	 Chloride	 is	 known	 to	 bind	 to	 the	 active	 site	 and	 therefore	 inhibit	 Taspase	
competitively	[56].	For	this	reason,	the	presence	of	a	chloride	ion	in	the	active	site	is	also	expected	
to	compete	with	substrate	analog	inhibitors.	This	hypothesis	is	supported	by	the	lower	affinity	of	
Comp9	in	the	presence	of	450	mM	NaCl	(22.1	µM),	compared	to	the	salt	free	binding	affinity	(0.4	
±	0.09	µM).	Consequently,	sophisticated	equations	are	needed	to	describe	this	system	with	three	
ligands	(substrate,	inhibitor,	chloride)	binding	competitively	to	one	binding	site.	However,	if	the	
substrate	concentration	 is	kept	constant,	 the	Cheng‐Prusoff	equation	 [124]	 can	be	applied	 in	a	
modified	form	to	estimate	the	salt	influence	on	inhibitor	binding	using	the	known	chloride	affinity	
(68	±	7	mM;	supplemental	figure	7.12).	
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This	shows	that	30	%	of	the	30‐fold	lower	inhibitory	effect	in	lysates	can	be	attributed	to	higher	
salt	concentrations.	However,	to	explain	the	remaining	70	%,	corresponding	to	a	10‐fold	reduction	
of	the	inhibitory	effect,	other	factors	need	to	be	taken	into	account.	In	particular,	the	six	peptide	
bonds	of	the	inhibitor	might	be	cleaved	by	other	proteases,	since	the	protease	inhibitors	present	
in	the	lysis	buffer	cannot	guarantee	complete	inhibition.	Moreover,	unspecific	binding	to	other	
proteins	can	lower	the	efficiency	of	the	inhibitor.	Nevertheless,	these	studies	confirmed	that	the	
succinimide	inhibitors	inhibit	eukaryotic	Taspase	in	cell	lysates,	although	the	inhibitory	potential	
is	rather	weak.	
DISCUSSION	 SUCCINIMIDE	PEPTIDES	INHIBIT	TASPASE	COMPETITIVELY	
	
120	
	
Another	application	of	the	photoreactive	inhibitor	derivative	(Comp9)	is	activity	based	protein	
profiling	 (ABPP).	 For	 this,	 the	 compound	 was	 added	 to	 Hela	 cell	 lysate	 spiked	 with	 5	 µM	
recombinant	Taspase.	Subsequent	cross‐linking	of	the	inhibitor	and	attachment	of	a	fluorescent	
dye	allowed	detection	of	all	proteins	interacting	with	the	inhibitor	by	fluorescence	imaging	(figure	
3.38).	The	SDS‐PAGE	gel	reveals	only	two	bands	corresponding	to	the	sizes	of	full‐length	Taspase	
and	the	α‐subunit.	Here,	the	band	for	the	full‐length	enzyme	can	either	represent	an	interaction	
with	 the	 proenzyme,	 or	 more	 likely	 an	 interaction	 with	 the	 SDS‐resistant	 αβ‐dimer	 (see	
section	 4.1.3).	 Furthermore,	 the	 absence	 of	 other	 bands	 in	 the	 lysate	 could	 indicate	 that	 the	
inhibitor	binds	selectively	to	Taspase.	However,	 the	comparatively	high	concentration	of	5	µM	
recombinant	Taspase	added	to	the	lysate	precludes	an	unequivocal	exclusion	of	binding	to	less	
abundant	off‐target	proteins	below	the	detection	background.	
	
In	vivo	applications	
For	cellular	applications,	an	inhibitor	needs	to	cross	the	hydrophobic	cell	membrane.	For	this,	a	
molecule	 must	 generally	 possess	 lipophilic	 groups.	 For	 small	 molecules,	 the	 octanol/water	
partition	coefficient	(logP)	is	often	used	to	predict	the	likeliness	of	membrane	passage.	For	the	
developed	succinimide	inhibitors,	a	 logP	value	of	0.21	±	0.91	was	calculated,	which	indicates	a	
good	passage	of	the	cell	membrane	[171].	However,	other	properties,	such	as	size,	the	number	of	
hydrogen	bond	donors	and	acceptors,	and	molar	refractivity,	are	also	important	factors	for	cell	
penetration.	 Table	 4.2	 shows	 that	 the	 succinimide	 compounds	 fail	 to	 fulfil	 these	 criteria,	 also	
known	as	rule‐of‐five	[172],	mainly	because	of	their	high	molecular	weight.	
	
Table	4.2	Parameters	for	druglikeliness	of	the	peptidyl‐succinimide	inhibitors.	
Parameter	 Qualifying	rangea Comp9
logP	 ‐0.4	to	5.6a	 2.83 ±	0.97c
Mw	 160	to	480	Daa	 1296 Da
Molar	refractivity	 40	to	130a	 333c
Number	of	atoms	 20	to	70a	 168
H‐bond	donors	 ≤ 5b	 9
H‐bond	acceptors	 ≤	10b	 15
a	according	to	[171];	b	according	to	[173];	c	predicted	with	ChemSketch	
	
Nevertheless,	eukaryotic	cells	were	assayed	for	the	ability	to	take	up	a	fluorescent	derivative	of	
the	 succinimide	 compounds.	 Unexpectedly,	 the	 compound	 was	 indeed	 able	 to	 cross	 the	 cell	
membrane	and	was	found	evenly	distributed	in	the	cells	after	5	hours	(figure	3.39c).	Importantly,	
the	 uptake	was	more	 than	 twofold	 higher	 if	 the	 cells	 were	 incubated	 in	 serum‐free	medium.	
Hence,	a	 fraction	of	the	inhibitor	 is	obviously	either	degraded	or	bound	to	serum	proteins	 like	
albumin.	However,	the	assay	is	only	qualitative,	so	that	the	intracellular	inhibitor	concentration	
could	not	be	determined.	
Using	a	cellular	Taspase	activity	assay,	the	inhibitory	potential	of	the	succinimide	compounds	was	
tested	in	vivo.	However,	these	inhibitors	failed	to	inhibit	Taspase	in	cells	after	18	hours	challenge	
with	50	µM	Comp9	(figure	3.39e).	The	most	likely	explanation	for	the	inhibitors	to	be	inactive	in	
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vivo	despite	their	promising	in	vitro	activity	is	that	their	size	prevents	sufficient	internalization.	
Consequently,	the	intracellular	concentrations	are	probably	too	low	to	cause	an	inhibitory	effect.	
Furthermore,	the	cellular	chloride	concentrations	of	roughly	50	mM	[174–176]	further	reduce	the	
affinity	 of	 the	 inhibitor,	 as	 explicated	 above.	 Moreover,	 degradation	 or	 modification	 of	 the	
inhibitor	 by	 cellular	 proteases	 and	 transferases,	 respectively,	 as	 well	 as	 binding	 to	 off‐target	
proteins	can	limit	its	effectiveness.	
Altogether,	the	peptidyl‐succinimide	 inhibitors	display	a	novel	class	of	Taspase	inhibitors	with	
promising	in	vitro	inhibition	potential.	In	particular,	the	newly	discovered	succinimide	scaffold	is	
expected	to	be	useful	for	rational	drug	design	in	subsequent	studies.	Suggestions	to	improve	the	
currently	limited	in	vivo	bioactivity	of	the	compounds	are	discussed	in	the	outlook	section	below.	
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5 Outlook	
In	this	project,	three	different	strategies	were	applied	to	find	novel	Taspase	inhibitors.	While	the	
bioinformatics	 approach	 did	 not	 yield	 active	 compounds,	 silica	 nanoparticles	 were	 found	 to	
inhibit	 Taspase	 noncompetitively.	 However,	 the	 most	 promising	 compounds	 were	 substrate	
analog	peptides	 containing	 a	 succinimide	moiety,	 because	 it	 is	 not	 expected	 that	 selectivity	 is	
achievable	 for	 uncoated	 nanoparticles	 by	 rational	 design	 with	 the	 current	 knowledge.	 These	
compounds	exhibited	good	inhibitory	potential	in	vitro,	while	the	in	vivo	potential	was	rather	low.	
Hence,	these	compounds	might	be	improved	to	achieve	higher	stability	and	better	bioavailability.	
Primarily,	 better	 bioavailability	 requires	 a	 reduction	 of	 the	 molecular	 weight	 and	 increased	
hydrophobicity	[172,177].	To	this	end,	the	molecular	weight	can	be	reduced	by	roughly	15	%	by	
removing	 the	N‐terminal	 Fmoc	 group,	which	was	 shown	 to	 be	 irrelevant	 for	 binding.	 Cellular	
experiments	to	elucidate	the	Taspase	consensus	sequence	revealed	that	the	presence	of	only	one	
of	the	two	aspartates	at	P3’	and	P4’	is	sufficient	for	cleavage	[70].	Consequently,	the	peptide	part	
of	 the	 inhibitor	 could	be	 shortened	by	 the	C‐terminal	 aspartate	at	P4’,	 if	 the	P3’	 asparagine	 is	
replaced	by	 aspartate.	 Furthermore,	 a	 substitution	 of	 the	 aspartic	 acid	 by	 benzoic	 acid	would	
contribute	to	higher	hydrophobicity	and	therefore	increase	cellular	uptake.	However,	increased	
hydrophobicity	also	increases	the	risk	of	unspecific	binding	to	other	proteins	and	should	therefore	
be	tested	thoroughly.	
Moreover,	stability	and	resistance	against	degradation	by	cellular	proteases	can	be	tested	in	cell	
lysates	with	the	fluorescent	derivative.	If	 fragmentation	is	observed	after	HPLC	analysis,	either	
the	side	chains	or	the	peptide	backbone	can	be	altered.	With	regard	to	the	latter,	a	substitution	of	
the	 peptide	 bond	 by	 N‐methyl,	 ether,	 ketomethylene	 or	 retro‐inverso	 groups	 is	 a	 common	
approach	(figure	5.1;	[178]).		
	
	
Figure	5.1	Substitutions	for	amide	bonds.	
Possible	 substitutions	 for	 amide	 bonds	 in	 peptidomimetics	 include	N‐methyl,	 ketomethylene	 and	 ether	
groups.	These	modifications	yield	higher	stability	and	resistance	against	cellular	proteases.	According	to	
[178].	
	
Furthermore,	side	chain	modifications	can	both	stabilize	the	compound	and	improve	the	affinity.	
Especially	modifications	of	the	Cβ	atom	are	known	to	reduce	the	susceptibility	to	chymotryptic	
cleavage	[178],	but	also	other	side	chain	modifications	are	a	proven	tool	to	enhance	the	potential	
of	 peptidic	 ligands.	 For	 example,	 methylation,	 methoxy	 or	 benzyl	 ether	 modifications	 greatly	
enhanced	 the	 affinity	 of	 analogs	 for	 the	 neuropeptide	 substance	 P	 [179].	 Altogether,	 critical	
evaluation	of	these	modifications	might	help	to	enhance	the	 in	vivo	potency	of	the	succinimide	
inhibitors.	
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Finally,	 co‐crystallization	of	Taspase	and	 the	 inhibitor	 could	 reveal	 the	active	 conformation	of	
Taspase.	This	facilitates	bioinformatics	approaches	and	could	ultimately	yield	potent	inhibitors	
by	virtual	docking.	
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6 Abstract	
The	threonine	protease	Taspase1	is	of	high	interest	as	new	target	for	cancer	therapeutics,	due	to	
its	 implication	 in	 leukemias	and	solid	 tumors.	Although	Taspase	 is	not	an	oncogene	 itself,	 it	 is	
crucially	 required	 for	 the	 proteolytic	 activation	 of	 the	 MLL	 oncogene	 as	 well	 as	 MLL	 fusion	
proteins	generated	by	chromosomal	translocations.	Hence,	MLL‐dependent	cells	can	successfully	
be	 targeted	 by	 inhibition	 of	 Taspase	 activity.	However,	 Taspase	 is	 insensitive	 to	 inhibition	 by	
general	 serine,	 cysteine	 or	 metalloprotease	 inhibitors.	 Furthermore,	 the	 limited	 number	 of	
available	Taspase	 inhibitors	display	 either	 low	 inhibitory	potential	 or	 broad	bioactivity.	 Thus,	
novel	Taspase	inhibitors	are	still	urgently	required.	
In	a	first	step,	detailed	characterization	revealed	for	the	first	time	that	recombinant	Taspase	and	
protein	 overexpressed	 in	 eukaryotic	 cells	 are	 comparable	 with	 respect	 to	 their	 catalytic	
parameters.	
Moreover,	the	specific	catalytic	activity	(0.03	U/mg)	was	determined,	as	well	as	a	20‐fold	higher	
efficiency	 regarding	 cleavage	 of	 the	 CS2	 cleavage	 site	 of	 MLL	 over	 CS1.	 Regarding	 stability,	
Taspase	 rapidly	 loses	 its	 catalytic	 activity	 (half‐life	 <	 3	 h),	 unless	 it	 is	 stabilized	 by	 high	
concentrations	of	NaCl	(≥	450	mM).	Additionally,	the	autocatalytic	processing	event	required	for	
catalytic	 competence	was	 found	 to	occur	on	a	 time	 scale	of	2‐3	days.	The	 flexible	 loop	 region	
between	glycine	178	and	aspartate	233	generated	by	this	activation	event	is	not	resolved	in	the	
crystal	structure.	Hence,	NMR	and	CD	spectroscopy	were	applied	and	the	results	suggest	a	helix‐
turn‐helix	structure.	Furthermore,	analytical	gel	filtration	pinpointed	that	Taspase	is	active	as	a	
hetero‐tetramer	in	solution.	With	these	data,	a	fluorogenic	in	vitro	assay	was	optimized	for	initial	
inhibitor	tests.	
While	the	controversially	discussed	bisarsonic	inhibitor	NSC48300	and	compounds	derived	from	
virtual	docking	exhibited	no	inhibitory	effect,	both	silica	nanoparticles	and	succinimide	peptides	
were	 discovered	 as	 novel	 Taspase	 inhibitors.	 In	 fact,	 silica	 nanoparticles	 are	 known	 to	 bind	
proteins,	 albeit	 nanoparticle‐mediated	 inhibition	 of	 enzyme	 activity	 is	 scarcely	 described.	
Surprisingly,	 IC50	 values	 in	 the	 nanomolar	 and	 picomolar	 range	 indicate	 high	 affinity	 binding,	
which	was	observed	in	vitro	and	in	cells.	In	addition,	comparison	of	nanoparticles	with	different	
diameters	 (8‐125	nm)	suggests	a	positive	correlation	of	size	and	affinity.	Subsequent	analyses	
characterized	the	inhibition	type	as	noncompetitive	and	pinpointed	that	Taspase	does	not	change	
its	structure	upon	binding.	Importantly,	inhibition	by	nanoparticles	is	no	general	feature,	as	three	
other	enzymes	(lactate	dehydrogenase,	chymotrypsin,	and	proteinase	K)	showed	no	or	only	weak	
inhibition	by	silica	nanoparticles.	
Another	 approach	 for	 Taspase	 inhibition	 exploited	 the	 cleavage	 sequence	 and	 the	 proposed	
mechanism	to	design	substrate	analog	peptides	with	a	succinimide	moiety	at	the	cleavage	site.	
The	most	promising	compound	exhibited	a	Ki	value	of	400	±	88	nM	and	displays	thus	a	tenfold	
better	inhibitory	potential	than	the	best	reported	Taspase	inhibitor.	Moreover,	the	competitive	
inhibition	type	and	the	resistance	against	Taspase	cleavage	were	verified.	However,	degradation	
by	 other	 proteases	 and/or	 limited	 cellular	 uptake	 as	 well	 as	 competition	 with	 chloride	 ions	
prevents	the	in	vivo	inhibition	of	Taspase.	
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Altogether,	these	findings	demonstrate	the	potential	of	silica	nanoparticles	as	well	as	succinimide	
peptides	as	Taspase	inhibitors	and	tools	for	subsequent	studies.	
	
Zusammenfassung	
Die	 Threonin‐Protease	 Taspase1	 stellt	 aufgrund	 ihrer	 Beteiligung	 an	 Leukämien	 und	 soliden	
Tumoren	einen	wichtigen	neuen	Ansatzpunkt	für	Krebsmedikamente	dar.	Obwohl	Taspase	selbst	
kein	Onkogen	ist,	ist	sie	unabdingbar	für	die	proteolytische	Aktivierung	des	Onkogens	MLL	und	
der	 durch	 Translokationen	 entstandenen	 MLL‐Fusionsproteine.	 Deshalb	 reagieren	 MLL‐
abhängige	Zellen	besonders	sensitiv	auf	Taspase‐Inhibition.	Allerdings	sind	sämtliche	allgemei‐
nen	Serin‐,	 Cystein‐	 und	Metalloprotease‐Inhibitoren	unwirksam	gegen	Taspase,	 und	 auch	die	
wenigen	 verfügbaren	 Taspase‐Inhibitoren	 besitzen	 entweder	 nur	 geringes	 Inhibitorpotential	
oder	 ein	breites	Wirkspektrum.	Daher	 sind	neue	Taspase‐Inhibitoren	nach	wie	vor	von	hoher	
Relevanz.	
Ein	 Vergleich	 rekombinanter	 Taspase	mit	 in	 eukaryotischen	 Zellen	 überexprimiertem	Protein	
zeigte	eine	vergleichbare	spezifische	katalytische	Aktivität	(0.03	U/mg).	Weiterhin	konnte	eine	
20‐fach	höhere	Effizienz	hinsichtlich	der	Spaltung	der	CS2‐Schnittstelle	von	MLL	gegenüber	der	
CS1‐Schnittstelle	festgestellt	werden.	Bei	Betrachtung	der	Proteinstabilität	fiel	auf,	dass	Taspase	
sehr	 schnell	 an	 Aktivität	 verliert	 (Halbwertszeit	 <	 3	 h),	 sofern	 das	 Protein	 nicht	 durch	 hohe	
Salzkonzentrationen	(≥	450	mM	NaCl)	stabilisiert	wird.	Zudem	wurde	 für	die	autokatalytische	
Prozessierung	des	Proenzyms,	welche	wichtig	zur	Erlangung	katalytischer	Kompetenz	 ist,	eine	
Zeitspanne	von	2‐3	Tagen	ermittelt.	Der	dabei	entstehende	flexible	Bereich	zwischen	Glycin	178	
und	 Aspartat	 233	 ist	 in	 der	 Kristallstruktur	 ungeordnet,	 konnte	 aber	 dank	 NMR‐	 und	 CD‐
Spektroskopie	 als	 potentielles	 Helix‐Turn‐Helix‐Motiv	 identifiziert	 werden.	 Des	 Weiteren	
belegten	analytische	Gelfiltrationen	die	Aktivität	von	Taspase	als	Hetero‐Tetramer.	Mithilfe	dieser	
Informationen	wurde	ein	in	vitro	Assay	optimiert	und	für	Inhibitortests	verwendet.	
Während	 der	 kontrovers	 diskutierte	 Inhibitor	 NSC48300	 und	 die	 mittels	 virtuellen	 Dockings	
ermittelten	 Substanzen	 keine	 Inhibition	 zeigten,	 konnten	 Silikatnanopartikel	 und	 Succinimid‐
Peptide	 als	 neue	 Taspase‐Inhibitoren	 identifiziert	 werden.	 Obwohl	 Proteinbindung	 an	
Nanopartikel	 bekannt	 ist,	 ist	 eine	durch	diese	 vermittelte	Enzyminhibition	kaum	beschrieben.	
Umso	überraschender	sind	die	IC50‐Werte	im	nano‐	und	picomolaren	Bereich,	die	sowohl	in	vitro	
als	auch	in	Zellen	beobachtet	wurden.	Weiterhin	konnte	mit	verschiedenen	Nanopartikelgrößen	
eine	 positive	 Korrelation	 von	 Durchmesser	 und	 Affinität	 belegt	 werden.	 Weitere	 Analysen	
ergaben	 eine	 nichtkompetitive	 Inhibition	 und	 keine	 Strukturänderung	 bei	 Bindung.	
Bemerkenswerterweise	 stellt	 Enzyminhibition	 keine	 generelle	 Eigenschaft	 von	 Nanopartikeln	
dar,	da	drei	Kontrollenzyme	(Lactatdehydrogenase,	Chymotrypsin	und	Proteinase	K)	kaum	durch	
Nanopartikel	inhibiert	wurden.		
In	einem	anderen	Ansatz	wurde	die	Taspase‐Schnittsequenz	und	der	vermutete	Mechanismus	für	
das	Design	peptidischer	Substratanaloga	mit	Succinimid‐Motiv	an	der	Schnittstelle	genutzt.	Die	
beste	 Verbindung	 zeigte	 einen	Ki‐Wert	 von	 400	 ±	 88	nM	und	 ist	 damit	 ein	 zehnfach	besserer	
Hemmstoff	 als	 der	 beste	 zuvor	 beschriebene	 Taspase‐Inhibitor.	 Des	 Weiteren	 konnte	 die	
kompetitive	 Hemmung	 und	 die	 Stabilität	 gegenüber	 Abbau	 durch	 Taspase	 gezeigt	 werden.	
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Allerdings	verhindern	schlechte	Zellaufnahme	und/oder	Abbau	durch	andere	Proteasen	sowie	
Kompetition	mit	Chlorid‐Ionen	eine	Inhibition	in	vivo.	
Insgesamt	 belegen	 diese	 Ergebnisse	 das	 Potential	 von	 Silikatnanopartikel	 sowie	 Succinimid‐
Peptiden	als	Taspase‐Inhibitoren	und	Werkzeuge	für	nachfolgende	Studien.	 	
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7 Supplement	
7.1 Recording	and	processing	of	NMR	spectra	
	
Table	7.1	Pulses	used	to	record	NMR	spectra.	
Pulse	 Power	
level	[W]	
Length	 Description
p1	 7.8239	 20.86	µs	 1H	90°	high	power	pulse
p3	 40.617	 18	µs	 13C	90°	high	power	pulse
p21	 89.492	 35.5	µs	 15N	90°	high	power	pulse
pcpd1	 0.17596	 50	µs	 1H	DIPSI‐2	decoupling
pcpd2	 3.6535	 60	µs	 13C	decoupling	
pcpd3	 4.352	 180	µs	 15N	GARP	decoupling	
sp1	 0.00039212 	 1H	90°	shaped	pulse	for	H2O	on	resonance	
sp2	 53.544	 	 13C	90°	shaped	pulse	for	Cali on	resonance	
sp3	 47.381	 	 13C	180°	shaped	pulse	for	Cali on	resonance	
sp5	 47.381	 	 13C	180°	shaped	pulse	for	C=O	off	resonance	
sp8	 53.544	 	 1H	90°	shaped	pulse	for	time	reversed	pulse	
d1	 	 2	s	 relaxation	delay
d9	 	 90	µs	 TOCSY	mixing	time
	
	
Table	7.2	Recording	parameters	for	NMR	spectra.	
Spectrum	 F1	 F2	 F3	
pulse	program	
nuc	
SWH	
[ppm]	
O1	
[ppm]	 TD	
AQ‐
mode* nuc	
SWH	
[ppm]
O1	
[ppm]	 TD	
AQ‐
mode* nuc	
SWH	
[ppm]	
O1	
[ppm]	 TD	
AQ‐
mode*	
1H‐15N	HSQC	
hsqcetf3gpsi2	 15N	 40	 115	 256	 DQD	 1H	 16.08 4.	695	 1024	 E‐AE	 ‐	 ‐	 ‐	 ‐	 ‐	
sofast‐HMQC	
sfhmqcf3gpph	 15N	 34	 115	 200	 DQD	 1H	 15	 4.	695	 1024	 STPPI ‐	 ‐	 ‐	 ‐	 ‐	
15N‐TOCSY‐HSQC	
dipsihsqc3gpsi3d	
1H	 15.94	 4.695	 128	 STPPI 15N	 39	 119	 48	 STPPI 1H	 16	 4.696	 2048	 DQD	
HNCACB	
hncacbgpwg3d	
13C	 80	 39	 128	 STPPI 15N	 34	 119	 40	 STPPI 1H	 15	 4.696	 2048	 DQD	
CBCACONH	
cbcaconhgpwg3d	
13C	 75	 39	 128	 STPPI 15N	 34	 119	 36	 STPPI 1H	 15	 4.696	 2048	 DQD	
HBHANH	
hbhanhgpwg3d	
1H	 15	 4.695	 128	 STPPI 15N	 34	 119	 40	 STPPI 1H	 8	 4.695	 2048	 DQD	
HBHACONH	
hbhaconhgpwg3d	
1H	 15	 4.695	 128	 STPPI 15N	 34	 119	 40	 STPPI 1H	 8	 4.695	 2048	 DQD	
HCCH‐TOCSY	
hcchdigp3d	
1H	 8	 4.695	 128	 STPPI 13C	 75	 39	 64	 STPPI 1H	 16	 4.695	 2048	 DQD	
HNCA	
hncagpwg3d	
13C	 32	 54	 64	 STPPI 15N	 30	 117	 40	 STPPI 1H	 8.4	 4.695	 2048	 DQD	
*	E‐AE:	Echo‐Antiecho;	STPPI:	States‐TPPI	
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Table	7.3	Processing	parameters	for	NMR	spectra.	
	 F1	 F2	 F3	
Spectrum	
nuc	
SI	
[ppm]	 MC2*	 REV	 WDW	 nuc	
SI	
[ppm] MC2*	 REV	 WDW nuc	
SI	
[ppm]	 MC2*	 REV	 WDW
15N‐HSQC	 15N	 2048	 E‐AE	 False	 Qsine	 1H	 4096	 ‐	 False	 Qsine	 ‐	 ‐	 ‐	 ‐	 ‐	
sofast‐HMQC	 15N	 1024	 STPPI	 False	 Qsine	 1H	 2048	 ‐	 False	 Qsine	 ‐	 ‐	 ‐	 ‐	 ‐	
15N‐TOCSY‐HSQC	 1H	 256	 STPPI	 False	 Qsine	 15N	 128	 E‐AE	 False	 Qsine	 1H	 1024	 ‐	 False	 Qsine	
HNCACB	 13C	 256	 STPPI	 False	 Qsine	 15N	 128	 STPPI True	 Qsine	 1H	 2048	 ‐	 False	 Qsine	
HBHACONH	 13C	 256	 STPPI	 False	 Qsine	 15N	 64	 STPPI True	 Qsine	 1H	 2048	 ‐	 False	 Qsine	
HBHANH	 1H	 256	 STPPI	 False	 Qsine	 15N	 128	 STPPI True	 Qsine	 1H	 2048	 ‐	 False	 Qsine	
HBHACONH	 1H	 128	 STPPI	 False	 Qsine	 15N	 64	 STPPI True	 Qsine	 1H	 2048	 ‐	 False	 Qsine	
HCCH‐TOCSY	 1H	 512	 STPPI	 False	 Qsine	 13C	 256	 STPPI False	 Qsine	 1H	 2048	 ‐	 False	 Qsine	
HNCA	 13C	 128	 STPPI	 False	 Qsine	 15N	 64	 STPPI True	 Qsine	 1H	 1024	 ‐	 False	 Qsine	
*	E‐AE:	Echo‐Antiecho;	STPPI:	States‐TPPI	
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7.2 Bacterial	vector	maps	
	
Figure	7.1	Maps	of	bacterial	expression	vectors.	
a	Map	of	the	modified	pET‐22b	vector	containing	wild	type	Taspase	with	C‐terminal	His‐tag.	Primer	binding	
sites	for	the	loop	cloning	are	indicated.	b	Map	of	the	modified	pET‐41b	vector	containing	active	Taspase	
with	N‐terminal	His‐tag.	 The	 ribosomal	 binding	 site	 (RBS)	 between	 the	 two	 subunits	 has	 the	 sequence	
“AGGAGG”.	c	Map	of	the	modified	pET‐22b	vector	containing	inactive	Taspase	mutant	with	C‐terminal	His‐
tag.	D233	and	T234	at	the	active	site	were	mutated	to	A233	and	A234,	respectively.	d	Map	of	the	modified	
pET‐41b	vector	containing	the	Taspase	loop	(G178‐D233)	with	N‐terminal	GST‐tag.	All	vectors	are	IPTG‐
inducible	and	resistance	genes	as	well	as	restriction	sites	used	for	cloning	are	indicated.	 	
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7.3 Eukaryotic	vector	maps	
	
Figure	7.2	Maps	of	eukaryotic	vectors	used	for	transfection.	
a	Map	 of	 the	 pC3	 vector	 containing	wild	 type	 Taspase	with	 C‐terminal	 eGFP.	b	Map	 of	 the	 pC3	 vector	
containing	inactive	Taspase	(T234V)	with	C‐terminal	BFP.	c	Map	of	the	pC3	vector	containing	the	reporter	
substrate	 (BioTasp)	used	 for	 the	cellular	Taspase	activity	assay.	The	coded	protein	comprises	a	nuclear	
localization	 signal	 (NLS),	 eGFP,	 glutathione	 S‐transferase	 (GST),	 CS1	 Taspase	 cleavage	 site	 (CS1),	 CS2	
Taspase	cleavage	site	(CS2)	and	a	reverse	nuclear	export	signal	(NES).	Resistance	genes	and	restriction	sites	
are	indicated.	
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7.4 Taspase	loop	cloning	scheme	
	
Figure	7.3	Schematic	for	cloning	of	the	Taspase	loop.	
The	Taspase	 loop	was	 amplified	 from	 the	 plasmid	 for	wild	 type	Taspase	 (top	 left	 panel)	 by	 PCR	 using	
primers	with	binding	sites	indicated	in	purple.	The	target	vector	(top	right	panel)	was	digested	with	ApaI	
and	XhoI.	Respective	restriction	sites	are	 indicated.	Vector	and	 insert	were	 ligated,	yielding	the	Taspase	
loop	with	N‐terminal	GST	tag	(lower	panel).	
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7.5 Purification	of	Taspase	
	
Figure	7.4	Purification	of	the	inactive	Taspase	mutant.	
Purification	 of	 inactive	 Taspase	 was	 performed	 as	 described	 for	 wild	 type	 Taspase	 (section	 3.1.3).	
a	Chromatogram	of	the	NiNTA	column	elution.	The	fractions	highlighted	in	blue	were	used	for	gel	filtration,	
while	 the	 fractions	 highlighted	 in	 green	 were	 purified	 again	 by	 NiNTA	 affinity	 chromatography.	 b	
Chromatogram	 of	 the	 NiNTA	 affinity	 chromatography	 of	 the	 peak	 highlighted	 green	 in	 (a).	 Fractions	
highlighted	 in	blue	were	used	 for	gel	 filtration.	c	The	SDS‐PAGE	gel	shows	 inactive	Taspase	with	minor	
impurities	after	NiNTA	affinity	chromatography.	d	and	e	show	gel	filtration	chromatograms	after	NiNTA	
affinity	chromatography	runs	displayed	in	(a)	and	(b),	respectively.	The	fractions	highlighted	in	blue	were	
concentrated,	shock	frozen	and	stored	at	‐20	°C.	f	The	SDS‐PAGE	gel	confirms	pure	inactive	Taspase	after	
gel	filtration.	
	
	
Figure	7.5	Purification	of	the	first	elution	peak	after	NiNTA	affinity	chromatography.	
As	 the	 first	elution	peak	after	NiNTA	affinity	chromatography	contained	a	significant	amount	of	 impure	
Taspase	(section	3.1.3),	the	peak	fractions	were	diluted	to	reduce	the	imidazole	concentration	to	10	mM	
and	again	applied	to	a	NiNTA	column.	All	parameters	were	taken	from	the	first	purification,	described	in	
section	 3.1.3.	 a	 Chromatogram	 of	 the	 NiNTA	 column	 elution.	 The	 fractions	 highlighted	 in	 blue	 were	
concentrated	 and	 gel	 filtrated	 as	 described	 in	 the	 main	 text	 (section	 3.1.3).	 b	 Chromatogram	 of	 the	
subsequent	gel	filtration.	The	fractions	highlighted	in	blue	were	concentrated	to	18	mg/ml	and	stored	at	‐
20	°C.	
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7.6 Expression	test	of	active	Taspase	
The	bicistronic	construct	for	active	Taspase	comprises	the	amino	acids	1	to	206	(His‐tagged	α‐
subunit)	and	amino	acids	234	to	420	(β‐subunit;	figure	2.3).	Initial	expression	tests	showed	poor	
solubility	of	both	subunits,	as	well	as	degradation,	when	expressed	longer	than	3	hours,	plus	an	
increased	number	of	dead	cells.	This	hints	at	a	potential	toxicity	of	the	expressed	protein.	Hence,	
expression	was	 optimized	 in	 the	 C43(DE3)pLysS	 strain,	which	 is	 effective	 in	 expressing	 toxic	
proteins.	
Additionally	to	the	three	temperatures	(20	°C,	30	°C,	37	°C)	and	the	three	expression	times	(3	h,	
6	h,	over	night),	the	combination	of	high	cell	density	(OD600=1.5)	and	short	expression	time	was	
tested.	The	respective	SDS	gels	of	pellet	and	supernatant	fractions	after	ultracentrifugation	are	
shown	in	figure	7.6.	
	
	
Figure	7.6	SDS‐PAGE	gels	of	expression	test	for	active	Taspase.	
Expression	of	active	Taspase	was	tested	in	E.	coli	BL21(DE3)T1r	cells	at	20	°C,	30	°C	and	37	°C	after	3	h,	6	h	
and	over	night	(o.n.).	Additionally,	expression	levels	at	37	°C	were	analyzed	1	h,	2	h	and	5	h	after	induction	
of	cells	with	an	OD600	of	1.5	(37	°C	OD600=1.5).	Supernatant	(S)	and	pellet	fractions	(P)	were	compared	to	a	
sample	before	induction	by	IPTG	(‐IPTG)	and	indicated	optimum	expression	conditions	at	37	°C	after	6	h	or	
over	night.	The	expected	sizes	of	α‐subunit	(α)	and	β‐subunit	(β)	are	indicated	by	arrows.	
	
The	highest	 expression	 levels	of	 soluble	protein	are	 achieved	at	37	 °C	after	6	h	or	over	night.	
Nevertheless,	it	should	be	noted	that	the	total	amount	of	active	Taspase	is	significantly	lower	than	
for	wild	type	protein.	
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7.7 Calibration	for	analytical	gel	filtration	
	
Figure	7.7	Calibration	plot	for	Superdex	200	10/300.	
Calibration	was	performed	with	gel	filtration	buffer	(section	2.1.3)	containing	100	or	450	mM	NaCl	(green	
and	blue,	respectively).	Ferritin	(450	kDa),	aldolase	(161	kDa),	conalbumin	(75	kDa),	α‐amylase	(54	kDa)	
and	 ribonuclease	 A	 (13.7	 kDa)	 were	 used	 as	 references.	 Elution	 volumes	 were	 plotted	 against	 the	
logarithmic	molecular	weight	and	linear	regression	was	performed.	The	dashed	lines	indicate	the	elution	
volume	(14.5	ml)	and	corresponding	log(Mw)	(2.01	=	102	kDa).	
7.8 Analytical	gel	filtration	with	lower	salt	conditions	
	
Figure	7.8	Analytical	gel	filtration	of	Taspase	with	100	mM	NaCl.	
Analytical	gel	filtrations	with	wild	type	(wt),	inactive	and	active	Taspase	were	performed	as	described	in	
the	main	text	(section	3.2.4).	Wild	type	and	inactive	Taspase	show	an	apparent	molecular	weight	of	around	
100	kDa,	while	the	shorter	active	Taspase	elutes	at	around	90	kDa.	
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7.9 NMR	shifts	of	Taspase	
Table	7.4	NMR	shifts	for	wild	type	Taspase.	
Shift	values	are	presented	in	ppm.	
aa	 Res	 HN	 N	 Cα	 Cβ	 Hα	 Hβ	 Hγ	 Hδ	 Hε	
9	 Ser	 8.379	±	0.004	 117.112	±	0.142	 58.552	±	0.096 64.041	±	0.199	 4.499	±	0.005	 3.894	±	0.029	 ‐	 ‐	 ‐	
10	 Gly	 8.382	±	0.006	 110.706	±	0.097	 45.332	±	0.078 ‐	 3.95	±	0.017	 ‐	 ‐	 ‐	 ‐	
11	 Glu	 8.223	±	0.005	 120.5	±	0.049	 56.763	±	0.055 30.194	±	0.015	 4.259	±	0.007	 1.997	±	0.017	 2.197	±	0.042	 	 	
12	 Gly	 8.386	±	0.003	 109.791	±	0.086	 45.18	±	0.011 ‐	 3.914	±	0.02	 ‐	 ‐	 ‐	 ‐	
13	 Leu	 7.994	±	0.005	 122.667	±	0.032	 53.124	±	0.028 41.668	 4.599	±	0.011	 1.594	±	0.009	 1.533	 0.896	±	0.002	 ‐	
23	 Gly	 8.263	±	0.005	 107.765	±	0.036	 45.327	±	0.005 ‐	 3.912	±	0.011	 ‐	 ‐	 ‐	 ‐	
24	 Lys	 8.02	±	0.004	 120.824	±	0.055	 56.274	±	0.054 33.037	±	0.083	 4.305	 1.72	±	0.01	 1.382	 ‐	 3.006	
25	 Ile	 8.15	±	0.006	 122.453	±	0.08	 61.219	±	0.057 38.712	±	0.114	 4.206	±	0.002	 1.831	±	0.027	 1.258	/	1.463	 ‐	 ‐	
26	 Thr	 8.2	±	0.004	 118.662	±	0.061	 61.838	±	0.079 70.13	±	0.084	 4.32	±	0.012	 ‐	 ‐	 1.164	 ‐	
27	 Ala	 8.287	±	0.005	 126.192	±	0.059	 52.94	±	0.091 19.053	±	0.094	 4.238	±	0.027	 1.36	±	0.019	 ‐	 ‐	 ‐	
28	 Lys	 8.187	±	0.003	 120.311	±	0.069	 ‐	 ‐	 4.21	±	0.015	 1.716	±	0.022	 ‐	 ‐	 ‐	
32	 Thr	 8.06	±	0.003	 115.009	±	0.064	 62.212	±	0.055 69.791	±	0.074	 4.265	±	0.008	 	 1.091	 ‐	 ‐	
33	 Lys	 8.219	±	0.004	 123.407	±	0.104	 56.576	±	0.081 32.539	 4.259	 1.741	±	0.007	 	 ‐	 ‐	
34	 Gln	 8.331	±	0.003	 121.675	±	0.047	 56.822	±	0.08 30.11	±	0.13	 4.214	±	0.007	 1.978	±	0.019	 2.202	 ‐	 ‐	
221	 Gln	 8.281	±	0.002	 122.044	±	0.021	 56.506	±	0.128 29.762	 4.299	±	0.028	 2.02	±	0.013	 ‐	 ‐	 ‐	
222	 Ser	 8.213	±	0.006	 116.916	±	0.11	 58.492	±	0.012 63.854	 ‐	 3.817	 ‐	 ‐	 ‐	
223	 Ser	 8.322	±	0.009	 117.672	±	0.154	 58.731	±	0.131 63.948	 ‐	 3.899	±	0.02	 ‐	 ‐	 ‐	
224	 Glu	 8.37	±	0.007	 122.597 ±	0.119	 56.784	±	0.054 30.032	±	0.025	 4.25	±	0.012	 1.79	±	0.009	 ‐	 ‐	 ‐	
225	 Lys	 8.181	±	0.003	 121.261	±	0.157	 56.585	±	0.113 32.936	 4.262	±	0.016	 1.735	±	0.011	 ‐	 ‐	 ‐	
226	 Glu	 8.282	±	0.003	 121.292	±	0.072	 57.157	±	0.007 29.807	 4.202	±	0.004	 2.02	±	0.021	 2.223	 ‐	 ‐	
227	 Asn	 8.368	±	0.004	 119.275	±	0.056	 53.357	±	0.041 39.106	±	0.031	 4.159	 2.772	±	0.011	 ‐	 ‐	 ‐	
228	 Asp	 8.302	±	0.008	 121.214	±	0.057	 54.354	±	0.096 41.452	±	0.072	 ‐	 2.675	±	0.013	 ‐	 ‐	 ‐	
229	 Ser	 8.298	±	0.002	 116.311	±	0.091	 58.872	±	0.131 63.95	±	0.134	 4.433	±	0.006	 3.88	±	0.013	 ‐	 ‐	 ‐	
230	 Gly	 8.431	±	0.004	 110.723	±	0.151	 45.496	±	0.068 ‐	 3.965	±	0.021	 ‐	 ‐	 ‐	 ‐	
231	 Thr	 7.959	±	0.006	 113.633	±	0.051	 61.926	±	0.078 70.004	±	0.124	 4.323	±	0.023	 4.03	±	0.005	 1.171	±	0.012	 ‐	 ‐	
232	 Leu	 8.287	±	0.003	 124.764	±	0.116	 55.2	±	0.062 42.366	±	0.151	 4.388	±	0.014	 1.616	±	0.014	 1.585	 0.84	/	0.889	 ‐	
233	 Asp	 7.837	±	0.004	 126.462	±	0.032	 55.802	±	0.053 42.484	±	0.072	 4.337	 2.529	/	2.589	 ‐	 ‐	 ‐	
251	 Ser	 8.284	±	0.004	 119.094	±	0.067	 58.483	±	0.095 63.81	±	0.002	 4.39	±	0.022	 3.84	±	0.015	 ‐	 ‐	 ‐	
428	 His	 8.014	±	0.056	 125.365	±	0.085	 ‐	 ‐	 ‐	 3.095	±	0.026	 ‐	 ‐	 ‐	
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7.10 1H‐15N	HSQC	spectra	of	Taspase	
	
Figure	7.9	Time	dependence	of	the	Taspase	NMR	spectra.	
1H‐15N	HSQC	spectra	of	wild	type	Taspase	were	recorded	of	freshly	thawed	protein	(black)	and	after	one	
week	(red).	Peaks	of	the	freshly	thawed	protein	are	labeled;	a	labeling	of	all	assigned	peaks	can	be	found	in	
figure	3.12a.	
	
	
Figure	7.10	Comparison	of	wild	type	and	mutant	Taspase.	
1H‐15N	HSQC	spectra	of	wild	type	Taspase	(red)	and	inactive	Taspase	(blue)	after	7	days	incubation	at	30	°C.	
All	backbone	peaks	of	the	inactive	mutant	can	be	found	in	the	spectrum	of	the	wild	type	protein.	The	10	
peaks	visible	only	 in	the	wild	type	protein	are	 labeled.	9	of	 these	peaks	are	 located	 in	the	 loop	which	 is	
released	by	autocatalytic	activation.	A	labeling	of	all	assigned	peaks	can	be	found	in	figure	3.12a.	
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7.11 Expression	test	of	the	GST‐tagged	Taspase	loop	
	
Figure	7.11	Expression	test	for	the	Taspase	loop.	
Expression	of	the	GST‐tagged	Taspase‐loop	(GST‐loop)	was	tested	in	LB	medium	at	25	°C,	30	°C	and	37	°C	
after	 3	 h,	 6	 h	 and	 over	 night	 (o.n.).	 After	 centrifugation,	 supernatant	 (S)	 and	 pellet	 (P)	 fractions	were	
compared	to	a	sample	before	induction	by	IPTG	(‐IPTG).	Optimum	expression	conditions	with	maximum	
GST‐loop	content	was	found	for	expression	at	25	°C	over	night.	
7.12 NaCl	inhibits	Taspase	activity	
	
Figure	7.12	Inhibition	of	Taspase	activity	by	NaCl.	
Activity	measurements	of	wild	type	Taspase	in	the	presence	of	different	NaCl	concentrations	confirmed	an	
inhibitory	effect	of	NaCl.	Nonlinear	fitting	yielded	IC50	=	68	±	7	mM.	
	
7.13 Western	blot	analysis	of	Taspase	levels	in	human	cell	lysates	
50	µg	cell	lysates	and	0.5	µg	recombinant	wild	type	Taspase	were	separated	in	a	12.5	%	SDS‐PAGE	
gel.	Western	blotting	on	nitrocellulose	membrane	(Whatman)	was	performed	for	45	minutes	at	
40	mA	per	gel	(80	mA	for	2	gels).	Membranes	were	blocked	with	5	%	milk	powder	in	TBST	for	
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2	hours	at	room	temperature,	before	the	primary	antibodies	were	added	in	5	%	BSA	over	night	at	
4	°C.	The	Taspase	antibody	(Origene;	goat	anti	mouse)	was	diluted	1:500	and	the	β‐actin	antibody	
(Abgent;	sheep	anti	rabbit)	was	used	in	a	1:250	dilution	in	TBST	+	5	%	milk	powder.	Subsequently,	
the	membrane	was	washed	three	times	with	TBST	and	the	respective	secondary	antibody	(anti	
mouse	for	Taspase;	anti	rabbit	for	β‐actin)	was	applied	in	a	1:10000	dilution	in	5	%	milk	powder	
for	2	hours	at	room	temperature.	The	membrane	was	washed	again	three	times	with	TBST	and	an	
ECL	 kit	 (Thermo	 Scientific)	 was	 applied	 according	 to	 the	 manufacturer’s	 instructions	 for	
visualization.	 Films	 (Thermo	 Scientific)	 were	 exposed	 for	 2	 minutes	 and	 developed	 using	 a	
Cawomat	2000.	
	
	
Figure	7.13	Western	blot	of	Taspase	in	cell	lysates.	
50	µg	eukaryotic	cell	lysates	of	Hela,	human	embryonic	kidney	293T	(HEK),	human	colon	carcinoma	116	
(HCT)	and	0.5	µg	of	recombinant	Taspase	as	positive	control	were	separated	by	SDS‐PAGE,	blotted	on	a	
nitrocellulose	membrane	and	Taspase	was	detected	with	a	 specific	monoclonal	antibody	(upper	panel).	
Taspase	concentrations	were	below	the	detection	limit	in	all	three	cell	lines	tested.	Recombinant	Taspase	
shows	two	bands,	corresponding	to	the	full‐length	enzyme	and	the	α‐subunit.	β‐actin	(lower	panel)	was	
used	as	loading	control.	
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7.14 ESI‐LC‐MS	of	NSC48300	
	
Figure	7.14	ESI‐LC‐MS	of	the	Taspase	inhibitor	NSC48300.	
a	Chromatogram	of	the	LC‐MS	analysis	in	negative	mode.	The	peak	at	1.27	min	contains	the	NSC48300.	b	
Full‐range	negative	mode	mass	spectrum.	Peaks	are	labeled	with	the	most	probable	molecules	and	their	
structure.	The	expected	mass	of	NSC48300	is	416	Da.	
	
7.15 Model	quality	statistics	
	
Figure	7.15	Model	quality	of	the	full‐length	Taspase	homology	model.	
A	homology	model	of	full‐length	Taspase	was	generated	based	on	the	crystal	structure	PDB	2a8i.	75	amino	
acids	were	added	to	the	template.	Model	quality	(and	Z	score)	are	as	follows.	Dihedrals:	optimal	(1.317);	
packing	1D:	satisfactory	(‐1.450);	packing	3D:	good	(‐0.718);	overall:	good	(‐0.708).		
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7.16 Binding	controls	with	nanoparticles	
	
Figure	7.16	Nanoparticles	bind	parvalbumin	with	low	affinity.	
Anisotropy	titrations	of	Atto488‐labeled	parvalbumin	with	Amsil8	nanoparticles	yield	an	EC50	value	of	3	±	
0.8	µM,	which	is	a	300	000‐fold	weaker	interaction	compared	to	Taspase.	
	
	
7.17 Cell	morphology	in	the	presence	of	nanoparticles	
	
Figure	7.17	Nanoparticles	do	not	alter	cell	morphology.	
Cell	morphology	of	Hela	cells	incubated	with	200	µg/ml	silica	nanoparticles	for	18	hours	(lower	panel)	are	
similar	to	untreated	cells	(top	panel;	ctrl).	GFP	fluorescence	is	displayed	for	cell	shape.	
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7.18 Titration	curves	of	succinimide	peptides	
	
Figure	7.18	Inhibition	curves	of	the	peptidyl‐succinimide	peptides.	
Taspase	activity	was	tested	in	a	fluorogenic	in	vitro	assay	at	different	inhibitor	concentrations.	Curves	were	
normalized	and	nonlinear	fitting	was	applied	to	obtain	IC50	values.	A	list	of	the	IC50	values	and	the	structures	
of	the	compounds	can	be	found	in	table	3.2.	
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7.19 Passage	through	50	kDa	membrane	
	
	
Figure	7.19	Taspase	can	pass	a	50	kDa	membrane.	
Taspase	was	diluted	in	gel	filtration	buffer	and	10‐fold	concentrated	again	in	a	50	kDa	Centricon.	This	10‐
fold	dilution	followed	by	10‐fold	concentration	was	repeated	two	more	times.	The	fraction	retained	by	the	
50	kDa	membrane	was	analyzed	by	SDS‐PAGE	(first	lane).	The	flow‐through	was	collected	and	concentrated	
in	a	30	kDa	Centricon	(second	lane).	Subsequently,	the	protein	was	diluted	10‐fold	and	concentrated	again	
two	times.	The	flow‐through	was	concentrated	in	a	10	kDa	Centricon	before	analysis	(third	lane).	As	a	result,	
Taspase	can	pass	a	50	kDa	membrane.	
	
	
7.20 Structure	of	the	Taspase	hetero‐tetramer	
	
	
Figure	7.20	Location	of	the	C‐termini	in	the	hetero‐tetramer	of	Taspase.	
The	C‐termini	(red)	of	Taspase	are	located	60	Å	apart	at	the	opposite	ends	of	the	hetero‐tetramer.	Enforced	
dimerization	by	C‐terminal	tags,	as	performed	in	[68],	is	therefore	likely	to	result	in	a	dimer	with	different	
conformation.	
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7.21 Molecular	plugs	tested	as	Taspase	inhibitors	
	
Figure	7.21	Molecular	plugs	fail	to	inhibit	Taspase.	
a	Several	compounds	designed	by	the	Schmuck	group	as	molecular	plugs	for	a	variety	of	other	enzymes	
were	prescreened	 for	Taspase	 inhibition	 in	vitro.	Measurements	were	 taken	 in	3	%	DMSO	to	guarantee	
solubility	of	the	compounds	and	referenced	to	a	DMSO	control.	Error	bars	indicate	standard	deviations	from	
two	 independent	 experiments.	 The	 compounds	 are	 listed	 in	 supplemental	 figure	 7.22	 below.	 b	 Two	
compounds	 with	 promising	 inhibitory	 values	 in	 the	 prescreen	 and	 sufficient	 water	 solubility	 were	
deliberately	selected	for	titrations.	Both	compounds	revealed	no	inhibitory	effect.	
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Figure	7.22	Structure	of	the	molecular	plug	compounds.	
Structures	of	the	molecular	plug	compounds	tested	for	Taspase	inhibition.	All	compounds	are	courtesy	of	
the	Schmuck	group.	
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